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ABSTRACT 
The use of radiation is broad in biological systems, in different areas of research 
mostly in health. 
Radiation is used to kill cancer. In radiation therapy proper calculation is done so that 
a maximum dose is delivered  to the cancer . Inspite of this precaution, radiation 
effects healthy tissue. This effect is especially dangerous when the tumor is located 
near important organs. Thus in radiation therapy,  it is important to reduce the dose 
and the damage to the healthy tissues and organs. The damage on the healthy tissues 
due to radiation therapy in cancer could be reduced by reducing the radiation dose to 
get the same treatment effect or by enhancing the radiation. The enhancement of 
radiation effect in vitro and in vivo can be obtained by targeted drug delivery on the 
cancer. Also photo dynamic therapy can be supplemented by the use of radiation 
therapy on the cancer by targeted drug delivery. 
Another use is the development of a bio dosimeter. In a large scale nuclear event it is 
important to measure the radiation dose exposed to humans. Also it is likely that the 
people who are exposed to radiation are not wearing the dosimeter. So a method of 
estimating radiation dose to a person exposed to radiation  without a physical 
dosimeter would be a very useful procedure. One possible method is the use of gene 
expression analysis, which is based on the fact that the expression of the genes will 
change due to the absorbed radiation. So developing a biological dosimeter based on 
the gene expression analysis  could quantify the radiation dose given to the patients 
during radiation therapy or to assess the risk of cancer developing in the general 
population. This biological dosimeter could even be used when the physical 
  
dosimeters are insufficient to estimate the risk caused by the radiation exposure or 
even years after being exposed to nuclear accidents. 
The main goal of the work presented here is to investigate the following topics 
- Use of gold pHLIP to enhance the radiation effect in cancer cells 
- Review on the in vivo research done to enhance radiation using gold 
nanoparticles 
- Analyze the gene expression results from irradiated drosophila melanogaster to 
develop a biological dosimeter. 
- Use of X-ray to activate targeted Copper Cysteamine nanoparticles 
photosensitizer  to reduce tumor size in mice. 
A review work I have done on the researches related to enhancement of radiation 
using gold nanoparticles in tumor bearing mice showed that the targeted nanoparticles 
are a promising method for achieving radiation enhancement due to their shape, size , 
surface chemistry and the properties of the nanoparticles..   
Gold nanoparticles are susceptible to X-rays compared to tissues and release extra 
electrons by Auger effect when the tumor treated with gold is irradiated. These auger 
electrons have low energy and are localized within the tumor site killing the cancer 
cells. However tumor targeting peptide pHLIP (pH Low Insertion Peptide) conjugated 
to gold nanoparticle specifically targets low pH medium (tumor) which when 
irradiated reduces the risk of killing healthy tissues near by and increases the uptake of 
the particles in the cancer mostly in the cellular membranes compared to only gold. 
The experimental results on cellular uptake of gold showed that there was an 
enhancement of gold uptake by 52%  at low pH compared to normal pH ( P value = 
  
.008)and also in targeted gold by 34% compared to non targeted gold at low pH (P 
value= .023). The images obtained by distribution of gold experiment showed that the 
cellular uptake of gold-pHLIP is higher compared to gold alone . The targeting of 
plasma membrane by gold-pHLIP is seen clearly on all the images and some staining 
of internal organelles and nuclei membranes as well. The clonogenic  assay 
experiment at 1.5Gray radiation showed a statistically significant 24% decrease in 
survival for cells treated with gold-pHLIP at low pH compared with cells treated with 
no gold. Also  a statistically significant 21% decrease in survival for cells treated with 
gold-pHLIP at low pH compared with cells treated with gold alone. Thus Gold 
nanoparticles conjugated with pHLIP significantly increases the amount of gold 
particles in cancer cells thus enhancing the radiation effect and increasing the amount 
of cancer cell death from radiation. 
Copper cysteamine nanoparticles placed in the tumor site release cytotoxic singlet 
oxygen molecules on irradiation. The Cu-Cy nanoparticles being photosensitizers kill 
tumor when activated by radiation. Photosensitizers are limited to shallow tumors. 
Here we use X-radiation to photosensitize the pHLIP targeted Cu-Cy nanoparticles to 
kill even the deeply seated tumors in vivo. The results from the in vivo experiment we 
have done shows significant tumor destruction under X-ray activation. ANOVA 
analysis showed that the mice treated with targeted particles had a significantly 
different tumor sizes than mice treated with no particles, as well as mice treated with 
non-targeted particles. Also the use of targeted copper cysteamine nanoparticles 
affected the survival time after irradiation, compared to irradiation using no particles 
on mice. This work confirms the effectiveness of Copper Cysteamine nanoparticles, 
  
targeted to tumors, as a photosensitizer when activated by radiation therapy. Thus the 
aid of radiation therapy to photodynamic therapy by the use of tumor targeted CuCy 
nanoparticles efficiently does tumor destruction shrinkage with the increase in mice 
survival. 
Gene expression analysis on a published data showed that the expression of genes are 
radiation dose dependent and some genes behaving predictably as a function of 
radiation dose at different time points after radiation can be used as a bio dosimeter. 
The data analysis showed that 6 genes from drosophila melanogaster show linear 
response (R
2
 > 0.9) with radiation dose at all time points after irradiation. Four of 
these genes have human homologues. Dropping off the lowest radiation dose (10 
roentgen being very low for the fruit flies), 13 genes show a linear response with dose 
at all time points including 5 of 6 genes in whole data set. Of these 13 genes, 4 have 
human homologues and 8 have known functions. The Irbp (inverted repeat – binding 
protein) gene among the above is very important as it is a DNA repair gene. It is 
reasonable to predict that DNA damage is linear with radiation dose; thus, it is logical 
that some DNA repair genes may respond linearly in expression. Irbp has homologues  
in organisms that are as complex as humans  and chimpanzees and in organisms as 
Japanese rice . The expression of this panel of gene, particularly those with human 
homologues, could potentially be used as the biological indicator of radiation exposure 
in dosimeter applications. 
Thus we could use radiation to kill tumors more effectively or the  development of  a 
biological dosimeter  could help people to estimate the risk of cancer caused due to 
their exposure to radiation.   
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PREFACE 
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1. Antosh, M.P., Wijesinghe, D.D., Shrestha, S., Lanou, R., Huang, Y.H., 
Hasselbacher, T., Fox, D., Neretti, N., Sun, S., Katenka, N. and Cooper, L.N., 
2015. Enhancement of radiation effect on cancer cells by gold-
pHLIP. Proceedings of the National Academy of Sciences, 112(17), pp.5372-
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2016. Gold nanoparticles for radiation enhancement in vivo. Jacobs journal of 
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Abstract 
Previous research has shown that gold nanoparticles can increase the effectiveness of 
radiation on cancer cells. Improved radiation effectiveness would allow lower 
radiation doses given to patients, reducing side effects; alternatively, it would provide 
more cancer killing at current radiation doses.  Damage from radiation and gold 
nanoparticles depends in part on the Auger Effect, which is very localized; thus, it is 
important to place the gold nanoparticles on or in the cancer cells. In this work, we use 
the pH-sensitive, tumor-targeting agent, pH Low Insertion Peptide (pHLIP), to tether 
1.4 nm gold nanoparticles to cancer cells. We find that the conjugation of pHLIP to 
gold nanoparticles increases gold uptake in cells compared to gold nanoparticles 
without pHLIP, with the nanoparticles distributed mostly on the cellular membranes. 
We further find that gold nanoparticles conjugated to pHLIP produce a statistically 
significant decrease in cell survival with radiation, compared to cells without gold 
nanoparticles as well as to cells with gold alone. In the context of our previous 
findings demonstrating efficient pHLIP-mediated delivery of gold-nanoparticles to 
tumors, the obtained results serve as a foundation for further pre-clinical evaluation of 
dose enhancement.  
 
Keywords: Tumor, acidity, targeting, gold nanoparticles, radiation 
Statement of Significance  
 
Nanometer-sized gold particles are shown to increase the effectiveness of radiation in 
killing cancer cells. Improved radiation effectiveness allows less radiation to be used, 
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reducing side effects to patients. Alternatively, more cancer killing could be had for 
current radiation doses. Here we used pH Low Insertion Peptide (pHLIP) to tether 
gold nanoparticles to membranes of cancer cells. This increases their effectiveness 
because the radiation/particle effect is very localized. We find that pHLIP significantly 
increases the amount of gold particles in cancer cells, as well as the amount of cancer 
cell death from radiation. This methodology is promising for clinical research, as 
previous results show efficient targeting of gold nanoparticles to tumors by pHLIP.  
 
Introduction 
 
Gold is an inert and generally non-toxic material with unique properties suitable for 
many applications such as cancer diagnosis and treatment (1-7). Nanometer-size gold 
particles have recently been shown to increase radiation damage to tumors (2,8-11). 
With enhanced radiation, the same level of tumor killing can be had with less radiation 
to a patient, reducing side effects of radiation treatments. Similarly, more tumor killing 
can be had for the levels of radiation that are currently given.  
The increase in radiation effectiveness with gold nanoparticles is due largely to two 
causes. First, gold is capable of absorbing radiation at a significantly higher rate than 
tissue, up to about 100 times more for keV energies (2). Second, gold nanoparticles 
that interact with radiation can release extra electrons via the Auger Effect. The Auger 
Effect occurs when an atom releases electrons post-ionization. Multiple electrons, 
called Auger electrons, can be released per ionization. The Auger electrons usually 
have low enough energy so that their effect is localized to the area surrounding the 
gold nanoparticles; see for example figure 1 in ref.11. Thus, it is very important to 
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effectively deliver gold nanoparticles to cancer cells in tumors and locate them near 
DNA or other vital cellular structures and components.  
 
Specific delivery can be accomplished by conjugating gold (or other nanoparticles) to 
antibodies or ligands that target overexpressed proteins on cancer cell surfaces; this 
approach has been actively explored for many years for delivery of small molecules. 
However, several recent studies have raised serious questions about the efficacy of 
targeting ligands on the nanoparticle accumulation in tumor tissues. Multiple reports 
have shown that targeted nanoparticles did not lead to increased tumor accumulation 
over non-targeted controls, although increased cellular uptake was observed in each 
case (12-14).  In addition, histological studies showed that antibodies conjugated with 
gold nanoparticles do not penetrate deeply into tumors, but mostly stain peripheral 
tumor regions (15). The direct injection of micron-sized gold particles does not lead to 
tumor targeting, as particles stayed only at the injection site and were not able to 
diffuse even within a tumor, hindering tumor coverage (16).  
Our approach is based on targeting of tumor acidity, which correlates with tumor 
malignancy (17-19). The pH-sensitive targeting agents we are developing are based on 
the action of a family of pHLIPs (pH Low Insertion Peptides), which can “sense” 
acidity at the surface of cancer cells and deliver diagnostic and therapeutic molecules 
to tumors of different origins (20-25). It was shown that pHLIP can promote fusion of 
liposomes with cancer cells and cellular delivery of various payloads (26, 27) 
including small gold nanoparticles (26). Recently, pHLIP was successfully employed 
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for the targeting of various nanoparticles to tumors and other acidic diseased tissue 
(28-31).  
pHLIP has also been used to mediate pH-controlled delivery of both 13 nm water 
soluble gold nanoparticles coated with luminescent europium into human platelets in 
vitro (32), and  1.4 nm gold nanoparticles to tumors (33). Intratumoral and i.v 
administrations of both demonstrated a significant enhancement of tumor uptake of 
1.4 nm gold nanoparticles conjugated with pHLIP. Statistically significant reduction 
of gold accumulation was observed in acidic tumors and kidney when pH-nonsensitive 
K-pHLIP was used as a vehicle, suggesting an important role of pH in the pHLIP-
mediated targeting of gold nanoparticles.  
In this work, we made another important step toward clinical application of 1.4 nm 
gold nanoparticles conjugated with pHLIP. We show that pHLIP can deliver gold to 
cellular components in a pH-dependent manner and enhance the radiation damage in 
cells. 
 
Results 
In this work we used 1.4 nm diameter gold clusters functionalized with maleimide. 
Maleimide-gold clusters were conjugated with WT-pHLIP containing a single Cys 
residue at the N-terminus:  
ACEQNPIYWARYADWLFTTPLLLLDLALLVDADET 
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After conjugation, the construct was purified, lyophilized, redissolved in DMSO, 
quantified and used in experiments with cells. As a control (gold alone) we used non-
functionalized 1.4 nm gold clusters.  
 
Cellular Uptake and Distribution of Gold  
We investigated uptake of gold nanoparticles at normal and low pHs (pH 7.4 and 6.0, 
respectively), with and without pHLIP on human lung carcinoma (A549 cells). At pH 
6.0 pHLIP was found to increase cellular uptake of gold nanoparticles by 34% 
compared to gold nanoparticles alone (p value 0.023) (Fig.1 and SI Appendix, Table 
S1). The uptake of pHLIP-gold at pH 6.0 increased by 53% compared to the uptake at 
pH 7.4 (p value 0.008). The uptake of gold alone was also enhanced at pH 6.0 
compared with pH 7.4 (P value = 0.014). The uptake of gold-pHLIP was ~60% of the 
treated dose (1.8µg), which was about 1.1µg gold. Because each treatment had ~1 
million cells, the amount of gold per cell was ~ 1.1X10
-6
 µg.  We expect that uptake of 
pHLIP-gold at normal pH by noncancerous cells will be much lower, since pH at the 
surface of glycolytic cancer cells is about 6.6-6.8 even when bulk pH of media is 7.4 
(unpublished data). The uptake of gold alone was also enhanced at pH 6.0 compared 
to pH 7.4 (p value 0.014).  
Light microscopy was used  to establish the distribution of gold nanoparticles in cells. 
Bright field images of cells treated with gold-pHLIP or gold alone and enhanced with 
silver are shown in Figure 2. The cellular uptake of gold-pHLIP is higher compared to 
the uptake of gold alone (Figure 2A and -B; the images are taken using 20x objective). 
The representative bright field image of cell treated with gold-pHLIP and enhanced 
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with silver obtained at high magnification is  shown in figure 2C (the image  is taken 
using 100x objective). The overlay of fluorescent images of nuclear stained with DAPI 
(blue) and cellular membrane stained with HQ silver deposited on the gold-
nanoparticles (red) are shown in figure 2D. The targeting of the plasma membrane by 
gold-pHLIP is clearly seen on all images. We also observed some staining of internal 
organels and nuclei membranes. Targeting of mitochondria and nuclear membranes 
was observed in experiments with pHLIP-coated liposomes containing lipids 
conjugated with fluorescent dyes and gold nanoparticles (27).   
 
Clonogenic Assay 
Clonogenic assay experiments were performed to assess cell survival after treatment 
of cells with gold or gold-pHLIP and radiation of treated and non-treated cells. The 
results of the experiments are summarized in figure 3 and SI Appendix, Tables S2-S5.  
We tested 0, 1.5 and 3 Gray of radiation. Gold nanopoarticles alone or conjugated with 
pHLIP were not toxic for cells in the absence of radiation. For 1.5 Gray of radiation, 
we observed a statistically significant 24% decrease in survival for cells treated with 
gold-pHLIP at low pH, as compared to cells treated with no gold. We also observed a 
statistically significant 21% decrease in survival for cells treated with gold-pHLIP at 
low pH as compared to cells treated with gold alone. The effect of gold was not 
significant at 3 Gray of radiation, likely because the survival of cells at 3 Gray was 
low. 
Two different methodologies were used:  excess of gold or gold-pHLIP was removed 
after treatment with cells before radiation, or excess of gold and gold-pHLIP was not 
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removed (non-removal corresponds with the values shown in red in SI Appendix, 
Tables S2-S5). The clonogenic assay results in Fig. 3A include data obtained at both 
different methodologies. Fig. 3B shows the data obtained in the experiments when 
gold constructs were not removed before radiation. Surprisingly, overall the non-
removal data have better survival than the removal data; perhaps this is a result of the 
removal process stressing the cells.  
We assessed statistical significance for data obtained at 1.5 Gray of radiation by 
performing an analysis of variance (ANOVA), summarized in Table 1 and SI 
Appendix, Table S6. When determining the p values between different gold 
treatments, we accounted for the difference in methodology as an additional variable 
in the analysis of variance (see Methods section for more details). Our data clearly 
indicate that cell treatment with gold-pHLIP results in a statistically significant 
decrease in cell survival as compared to a treatment with no gold (p value 3.610-5) or 
gold alone (p value = 0.015).   
In a separate experiment, cells were treated with gold constructs at pH 7.4, where 
pHLIP is less effective at inserting into the cellular membranes. Only small and 
statistically insignificant differences in survival between non-treated and treated cells 
were seen; the data is given in SI Appendix, Tables S2, S3, and S5. 
 
Discussion 
The treatment of cancer involves a trade-off between killing all cancer cells and 
impacting healthy tissue and organs as little as possible. To reduce side effects and 
enhance lethal effects of radiation for cancer cells the approaches of binary therapy 
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were introduced. Binary radiation therapy targets cells at the biological level with a 
noncytotoxic agent that is “activated” by low energy radiation, thereby destroying 
cancer cells wherever they may reside, while sparing normal cells in proximity to the 
diseased cells. A number of binary radiation therapies have been and are being 
explored (9, 34-36) one of the more promising approaches is based on dose 
enhancement through Auger electron emission secondary to the photoelectric effect 
dominant at low photon energies. Auger electron emission generates a cascade of low-
energy electrons that travel very short distances and deposit their energy locally. The 
number of Auger electrons generated in targeted cells can be increased significantly 
by introducing material of a high atomic number (high-Z) into the target as long as the 
radiation energy is at or near the K, L, or M electron shell binding energies for the 
material. High-Z nanoparticles made of iodine, gadolinium, or gold are predicted to 
produce a clinically achievable dose enhancement of as much as 10 fold. Because low 
energy electrons travel very short distances, it is crucial to deliver and accumulate 
high-Z material on or in cancer cells in tumors.  
Our strategy is to deliver gold, which is an inert, high-Z material widely used in 
medicine, to cancer cells for enhancement of radiation effects. The delivery approach 
we propose is based on the energy of membrane-associated folding of peptides from 
the pHLIP family to target cellular membranes in a pH-dependent manner (22, 24, 37). 
At pH <7.0 pHLIPs insert into the lipid bilayer of the membrane, which is 
accompanied by a coil-helix transition and formation of a transmembrane helix. It has 
been shown that pHLIP delivery agents can target acidic tumors with high accuracy 
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and deliver nanoparticles, including gold, to cancer cells in tumors (33). In this work, 
we show the effect of gold-pHLIP on radiation-induced cell death.   
The dose enhancement depends strongly on the photon energies used for irradiation, as 
well as on the location and the size of gold nanoparticles. Regarding the photon 
energy, the ratio of gold absorption to human absorption is highest between ~10 and 
100keV, with the ratio reaching approximately as high as 100 (2). We used 250 kVp 
X-rays with Sn-Thoraeus filtering to use the high relative absorption by gold while 
also accounting for the fact that lower-energy photons will be absorbed at too small of 
a depth to be useful. Regarding the location, it is very important to deliver gold 
nanoparticles as close as possible to cancer cells, as the dose deposited by Auger 
electrons increases as distance from the gold nanoparticles decreases(11). We used 
pHLIP to locate the gold nanoparticles to cancer cells. Regarding the nanoparticle 
size, it is best to use as small a gold nanoparticle size as possible to minimize the 
energy deposited inside the gold by Auger electrons. Simulations by McMahon et al. 
(11) predict an increase in relative biological effectiveness for decreasing sizes of gold 
nanoparticles. We used 1.4-nm –diameter gold nanoparticles. 
The results of our present study indicate that pHLIP causes cells to take up more 1.4-
nm gold nanoparticles than cells without pHLIP. The gold nanoparticles deposited by 
pHLIP mostly accumulate on the plasma membrane. As a result, gold nanoparticles 
delivered to cells by pHLIP can enhance radiation-induced decreases in cell survival. 
Gold nanoparticles tethered to the lipid bilayer of the plasma membrane by pHLIP 
may trigger cell death by inducing oxidation of lipids, cholesterol and membrane 
proteins. The oxidized lipids are known to modify membrane physical properties, such 
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as thickness, permeability, level of hydration and polarity, lipid transbilayer diffusion, 
loss of lipid asymmetry and phase segregation, which results in apoptosis (38, 39). 
The exposure of phosphatidylserine lipids to the outer leaflet of the lipid bilayer, 
promoted by lipid oxidation, serves as a recognition signal for macrophages to 
phagocytose the apoptotic cell (40).  
The combination of the clonogenic and uptake results suggests that pHLIP is able to 
enhance radiation-induced death by targeting cancer cells and increasing gold uptake. 
This is particularly important for future pre-clinical testing. Experiments on cultured 
cells reflect steady-state conditions, when constructs are exposed to cancer cells 
during the time of incubation. However, in vivo studies reflect kinetic conditions, 
when blood flow is high and constructs have limited time to reach cancer cells and 
accumulate there. Our previous in vivo studies indicate that pHLIP targeting of 1.4 nm 
gold nanoparticles to tumors was 11 and 6 times higher compared to tumor targeting 
by gold alone (when administrated intratumorally and intravenously, respectively) 
(33).  Thus, in an upcoming experiment on mice, we expect to observe more 
significant enhancement of radiation-induced cancer killing in mice compared to data 
obtained on cells. This might open a new avenue for the treatment of acidic, highly 
metastatic tumors in humans. 
 
Methods 
Materials: Materials include nonfuctionalized (from Nanoprobes), monomaleimido 
nanogold (from Nanoprobes), Cys-pHLIP (synthesized and purified by CS Bio), Tris-
(2-carboxyethyl) phosphine, hydrochloride (from Life Technologies), Dulbecco’s 
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Modified Eagle’s Medium (from Sigma Aldrich), gluteraldehyde [25%(wt/wt) in 
water; from Sigma Aldrich], crystal violet (from Sigma Aldrich), Synaptophysin (from 
Molecular Probes by Life Technologies), DAPI (from Sigma Aldrich) and silver 
enhancement  reagent (from Nanoprobes). Cell type was  human lung carcinoma A549 
cells (from American Type Culture Collection). 
 
Preparation of Gold (Gold Alone), Gold conjugated to pHLIP (Gold-pHLIP): 
Gold nanoparticles were cluster gold, 1.4 nm diameter, from Nanoprobes, Inc. 
Monomaleimido nanogold was conjugated to Cys-pHLIP in 40 mM phosphate buffer 
containing 300 mM NaCl at pH 6.5. A reducing agent, Tris-(2-carboxyethyl) 
phosphine, was added into the reaction mixture (10x excess compared to pHLIP) to 
reduce pHLIP-S-S-pHLIP dimers and promote reaction with gold-malemide . The 
reaction vial was incubated overnight at room temperature on shaker. The next day, 
the gold-pHLIP conjugates were purified using Amicon Ultra (10K) centrifugal filters 
according to company recommended protocol. The product was then lyophilized, 
redissolved in DMSO. The concentration of peptide and nanogold was determined by 
absorbance at 280 nm ( =13,940 M−1 cm−1) and 420 nm ( =155,000 M−1 cm−1), 
respectively Nonfunctionalized gold (gold alone) was dissolved in DMSO and 
quantified using absorbance of gold at 420 nm.  
 
Cellular Uptake of Gold: Approximately 1 million cells A549 were treated with 0.3 
µM of either gold Alone or gold-pHLIP in cell suspension in serum free DMEM at pH 
6.0 and 7.4 for 1 hour. One nanogold particle(1.4nm in diameter) contains, on average, 
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60 gold atoms, and 0.3uM particles in 0.5mL solution correspond to 1.8µg of gold. 
After 1 hour of treatment, the cells were pelleted using centrifugation (2,000 rpm x g 
for 5 min) followed by removal of treatment and washing cells with PBS three times. 
The cells were then dissolved in concentrated nitric acid followed by sonication for 
about 2 hours. Concentrated solution samples were diluted to give 2%(wt/vol)  nitric 
acid and analyzed via inductively coupled plasma mass spectroscopy (Thermo-
Scientific x7 series) against calibration standards (IMS 103; UltraScientific). 
 
Cellular Distribution of Gold: About 20,000 A549 cells were seeded on collagen 
coated glass bottom dishes (MatTek) in 200 µl volume. The next day, cells were 
treated for 1 hour with gold and gold-pHLIP at 0.5 µM concentration at pH 6.0 in 
DMEM with no FBS. After treatment, the cells were washed 3 times with PBS 
followed by fixation in 4% formaldehyde for 20 min. The cells were permeabalized 
with 0.3% Triton X100 for 5 min, followed by washing with  PBS and  deionized 
water. Next, the cells were developed with freshly prepared HQ Silver reagent 
(Nanoprobes) for about 20 min, followed by washing with deionized water. Finally the 
cells were stained with 5 µM  DAPI in PBS for 5 min, followed by washing with 
deionized water. The cells were imaged using light microscope in bright field regime 
to visualize gold enhanced by silver, and in the fluorescent regime to monitor DAPI 
and silver fluorescence using cut off filters (ex:em 360 nm/460 nm andex:em 542 
nm/620 nm, respectively). 
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Irradiation of Cells: Irradiation was done using a Philips RT 250 X-ray machine, at 
settings of 250 kVp and 15 mA. A 0.4 mm Sn-Thoraeus Filter was used. The half-
value thickness for this setup is listed as 2.8mm Cu. The dose rate was ~ 1.5 
Gray/minute for each irradiation. Calibration readings were performed before each 
measurement using a Radcal 2026C dosimeter, and the reading was corrected for 
differences in temperature and pressure from standard temperature and pressure. The 
irradiation dose varied by ~ 7% between the center of the cell dish and the rightmost 
well in the irradiation plate that we used (there was ~ 1-2% variation in the leftmost 
well); the rightmost well was only used in experiments 7-11 and there were always at 
least 3 wells used per treatment. 
 
Clonogenic Assay: The day before irradiation, 25,000 A549 cells per well were 
seeded in 48-well plates the day before irradiation.  One plate with different treatment 
conditions was used for each radiation dose. The next day, the cells were treated with 
no gold, gold alone or gold-pHLIP at 8 µM concentration in 300 µl  DMEM with no 
FBS at pH 6.0 for 3h. In experiment 11, the medium pH during treatment was 7.4 
instead of 6.0. In one set of experiments, the excess of gold was removed and 500 µl 
of fresh DMEM medium of pH 7.4 with 10% FBS was added. In the other set of 
experiments the excess of gold was not removed, then 200 µl of fresh DMEM medium 
of pH 7.4 with 25% serum was added into wells to have 10% of FBS in final volume 
in the well. The treatment period was ~ 3 h.  
Cells were irradiated as described in the irradiation methods; control cells 
accompanied the irradiated cells to and from the x-ray machine. Irradiated cells were 
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dissociated and combined for each treatment type, counted (using a Coulter Counter 
Z1 instrument from Beckman Coulter for experiments 1-11 and an Auto T4 instrument 
from Nexcelom Bioscience for experiments 12-17) and then reseeded in a 6-well plate. 
Two hundred  cells per well were seeded for 0- and 1.5- Gray radiation doses and 500 
cells per well were seeded for 3- Gray radiation dose. In generally, six wells were 
seeded per treatment type; the number of entries in SI Appendix, Table S2 is the 
number of wells. A table entry with 12 values represents a treatment that was done 
twice in the same experiment, with the results combined. After ~ 10 days, each well 
was fixed and stained using a 2- mL mixture of 4% glutaraldehyde and 0.5% crystal 
violet in distilled water. Stained cell colonies were hand-counted under a microscope. 
A colony was defined as a distinct group of cells that contained 50 or more cells.  
 
Analysis of Cellular Uptake Data: The values in SI Appendix, Table S1 are six 
readings from a mass spectrometer. P values for statistical significance were computed 
using the t test, because the between-reading variance was much greater than the error 
in each reading.  
 
Analysis of Clonogenic Assay Data: To calculate statistical significance, the data 
summarized in SI Appendix, Tables S2-S5 were analyzed using an ANOVA, followed 
by a post hoc test using Tukey’s Honest Significant Difference. Each individual 
measurement from the clonogenic assay dish was treated as a biological replicate, and 
normalized to the average of the “0 Radiation, No Gold” measurements from the same 
experiment.  
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The linear model fitted for the ANOVA had three variables: normalized survival 
(dependent variable), gold treatment (independent variable) and removal/non-removal 
of excess gold (independent variable). We left the data for 0 Radiation out of the 
analysis because normalizing by the “0 Radiation, No Gold” data points introduces a 
correlation if we use the data by which we are normalizing. We analyzed the data for 
1.5 Gray and 3 Gray separately because we were only really interested in the effect at 
1.5 Gray. 
In the 1.5 Gray data, the interaction term between gold treatment and removal/non-
removal was significant. This is consistent with the gold treatments having different 
effectiveness depending on whether or not the excess gold was removed.  
We also did one experiment at high pH, as mentioned in the results section. This was 
analyzed with a separate analysis of variance. The data are included as experiment 11 
in SI Appendix, Tables S2. S3, and S5.  
 
In Fig. 3, error shown is the SEM (41). SE was calculated using R, as SD divided by 
square root of the number of samples. In checking the procedure for this calculation, 
we used StatPlus, version v5 (AnalystSoft Inc.). 
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Tables 
 
Table 1. Summary of ANOVA results for 1.5 Gray radiation. Detailed results are in SI 
Appendix, Table S6. 
 
 
Model 
Normalized Survival=Treatment+Removal+(TreatmentRemoval) 
                                                                   P Values 
No Gold vs. Gold pHLIP 3.6410-5 
Gold pHLIP vs. Gold Alone 0.015 
No Gold vs. Gold Alone 0.832 
Removal vs. Non-Removal 5.9510-6 
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Figures 
 
 
 
 
 
Figure 1. Cellular uptake of gold. Values are averaged from normalized readings on a 
mass spectrometer, as detailed in Methods. All measurements are given in SI 
Appendix, Table S1. Data are normalized to gold Alone at pH 7.4. 
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Figure 2. Gold distribution in cells. The bright field (A-C) and fluorescence (D) 
images of cells treated with gold (A) and gold-pHLIP (B-D), followed by washing, 
fixation and enhancement with HQ silver, are shown at different magnifications (the 
bar on each image shows 10 µm- scale). The overlay of fluorescent images of nuclear 
stained with DAPI (blue) and cellular membrane stained with HQ silver (red) are 
shown on  D. 
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Figure 3: Average cell survival after radiation and treatment (or no treatment, control) 
with gold or gold-pHLIP at pH 6.0.  The data shown in A are from the experiments 
with either removal or non-removal of excess gold before radiation. The data shown in 
B are only from the experiments with non-removal of excess gold before radiation. 
Error shown is SEM.  
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Supplementary Information (SI) Appendix 
 
Table S1. Cellular uptake of gold-pHLIP and gold. The mean and standard 
deviation of these data points are presented in figure 1, and the calculation of 
statistical significance is described in the methods section. Data are normalized so that 
Gold Alone, pH 7.4 has a mean of 1. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Gold-pHLIP, pH 6.0 1.602±0.038, 1.538±0.013, 2.441±0.012, 2.006±0.006, 2.012±0.006, 
2.023±0.000 
Gold-pHLIP, pH7.4 0.838±0.006, 0.901±0.010, 1.525±0.006, 1.246±0.003, 1.826±0.004, 
1.246±0.006 
Gold Alone, pH 6.0 1.023±0.005, 1.122±0.006, 1.733±0.004, 1.687±0.005, 1.542±0.004, 
1.577±0.006 
Gold Alone, pH 7.4 1.004±0.008, 0.996±0.005, 1.339±0.004, 1.032±0.006, 0.835±0.012, 
0.794±0.002 
 28 
 
Table S2. Clonogenic Assay Colony Counts. For 0 and 1.5 Gray radiation, 200 cells 
were seeded; 500 cells were seeded for 3 Gray radiation. Treatment for experiments 1-
10 and 12-17 were done at pH 6.0; experiment 11 was done at pH 7.4. The values 
shown in red were obtained in the experiments where excess of gold constructs was 
not removed before radiation; the other data were obtained in the experiments where 
the excess gold was removed before radiation. The input for the analysis of variance 
(detailed in the methods section) was the values from this table, divided by the mean 
of the “0 Radiation, No Gold” values for its corresponding experiment. 
 
Exp.1 Exp.2 Exp.3 Exp.4 Exp.5 Exp.6 Exp.7 Exp.8 Exp.9 Exp.10 Exp.11 Exp.12 Exp.13 Exp.14 Exp.15 Exp.16 Exp.17
1.5 Gray 
Radiation, 
Gold Alone
56,31,3
6,56,33
,29
30,16,2
4,18,12,
24
37,39,4
1,31,30
,49
57,37, 
41,49, 
34,49
1.5 Gray 
Radiation, 
Gold-pHLIP
34,20,
28,43,
28,26
27,27,
36,25,
23,29
16,17,1
7,21,12
,18
23,22,2
0,30,15
,22
16,15,1
6,18,10,
13
36,28,3
9,29,20
,44
41,34, 
39,45, 
44,48
3 Gray 
Radiation, 
Gold Alone
44,24,4
2,39,41
,26
36,33,4
1,20,16,
31
66,56,6
5,49,38
,61
63,48, 
49,50, 
39,63
102,98,
99
32,24,2
5,32,32
,31,35,
28,32,3
6,35,33
69,76,8
9,83,73
,90,82,
72,77,8
5,64,86
0 Radiation, 
No Gold
48,47,6
3,64,58
,73,57,
33,63,7
1,62,57
74,50, 
67,57, 
70,72, 
72,69, 
77,69, 
63,82
81,66,9
6,70,47
,88
54,35,
44,49,
42,47,
55,59,
40,58,
54,48
59,54,
51,73,
65,65
60,49,
43,62,
55,70
55,54,4
8,43,48
,57
54,47,5
5,59,57
,52
39,39,4
6,47,33,
45,
47,37,4
8,30,42,
44
59,53,6
9,71,56
,65
67,49, 
53,68, 
56,65
49, 65, 
44, 41, 
50, 51
80,58, 
59
12,16,1
1,18,15
,13,14,
14,16,1
9,15,22
33,45,4
5,28,34
,40
27,21,
26,20,
16,27
46,37,
43,31,
28,46
24,26,4
5,34,23,
36
71,53,5
6,66,54
,55
63,51, 
66,48, 
49,56
45, 57, 
43, 40, 
41, 38
53, 62, 
58, 65, 
53, 55
29,25,
27,28,
31,35
52,45,5
5,44,42
,56
27,21,2
4,35,31
,27
33,25,2
9,34,21,
33
61,44,7
2,50,66
,73
60,53, 
60,67, 
53,55
46,25,3
0,32,32
,18
26,23,2
1,31,19
,31
23,32,2
5,24,21,
27
59,46,5
6,62,36
,53
50,37, 
38,61, 
44,51
57, 54, 
50, 54, 
64, 
49,37, 
32, 42, 
37, 47, 
42
49, 38, 
53, 33, 
50, 
44,41, 
50, 64, 
67, 69, 
50
0 Radiation, 
Gold Alone
0 Radiation, 
Gold pHLIP
1.5 Gray 
Radiation, 
No Gold
3 Gray 
Radiation, 
No Gold 
32,29,
30,25,
17,24
39,33,4
7,52,57
,50
35,33,2
9,18,23
,23
21,18,2
7,28,20,
28
51,28,6
1,49,42
,57
65,49, 
60,62, 
51,62
3 Gray 
Radiation, 
Gold-pHLIP
58,46,
43,52,
46,39
62, 61, 
54, 64, 
57, 
61,59, 
56, 60, 
50, 43, 
53
42, 40, 
52, 59, 
40, 
49,33, 
47, 37, 
43, 38, 
47
39, 45, 
49, 41, 
37, 
48,48, 
52, 50, 
57, 49, 
49
65, 49, 
44, 55, 
46, 
42,37, 
43, 39, 
34, 33, 
34
104,99,
85
27,17,3
1,25,22
,34,21,
7, 
21,39,2
2,14
44,26,3
7,54,35
,52
43,27,
36,39,
24,26
59,57,
54,62,
43,53
44, 44, 
38, 32, 
42, 46
42, 50, 
41, 42, 
51, 44
56, 63, 
41, 50, 
48, 48
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Table S3. Summary of Clonogenic Assay Colony Counts: Means and St.D. Data 
are calculated using  SI Appendix, table 2. The values shown in red were obtained in 
the experiments where excess of gold constructs was not removed before radiation; the 
other data were obtained in the experiments where the excess gold was removed 
before radiation 
 
 
 
 
 
 
 
 
 
Exp.1 Exp.2 Exp.3 Exp.4 Exp.5 Exp.6 Exp.7 Exp.8 Exp.9 Exp.10 Exp.11 Exp.12 Exp.13 Exp.14 Exp.15 Exp.16 Exp.17
0 Radiation,          
No Gold
100±2 31±4 79±8 49±8 61±8 57±10 51±5 54±4 42±5 58±11 69±9 51±11 57±6 44±7 47±6 43±9 47±9
0 Radiation,      
Gold Alone
75±18 41±7 62±7 60±8
0 Radiation,     
Gold-pHLIP
31±9 59±7 56±8 44±7 58±5 41±5 45±4 51±8 50±8
1.5 Gray 
Radiation, 
No Gold
66±12 15±3 38±7 23±5 39±8 31±9 25±5 25±4 52±10 47±9
1.5 Gray 
Radiation, 
Gold Alone
40±12 21±7 38±7 45±9
1.5 Gray 
Radiation, 
Gold-pHLIP
30±8 28±4 17±3 22±5 15±3 33±9 42±5
3 Gray 
Radiation, 
No Gold
96±10 23±9 41±11 33±8 55±7 29±3 49±6 28±5 29±5 61±12 58±5
3 Gray 
Radiation, 
Gold Alone
36±9 30±10 56±11 52±9
3 Gray 
Radiation, 
Gold-pHLIP
47±7 26±5 46±9 27±7 24±5 48±12 58±7
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Table S4. Summary of Normalized Clonogenic Data for Low pH. Cells were 
treated with the constructs at low pH before radiation. The average values from SI 
Appendix, table S3 were divided by the average for “0 Radiation, No Gold” for each 
experiment. The values shown in red were obtained in the experiments where excess 
of gold constructs was not removed before radiation; the other data were obtained in 
the experiments where the excess gold was removed before radiation. 
 
 
 
 
 
 
 
 
 
Exp.1 Exp.2 Exp.3 Exp.4 Exp.5 Exp.6 Exp.7 Exp.8 Exp.9 Exp.10 Exp.12 Exp.13 Exp.14 Exp.15 Exp.16 Exp.17
0 Radiation,          
No Gold
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
0 Radiation,        
Gold Alone
0.947 0.996 1.072
0 Radiation,       
Gold-pHLIP
0.755 1.02 0.868 1.018 0.934 0.957 1.175 1.062
1.5 Gray 
Radiation, 
No Gold
0.659 0.493 0.476 0.468 0.629 0.6 0.466 0.61 0.897
1.5 Gray 
Radiation, 
Gold Alone
0.51 0.498 0.652
1.5 Gray 
Radiation, 
Gold-pHLIP
0.488 0.493 0.331 0.407 0.353 0.563
3 Gray 
Radiation, 
No Gold
0.385 0.299 0.21 0.267 0.357 0.206 0.386 0.204 0.281 0.421
3 Gray 
Radiation, 
Gold Alone
0.183 0.284 0.385
3 Gray 
Radiation, 
Gold-pHLIP
0.31 0.185 0.365 0.199 0.228 0.331
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Table S5. Summary of Normalized Clonogenic Assay Data for High pH. Cells 
were treated with the constructs at normal pH before radiation. This table is analogous 
to SI Appendix, table S 4, which is for the low pH experiments. 
 
 
 
Exp.11 
0 Radiation, No Gold 1.000 
0 Radiation, Gold Alone 0.871 
0 Radiation, Gold-pHLIP 0.810 
1.5 Gray Radiation, No Gold 0.684 
1.5 Gray Radiation, Gold Alone 0.650 
1.5 Gray Radiation, Gold-pHLIP 0.611 
3 Gray Radiation, No Gold 0.339 
3 Gray Radiation, Gold Alone 0.304 
3 Gray Radiation, Gold-pHLIP 0.340 
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Table S6. Detailed Results of ANOVA for 1.5 Gray Radiation. 
 
 
 
Model 
Normalized Survival = Treatment + Removal + (TreatmentRemoval) 
                ANOVA Results 
 Degrees of 
Freedom 
Sum of 
Squares 
Mean 
Squares 
F Value P Value 
Treatment 2 0.421 0.21 10.9 4.9610-5 
Removal 1 0.453 0.453 23.5 4.3910-6 
Treatment*Removal 2 0.122 0.061 3.2 0.0465 
Residuals 105 2.026 0.019   
                        Posthoc Test Results 
 Difference 
in Means 
Lower Bound 
of 95% 
Confidence 
Interval 
Upper Bound of 
95% Confidence 
Interval 
Adjusted P Value 
No Gold vs. Gold-pHLIP  0.136 0.065 0.206 3.6410-5 
Gold-pHLIP vs. Gold 
Alone 
-0.114 -0.209 -0.019 0.015 
No Gold vs. Gold Alone 0.022 -0.068 0.111 0.832 
Removal vs. Non-
Removal 
-0.13 -0.184 -0.076 5.9510-6 
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Abstract 
Enhancing the effect of radiation on tumors would be a significant improvement in 
radiation therapy. With radiation enhancement, less radiation could be used to achieve 
the same goals, lessening damage to healthy tissue and lessening side effects. Gold 
nanoparticles are a promising method for achieving this enhancement, particularly 
when the gold nanoparticles are targeted to cancer. This literature review discusses the 
properties of gold nanoparticles as well as existing in vivo radiation enhancement 
results using both targeted and non-targeted gold nanoparticles. 
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Abbreviations 
GNP : Gold nanoparticles 
PEG : Polyethylene Glycol 
kVp : Kilovolt Peak 
Gy : Gray 
pHLIP : pH-Low Insertion Peptide 
IV : Intravenous 
CTR : Complete Tumor Regression 
DTPA : Diethylenetriamine pentaacetic acid 
BSA : Bovine Serum Albumin 
 
Introduction 
In radiation therapy for cancer, radiation is delivered after precise calculations so that 
a maximum dose is given to the tumor and a minimum dose is given to healthy tissue. 
Despite these efforts, radiation still affects healthy tissue. This effect is especially 
dangerous when the tumor is located near important organs. Thus, it is important in 
radiation therapy to reduce the dose and the damage to healthy tissues and organs(1). 
One of the current strategies to reduce radiation is the use of radiation enhancers, 
which can absorb and make tumor cells more susceptible to it. They are designed to 
improve tumor cell killing, since making a tumor more susceptible to radiation means 
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that less radiation can be used. And if less radiation is used, there will be less adverse 
effects on normal tissues(2). 
Radiation enhancers can include materials like nanoparticles, e.g. carbon nanotubes, 
gold nanoparticles and quantum dots. In this paper, we will focus on the use of gold 
nanoparticles (GNPs). Gold is a good radiation enhancer. The radiosensitization of 
biomolecules by GNPs can be caused by locally increased radiation absorbed energy. 
Gold, a high Z material, is capable of absorbing radiation at significantly higher rates 
than tissue. The advantage in absorption can grow to about a factor of 100 for certain 
keV photon energies (20 keV shown in (3), can be checked in a database (4)). 
Additionally, gold nanoparticles that interact with radiation can release a number of 
Auger electrons via the Auger effect. The Auger effect occurs when an excited atom 
(for example, an ionized gold atom) releases its extra energy in a form of an electron 
instead of a photon.  
Radiosensitization can also be caused by modified sensitivity of targeted biomolecules 
to radiation (5). The efficiency of chemical radiosensitization mechanism is 
significantly influenced by the strong binding of GNPs to the biological target as 
DNA(5). Jain et al. (6) suggests a possible biological mechanism of radiosensitization 
by GNPs even in the absence of radiation, with GNPs potentiating the effect of 
bleomycin. The results showed that the GNPs caused chemosensitization to the 
radiomimetic agent bleomycin at a range of concentrations with a sensitizer 
enhancement ratio similar to that observed for the kilovoltage photons. 
Auger electrons have comparatively low energies (approximately 80 keV or less in 
gold), and because of this they have a short range of action in tissues. It can result in 
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the delivery of a precise and lethal dose in their immediate vicinity.  However, this 
short range also indicates that gold nanoparticles need to be located within tumors, 
near the vital cellular structures, in order to maximize the radiation enhancement 
effect(7, 8). This suggests the need for the gold nanoparticles to be targeted to cancer 
cells. 
In this paper, we will review the use of gold nanoparticles as a radiation enhancer in 
vivo. Specific topics include: 
 Properties of gold nanoparticles 
 Important Experimental Variables 
 In vivo radiation enhancement results for non-targeted gold 
nanoparticles 
 Nanoparticle Targeting 
 In vivo radiation enhancement results for targeted gold nanoparticles 
 
Properties of Gold Nanoparticles 
Gold nanoparticles properties include the following: 
i) Gold is an inert material and can be made to be biocompatible using 
surface modification, like surface coating of the GNPs (2, 3, 6-17). 
ii) Gold nanoparticles can be linked to biomolecules, either via stabilizers 
(polyethylene glycol, maleimide) or directly to sulfhydryl (-SH) groups 
of moieties such as peptides, antibodies, small molecules or proteins. 
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Tumor targeting can be achieved by conjugating the GNP surface to 
peptides, ligands, antibodies or drugs (2, 3, 6-9, 11-14, 16, 18, 19). 
iii) Gold nanoparticles, as any nanoparticle, have a large surface to volume 
ratio. The relatively large surface area provides opportunity for 
interactions with molecules. Having large number of surface ligands, 
gold nanoparticles allow flexible design and multi-functionality by 
incorporating mixed ligands (3, 12, 18) . 
iv) The nanoparticles including GNPs exhibit preferential deposition at 
tumor sites due to the enhanced permeation and retention (EPR) effect. 
This makes them to be effective as drug carriers and radiation 
enhancers (1, 8, 16). This is related to the small size of GNPs, and the 
leaky vasculature of tumors. 
v) The size of GNPs can be tuned to a wide range (1-1000 nm) and 
various shapes (2, 3, 6, 9, 12, 18, 19). 
 
Important Experimental Variables 
The following variables are known to affect the amount of radiation enhancement that 
the gold nanoparticles are capable of delivering: 
Concentration of gold: The concentration of gold nanoparticles in the tumor sites (and 
thus the number of gold atoms) affects the radiation enhancement capability. Hainfeld 
et al. (20)doubled the concentration of non-targeted gold nanoparticles (from 1.35 to 
2.7 grams of Au per kilogram mouse weight), and increased survival by 72% (from 
50% to 86%).  
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Size, Shape and Surface Chemistry of GNPs: There are various sizes and shapes of 
gold nanoparticles available, and this affects their uptake by the cells. Also, surface 
chemistry is an important parameter, which affects biodistribution and cellular uptake 
of nanoparticles. Chithrani et al. (21) found that the cellular uptake of spherical GNPs 
of 14, 30, 50, 74, 100 nm in diameter is size dependent. Cells in vitro had a maximum 
uptake for 50 nm sized spherical GNPs. The rod shaped nanoparticles exhibited less 
uptake by cells compared to spherical particles. For example, cells took up 500 and 
375% more 74 and 14 nm spherical gold nanoparticles than 74 × 14 nm rod-shaped 
gold nanoparticles, respectively. The authors noted that in addition to size and shape 
of GNPs the surface chemistry might also affect cellular uptake of nanoparticles. Non-
homogeneous coating of nanoparticles with citric acid ligands and presence of cetyl 
trimethylammonium bromide (CTAB) molecules at the surface of rod GNPs could 
result in lower cellular uptake.   In an in vitro study of GNPs as radiation enhancers in 
cancer therapy, 50 nm spherical GNPs showed the highest radiosensitization 
enhancement factor (REF)  (1.42 at 220kVp) compared to gold nanoparticles of 14 
and 74 nm (1.20 and 1.26 respectively) (10). 12.1 and 27.3 nm size spherical GNPs 
coated with polyethylene glycol (PEG) showed high radiation enhancement compared 
to 4.8 and 46.6 nm size, both in vitro and in vivo, with accumulation of GNPs in the 
tumor with high concentration (22). This is in contrast to the computation study 
performed by McMahon et al.(17) , which predicts an increase in radiation 
enhancement with decreasing size of spherical GNPs. Puvanakrishnan et al.(23) 
compared cellular uptake for gold nanoshells and gold nanorods. The results indicated 
a higher accumulation of smaller rod GNPs in tumor compared to the larger nanoshell 
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GNPs . However, the accumulation of nanorods and nanoshells in the liver increased 
significantly for higher doses. This suggests that the particle shape and size 
significantly affects tumor targeting and confirms that the smaller particles have 
enhanced accumulation in tumors compared to larger nanoparticles. Huang et al. 
(24)found that GNPs smaller than 10 nm have unique advantages over GNPs greater 
than 10 nm in localization and penetration of breast cancer cells, multicellular tumor 
spheroids and tumors in mice. The in vivo results showed that 2 and 6 nm tiopronin-
coated GNPs were distributed throughout the cytoplasm and nucleus whereas 15 nm 
samples became aggregated in the cytoplasm. Tumor bearing mice were intravenously 
injected with a dose of 5 mg of Au per kg of mice. After 24 hours the amount of gold 
in tumor was 2.93 micrograms per gram of tumor for 2 nm, 0.79 micrograms for 6 nm 
and 0.14 micrograms for 15 nm particles. Compared to 15 nm GNPs, the 2 nm and 6 
nm GNPs were widely distributed in different organs of the body due to small 
structures. Histological analysis showed that GNPs had almost no effect on tissues 
including liver, spleen, kidney, lung and heart, indicating good tissue biocompatibility 
of the GNPs. 
Cell Line Used in Studies with GNPs: Radiation enhancement by GNPs is cell line 
specific. They enhance the radiation when treated with some cells but not all. 
Significant radiosensitization occurred in MDA-MB-231 cells at 160 kVp. However, 
no significant radiosensitization was observed in DU 145 or L132 cells, even though 
there was uptake of GNPs in both of these cell lines. In an in vitro experiment, uptake 
of GNPs was greater in MDA-MB-231 cells than in DU 145 or L132 cells, and hence 
radiation enhancement was better in MDA-MB-231 cells.  (6). 
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Intracellular Localization of GNPs: The location of gold nanoparticles inside of the 
cells affects radiation enhancement; for example, a GNP attached to DNA 
(Deoxyribonucleic acid) will likely have a greater impact than a GNP in other 
locations (for example, the local effect model discussed in (25)). Typically, not 
targeted nanoparticles will enter cell via endocytotic pathway and will be trapped in 
endosomal/lysosomal compartments and might exit cell via the exocytosis process. 
The uptake and removal of particles depend on its size, shape and surface 
properties(26). The use of pH Low Insertion Peptides (pHLIP
®
 peptides) to target gold 
nanoparticles to cancer cells (in vitro) resulted in location of GNPs to the plasma and 
nuclear membranes (7, 15) . Ultra-small Au@tiopronin nanoparticles (2 and 6 nm) 
were localized throughout the cytoplasm and nucleus of cancer cells in vitro and in 
vivo, whereas 15 nm nanoparticles were found only in the cytoplasm and were 
aggregated (24). 
The targeting ligands: The targeting ligands enable nanoparticles to bind to cell 
surface receptors and enter the cells by receptor mediated endocytosis (18). 
Nanoparticles accumulate at the tumor sites due to leaky, immature vasculature due to 
enhanced permeability and retention effect (8, 13, 16). Chattopadhyay et al. (27) 
discusses the molecular targeting approach, which enables a larger amount of GNPs to 
cross the cellular membrane and accumulate in the cancer cell cytoplasm. The 
experimental result showed that the GNPs modified with trastuzumab for targeting 
HER-2 on breast cancer cells with 100kVp x-rays were more effective in decreasing 
the clonogenic cells survival as compared to the non-targeted GNPs (27). Kong et al. 
(28) found that the local concentration of GNPs in target locations can be increased by 
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localized delivery in comparison to the naked GNPs. 15nm GNPs with 
AET(cysteamine) were bound to the cell membrane when treated with MCF-7 cells 
whereas 15nm GNPs with Glu were distributed in the cytoplasm when treated with 
MCF-7 cells. More GNPs were taken up or bound to MCF-7 cells in case of Glu-
GNPs and AET-GNPs than the naked GNPs. With the combined effect of 200kVp, 
10Gy x-rays Glu-GNPs produced decreased cell survival compared to AET- GNPs 
(28) . Su et al. (16) used cyclic RGD conjugated with GNP,  labeled with Iodine-125 
as a radiosensitizer, for tumor targeting and enhanced radio-therapeutic efficacy. The 
results depicted consistent apoptosis and the volume loss, indicating effective 
suppression of tumor growth due to radiation therapy on the radio-labeled targeting 
ligand on GNPs compared to non targeted GNPs. 
Biocompatibility of GNPs: Coating gold nanoparticles with polyethylene glycol (PEG) 
or bovine serum albumin (BSA) can increase the likelihood of each nanoparticle 
reaching the tumor, since chemically modifying the GNPs by organic molecules such 
as PEG or BSA  helps GNPs to avoid reticuloendothelial system uptake and  to 
increase circulation time in blood (3, 8). BSA capped GNPs are easy to synthesize, 
resulting in uniform size and stability under physiological conditions (8). A non-
exhaustive list of similar or related methods includes the following: 
 Kim et al.(29) found that PEG-coated GNPs had a much longer blood 
circulation time (>4 h) than non-PEG-coated GNPs. 
 PEG coated GNPs can accumulate in mouse sarcoma flank tumors to 
concentration 10 times that of muscle and 50 times that of brain (12). 
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 Puvanakrishnan et al. (23) investigated the effect of PEG-coated gold 
nanoshells and gold nanorods, and its tumor targeting efficiency on mice with 
a subcutaneous tumor. Mice received an IV injection of single and multiple 
doses of gold nanoshells and gold nanorods. The uptake of nanoshells and 
nanorods in the tumor was seen to increase for the multiple doses compared to 
the single dose. The particle accumulation in tumors for three consecutive 
doses was increased by 2 for gold nanoshells and 2.45 for nanorods, compared 
to the single dose. Similarly for five consecutive doses the particle 
accumulation in tumors was increased by 3 fold for nanoshell GNPs and by 1.6 
fold for nanorod GNPs, in comparison to the single dose. The uptake of 
smaller PEG-coated gold nanorods was 12 times more compared to the uptake 
of larger PEG-coated gold nanoshells in the tumor after 24 hours. The results 
from this study suggest that multiple dosing might be an effective method to 
increase GNPs accumulation in tumors.  
Method of Administration of GNPs to Animals: Direct injection of GNPs by 
intra-tumoral administration can aid tumor uptake (15). Intravenous 
administration of gold nanoparticles still results in relatively large 
accumulation in tumor tissue, due to the enhanced permeability and retention 
effect discussed above, which is related to leaky vasculature within tumors (see 
for example (14)). 
Radiation energy (for photon irradiation): Dose enhancement caused by GNPs has 
been observed in kilovoltage and megavoltage beams (6, 10, 20). However, enhanced 
cell killing was monitored when cells and GNPs were irradiated with photons in the 
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kilovoltage range (9, 11, 30-32). Hainfeld et al. 2008(3) found that dose enhancement 
factor depends on both radiation energy and the amount of GNPs.  
The relative success of lower energy photons is likely due in part to the fact that, in 
general, lower energy photons have a higher absorption probability in gold than higher 
energy photons (4). However, lower energy photons also come with the complicating 
factor that they are less penetrating, and may not be able to reach tumors deeper than 
skin depth. For most clinical purpose MeV photons are used due to the fact that for 
high energy photons , the energy is distributed over a wide range in soft tissue (9). 
Chang et al. (31) used 6MeV electrons to irradiate a 1-inch diameter tumor region of 
the leg of the mouse model. Chitrani et al.(10) used low energy kVp and high energy 
MVp for irradiating cells. The results showed that greater radiation sensitization was 
seen for kVp compared to MVp for the cell experiments. Further it was evidently 
found for the first time that radiation sensitization was enhanced even at the clinically 
relevant high X-ray energy of 6MVp. Also Jain et al.(6) showed a radiosensitization 
effect on cells at MV X-ray energies as well  as at kV energies. The MDA-MB-231 
cells were seen to be radiosensitized at MV X-ray energies. Popovtzer et al.(33) 
showed a radiosensitization effect when cetuximab coated GNPs were used for tumor 
targeting in a clinically relevant radiation treatment of 6MV energy. The results 
showed that there was no increase in tumor diameter at all for CTX-GNP+RT 
compared to 1.0cm increase in tumor diameter for the control case. 
If the mechanism of cancer destruction is primarily Auger electrons after the 
photoelectric effect, an intriguing photon energy to use would be an energy just above 
the k-shell energy of gold, 80.7 keV (see for example, the X-Ray Attenuation 
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Database from the National Institute of Standards and Technology). Most interactions 
would occur with the k-shell electrons, and a photon energy just above the k-shell 
energy would take advantage of two factors: (1) the photoelectron released would be 
of low energy, and thus would be localized like the Auger electrons; (2) the 
photoelectric effect has a sharp spike in absorption coefficient at each shell energy, 
including the k-shell energy. 
Radiation dose: Increasing the radiation dose from 30 Gy to 35 Gy increases the 
survival rate of the mice for the same KeV energy of 100 kVp x-rays (34). However, 
at some point there must be a radiation dose of maximum effectiveness for a given 
experimental setup, since an extremely high dose of radiation would kill the 
experimental subjects. 
Radiation type:  In most of the experiments with gold nanoparticles photon irradiation 
was used, but experiments have also been done using proton,  electron and LET 
radiation. Kim et al. (35) found an increase in survival in mice treated with protons 
and either gold nanoparticles or magnetic nanoparticles. Chang et al (31) found an 
increase in radiation enhancement from gold nanoparticles using electron radiation. 
Liu et al. (36) found that the survival fraction for HeLa cells when irradiated with high 
LET carbon ions was significantly less than when irradiated with low LET X-rays. 
 
In vivo radiation enhancement results for non-targeted gold nanoparticles 
Although many gold nanoparticle radiation enhancement studies have been done in 
vitro, only a few studies have been performed in vivo. No specific tumor targeting was 
utilized in the studies described in this section.  
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Hainfeld et al.(20):  The pioneer study of use of GNPs as a radiation enhancement was 
done in BALB/C mice bearing subcutaneous EMT-mammary carcinoma. In one 
experiment, the treatment group of mice received 1.9 nm GNPs at a concentration of 
1.35 grams of gold per kg of mouse, injected intravenously into the tail, with 
irradiation started 2 minutes later. The animals received 30 Gy of radiation from a 250 
kVp x-ray machine. These mice survived with only 1 of 10 mice having a visible 
tumor after 1 month, compared to no retardation of tumor growth for mice receiving 
only x-rays or gold. 
In a second experiment, 50% of mice survived for one year after being given 1.35 
grams of gold per kg of mouse and 26 Gy of radiation. In contrast, 86% of mice 
survived after being given 2.7 grams of gold per kg of mouse. 20% of mice survived 
with just radiation, and 0% of mice survived with just gold or with no treatment. 
Other results showed that after injection of GNPs, many blood vessels became visible 
due to the gold absorption. Pharmacokinetics showed an early rapid rise followed by a 
slower clearance rate. Gold in tumor peaked at 7.0 ± 1.6 min and fell to half of its peak 
value at 41.2 ± 19.5 min; gold in muscle peaked at 5.3 ± 0.6 min and fell to half at 
24.2 ± 2.6 min. The data showed that the GNPs cleared nearly twice as fast from 
normal muscle as from tumor. The injected gold solution was dark black/brown and at 
the periphery of some tumors was similarly dark. These tumor periphery results 
showed almost twice the gold concentration of the main tumor mass. The periphery of 
one tumor contained 6.5 mg Au/g, with a tumor to normal tissue ratio of 8.6. This 
leads to the fact that a targeting molecule, such as an antibody or peptide, attached to 
the gold nanoparticle would further improve the tumor specificity and distribution of 
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GNPs within a tumor. The GNPs were shown to be non-toxic to the mice, based on 
preliminary toxicity testing. 
 
  Hainfeld et al.(37): In this study, Hainfeld et al. tested the effects of radiation dose, 
radiation energy and a preheating strategy. C3H/HeJ mice were given subcutaneous 
highly radiation resistant SCCVII head and neck squamous cell carcinoma. 1.9 nm 
GNPs were found to be more effective at 42 Gy than at 30 Gy for the same radiation 
energy (68 keV median energy photons). GNPs were also found to be more effective 
when used at 68 keV than at 157 keV for the same radiation dose (42 Gy). Further, 
GNPs were found to be more effective at 50.6 Gy, 157 keV than at 44 Gy, 157 keV. 
The effect of preheating the mice was also investigated. Mice were preheated for 12-
17 mins by submerging the legs of anesthetized mice containing tumor in 44
o
C water 
bath. GNPs were then injected (1.9 g/kg body weight) and the mice were heated again 
for 3 mins, and then irradiated a minute later with 30 Gy, 68 keV. As a result it was 
seen that the GNPs enhanced the synergy of hyperthermia and radiation therapy at 
sufficiently high radiation doses (30 Gy, compared to 15 and 23 Gy). The 
experimental results showed that there was not any damage in the leg of mice and that 
the tumor doubling time was 52 days for heat + radiation  + gold compared to 45 days 
for radiation alone. The surviving fraction was 79% for heat + radiation + gold 
compared to 14% for radiation alone.   
Hainfeld et al.(34): In this study, Hainfeld et al. treated brain cancer in mice using 
gold nanoparticles. 50% long-term survival (>1 year) was found using B6C3f1 mice 
bearing Tu-2449 brain tumors. Irradiation (100 kVp x-rays, 30 Gy) occurred 15 hours 
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after injection of 11 nm GNPs at a concentration of 4 grams of gold per kg of mouse. 
0% long-term survival was found for mice given no treatment, GNPs only and 
radiation only. 
Similarly, for a slightly higher radiation dose of 35 Gy, 56% long-term survival was 
found compared to 0% survival of mice with no treatment and 18% long-term survival 
for radiation only. 
Further results showed that IV injected GNPs specifically localized in brain glioma in 
a 19:1 tumor to normal brain ratio. The micro CT measured by the tumor uptake of 1.5 
± 0.2% (weight by weight) gold, which was considered to be the highest gold 
concentration ever achieved in tumor by IV injection. Atomic absorption spectroscopy 
measured the uptake to be 1.5 ± 0.2% (weight by weight) gold. The GNPs were 
initially distributed throughout the tumor, very different from the subcutaneous tumors 
where GNPs of 15 nm were largely confined to the tumor periphery. The amount of 
gold delivered was high enough to multiply a radiotherapy dose of tumor by a 
calculated factor of approximately 300%. Hainfeld predicts this is an indication of 
difference in tumor and vasculature growth pattern, perhaps indicating the brain tumor 
cells are more migratory, thus not severely compressing central blood vessels limiting 
internal blood flow. No toxicity was seen for the concentration of gold used in this 
study. 
Chang et al.(31): Chang et al. used electron radiation with gold nanoparticles. 
C57BL/6 mice with B16F10 melanoma were injected (IV) with 13 nm GNP at a 
concentration of 1 gram gold per kg of mouse. 24 hours later, 25 gray of 6 MeV 
electron radiation was given using a Varian 2100C linear accelerator. 
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The results showed a retarded tumor growth and increase in survival of mice receiving 
GNPs followed by radiation compared to the radiation alone, GNPs alone and control 
groups of mice. Survival of mice treated with gold nanoparticles and radiation was 
60% after 2 months, whereas survival was less than 20% for radiation treatment alone 
and 0% for gold nanoparticles alone or no treatment.  
Biodistribution of GNPs 24 hours post IV injection of GNPs showed the accumulation 
of GNPs inside the tumor, with a tumor to tumor surrounding muscle gold ratio of 
6.4:1. Also, higher concentrations of GNPs were found in the liver and spleen, 
indicating uptake of gold by the reticuloendothelial system.  
 The number of apoptotic cells detected in tumor by a TUNEL assay was significantly 
higher in mice treated with GNPs followed by radiation than in mice receiving only 
radiation, GNPs alone and control groups.   
Compared to Hainfeld et al.(20), fewer GNPs were injected IV into the mice in Chang 
et al. 2008  (31)  (2.7 g Au/kg versus 1 g Au/kg). Additionally, the irradiation was 
done 24 hours after injection, versus 2 minutes after injection in Hainfeld et al. 
(2004)(20). 
Bobyk et al.(38): Bobyk et al. studied the effect of gold nanoparticles and radiation in 
rats with brain tumors. Male Fischer rats bearing F 98 glioma cells were 
intracerebrally injected by 5 microliters of 15 nm GNP (25 mg/mL or 50 mg/mL) 20 
minutes before irradiation using 88 keV x-rays with a dose of 15 Gy.  
The untreated groups of rats had a mean survival time of 23.8 ± 1.6 days and the rats 
receiving GNPs alone had a mean survival time of 24.9 ± 0.8 days and 23.3 ± 0.7 days 
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for 25 mg/mL and 50 mg/mL. This suggests that the GNPs alone did not improve the 
animal life span. 
The group of rats that received radiation alone had a mean survival time of 33 ± 2.7 
days, an increase of 38.8%. The group of rats receiving GNPs and x-rays had mean 
survival times of 34.9 ± 1.7 days (25 mg/mL) and 41.6 ± 3.2 days (50 mg/mL). Thus, 
the higher concentration of GNPs, combined with radiation, showed a 74% increase in 
mean survival time. TEM results showed that GNPs are trapped by endosomes before 
being fused with lysosomes in vitro.  In vivo results also showed the internalization of 
15 nm GNPs by the endosomal pathway in cells on brain tissue biopsies but GNPs 
were not observed in the mitochondria, Golgi complex or nucleus. Additionally, 15 
nm GNPs were observed in the healthy and tumor brain tissues by electron 
microscopy at all time points, up to 6 days after GNP injection. The clinical signs of 
toxicity was not seen during the observation period on any mice which received the 
lowest concentrations of GNPs. At the same concentration of GNPs for different sizes 
the smaller ones are found to be more toxic than the larger ones in vivo. 
Joh et al.(39) coated 12 nm gold cores by PEG (polyethylene glycol) to make GNPs of 
hydrodynamic diameter of 23 nm. These GNPs were injected intravenously in female 
athymic mice bearing the most prevalent and aggressive primary brain tumor U 251. 
48 hours post injection of pegylated GNPs (1.25 grams of gold per kg of mouse), the 
brain of the mice was given a radiation dose of 20 Gy from a 175 kVp small animal 
radiation research platform. The combined treatment of GNPs and radiation therapy 
increased the DNA damage to brain blood vessels in vivo, resulting in increased 
survival of mice and delayed tumor growth. Joh et al. interpret these results as 
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suggesting that radiation-induced blood brain barrier disruption can be leveraged to 
improve the tumor-tissue targeting of GNPs, which would further optimize the 
radiation enhancement of brain tumors by GNPs. The GNP toxicity in vivo was very 
small in this study, as shown by the preliminary data. 
Zhang et al.(22) studied size-dependent radiation enhancement using PEG-coated 
GNPs. PEG-coated GNPs of sizes 4.8, 12.1, 27.3 and 46.6 nm (concentration 4 mg of 
gold per kg of mouse) were injected intraperitoneally to female BALB/C mice bearing 
U14 tumors. The tumors were then irradiated by 5 Gy of gamma radiation. Mice were 
sacrificed after 24 days. The results indicated that all sizes of PEG-coated GNPs 
decreased the tumor volume and weight after 5 Gy of radiation, but 12.1 and 27.3 nm 
PEG coated GNPs induced appreciable decreases of tumor volume and weight, 
indicating that these sizes of particles have greater radiation enhancement effects 
compared to 4.8 and 46.6 nm particles. The toxicity in vivo was appreciably less on 
the basis of immune response and blood biochemistry. However the liver was slightly 
damaged. Also it was found that the GSH-protected GNPs had efficient clearance 
through the kidney. 
Kim et al.(35): Kim et al. studied the effects of proton radiation combined with gold 
and iron nanoparticles in mice. Gold nanoparticles (coated with DTPA, 
diethylenetriamine pentaacetic acid-cysteine conjugate) or iron nanoparticles (coated 
with alginate) of sizes 14 ± 1.2 nm and 10.6 ± 0.8 nm respectively were injected 
intravenously to Balb/c mice with CT26 tumors either on their leg or flank. The 
injected dose of particles was either 100 or 300 mg of metal per kg mouse. 24 hours 
after injection, proton irradiation was given with radiation doses of 10-41 gray. Two 
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different strategies of proton radiation were employed: protons that were absorbed in 
the mouse (with the Bragg peak located on the tumor) and protons that traversed 
through the mouse. 
The results for tumor uptake showed that 15 minutes after injection of particles the 
tumor concentration was 137.4 ± 50.2 micrograms of gold per gram of tissue or 56.6 ± 
18.2 micrograms of iron per gram of tissue, while the corresponding muscle 
concentration were 7.5 micrograms of gold per gram and 6.5 micrograms of iron per 
gram tissue. The tumor to normal tissue ratio was 18.3 for gold and 8.7 for iron after 
15 minutes; after 24 hours it was 169.7 for gold and 88 for iron, thus enabling 
enhanced tumor dose deposition. The ratio of tissue uptake to total injected dose was 
less than 1% after administration of both 100 and 300 mg of metal per kg of mouse. 
 
In the irradiation experiment, mice receiving a gold or iron nanoparticle injection prior 
to various doses from the proton beam demonstrated 58% (absorbed protons) or 64-
100% (traversing protons) long-term survival. All animals that were not given 
radiation died in 2-4 weeks. All proton radiation alone groups showed slowed tumor 
growth and resulted in only 13% (absorbed protons) or 11% (traversing protons) long-
term remissions. 
Complete tumor regression (CTR) in mice showed a direct dependence on proton and 
nanoparticle doses. Either 45 Gy proton alone or 21 Gy irradiation with 300 mg/kg 
magnetic nanoparticles injections produced 100% CTR in mice. In vitro experiments 
showed an increase in the generation of reactive oxygen species from the metallic 
nanoparticle and proton radiation treatment. Gold nanoparticles had greater tumor 
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uptake and a more rapid clearance for normal tissue compared with iron nanoparticles, 
due to different surface coatings. 
Chen et al.(8): Chen et al. exploits the potential of BSA capped GNPs as an efficient 
sensitizer for glioblastoma, both in vitro and in vivo, on radiotherapy. Clonogenic 
assay was  performed  on U87 glioblastoma cells with or without BSA - GNPs of 
28nm hydrodynamic diameter with a series of doses in between 0-8 Gy at 160kVp X- 
ray. Also 250uL of, 1.3mg mL
-1
 BSA-GNPs was injected intravenously to the mice 
model having U87 glioblastoma tumor of diameter 0.8-1cm. The mice were then 
irradiated by 160kVp X rays with a dose of 3Gy after 2hr and  2Gy after 24 hr of 
treatment. The tumor volume was calculated every alternate day .All the mice were 
euthanized after 20 days of the treatment and the tumors were weighted. 
 
The in vitro RT showed that the percentage of cell apoptosis was larger for BSA-
GNPs + RT followed by RT alone then BSA-GNPs and the minimum percentage of 
apoptosis was for the control group. The in vivo RT showed that the relative tumor 
volume after 20 days of treatment was maximum for the control group and minimum 
for BSA-GNP + RT. The data obtained inferred that BSA-GNP + RT showed 
maximum tumor regression while X ray alone slowed down the tumor growth while 
BSA-GNP alone didn’t affect tumor growth compared to control group of mice. 
 
The weight of tumor for 4 different cases were in accordance with the results obtained 
for relative tumor volume, meaning that the weight of tumor was minimum for BSA-
GNP-RT and maximum for the control group. There was rapid clearance of GNP level 
 53 
 
from the mice after the administration of BSA-GNPs and the in vivo toxicity of BSA-
GNPs was determined by ICP-AES analysis of GNP level after the treatment of BSA-
GNPs. This analysis showed no toxicity. 
 
Nanoparticle Targeting: 
Successful targeting increases the likelihood that each gold nanoparticle will reach the 
tumor. Thus, there is the potential for targeted gold nanoparticles to improve the 
radiation enhancement effect. This is particularly true when the primary benefit from 
gold nanoparticles comes from Auger electrons, which have a short range, as 
discussed in the introduction. In addition to locating gold nanoparticles to cells, the 
resulting intercellular localization is also important, as discussed above. Targeting 
strategies can be divided into two categories: those that use cancer-targeting 
molecules, and other methods that do not. 
Cancer cell targeting molecules: 
 More specific tumor targeting can be done by surface conjugation (attachment) of 
antibodies, peptides and other tumor targeting molecules (12). This can improve the 
therapeutic index (16, 40). Conjugating gold nanoparticles with targeting molecules 
enhances the interaction of the GNPs with the cell surface by enabling the GNPs to 
bind to the cell surface receptors and enter cells by receptor-mediated endocytosis 
(18). A non-exhaustive list of targeting molecules used with gold nanoparticles (either 
in vitro or in vivo) includes the following strategies: 
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 Glucose capped GNPs are designed to take advantage of an increased 
cancer cell requirement for glucose in order to target the cell cytoplasm 
(28). 
 pH-Low Insertion Peptide (pHLIP® peptide) conjugated 1.4 nm GNPs 
target tumor acidity, which is achieved  in a result of membrane-associated 
folding of pHLIP
®
 peptide . Peptides of the pHLIP® family can tether 
cargo nanoparticles to the surface of cells in diseased tissues, and it can 
move cell-impermeable cargo molecules across the membrane into the 
cytoplasm (41-43). pHLIP
®
 peptide has been shown to increase uptake of 
gold by a factor of approximately 5-10 in mouse tumors (15). 
 Antibodies such as trastuzumab have been successfully used to modify 
GNPs. Trastuzumab conjugated GNPs has been used for targeting MDA-
MB-361 tumors in athymic mice, and combined with x-rays the tumors 
were reduced to half of their volume at 4 months compared with the 
treatment by x-rays alone (27). 
 GNPs functionalized with RGD peptide (Arg-Gly-Asp), NLS (Nuclear 
Localization signal) peptide (H-Cys-Gly-Gly-Arg-Lys-Lys-Arg-Arg-Gln-
Arg-Arg-Arg-Ala-Pro-OH) and pentapeptide (H-Cys-Ala-Leu-Asn-Asn-
OH) were shown to enhance tumor uptake of GNPs (26). 
 The conjugation of RGD  peptides to radiolabeled GNPs produced 
biocompatible and stable multimeric systems with target-specific molecular 
recognition. The properties listed below which are demonstrated by 
177
Lu-
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GNP-RGD compared to the other radiopharmaceuticals make it suitable to 
be used as a molecular targeting radiotherapy agent.  
177
Lu-GNP-RGD 
leads to significant reduction in VEGF gene expression, helps to reduce 
tumor metabolic activity, induces less tumor progression, fewer 
intratumoral vessel, yields more uptake and retention in tumor (44). 
 Choi et al.(45) modified the surface of 50 nm GNPs with PEG and 
transferrin (a tumor targeting ligand) to make particles of size 80 nm. 
4.5x10
11
 particles were injected IV to female A/J mice containing 
subcutaneous Neuro2A tumors, and all organs were collected after 24 
hours.  The results showed that the GNP localizations within a particular 
organ are influenced by the transferrin content whereas the nanoparticle 
accumulations in the tumors and other organs are independent of 
transferrin.  
 Shah et al.(46) found that 30 nm PEG-coated GNPs interact with blood 
cells in vivo, which results in longer blood circulation that correlates 
strongly with tumor uptake. In tumors, accumulation was increased by 10 
times using GNPs conjugated with a bioactive ligand (tumor necrosis 
factor) compared to untargeted GNPs. 
 
In vivo radiation enhancement results for targeted gold nanoparticles 
To the author’s knowledge, there  are only  a few papers currently existing where 
targeted gold nanoparticles are used to enhance radiation effects on tumor in vivo.  
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Chattopadhyay et al.(27) used 30 nm GNPs conjugated with monoclonal antibody 
transtuzumab (AuT) to target the human epidermal growth factor receptor-2 (HER-2). 
Female athymic CD1nu/nu mice bearing MDA-MB-361 cells were intra-tumorally 
injected with 4.8 mg/g of AuT (0.8 mg of GNPs per gram of mouse) followed by 11 
Gy, 100 KVp x-rays after 24 hours. They found a 46% reduction in tumor volume at 4 
months as compared to treatment with x-rays alone (16% increase in tumor 
volume).The analysis of the body weight index curves for different mice groups 
revealed no normal tissue toxicity by the use of  Au-Ts with RT. 
Su et al.(16) used 20nm GNPs conjugated with clinically used therapeutic 
radionuclide Iodine-125 labeled to cRGD as a tumor targeted radiosensitizer. IV 
injection of 100uL(containing 1mg Au) was given to Balb/c mice bearing NCI-H446 
lung tumors. Co-60 source, 5Gy γ rays  were used to irradiate the tumor tissues. RT 
effect was assessed by IV injection of Tc-99m-Annexin V (18.5MBq/mouse) after 2 
days of treatment for evaluation of apoptosis induced by radiosensitized RT and 
SPECT performed. 
The degree of apoptosis which is shown in numerical value was measured for 5 
different groups and the results showed that there was a significant difference between 
targeted radiosensitizer based RT (cRGD-GNP-RT) (9.8±2.7) and non-targeted 
radiosensitizer (GNP+RT) based RT (5.5±1.4) (P=0.011). Also, a significant 
difference was seen between radiolabeled (I-125) cRGD-GNP-RT (11.2±2.1) and non-
targeted radiosensitizer based RT (5.5±1.4) (P<0.01). However, a significant 
difference was not seen between the treated and untreated cases between I-125- 
cRGD-GNP-RT (11.2±2.1) and cRGD-GNP-RT(9.8±2.7) (P=0.093). This showed that 
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the radiosensitivity was enhanced by the targeting effect. The above results show that 
I-125 showed the therapeutic effect but the improvement compared to cRGD-GNP-RT 
was not statistically significant. However the proper choice of more effective 
radionuclide like I-131  can heavily enhance of therapeutic effect. 
Also, after 21 days the percentage volume increase  in tumor for different groups of 
mice was also measured and found that it was maximum in control (312.1%±96.9%), 
then in RT alone (137.1%±35.5%), then in GNP+RT(85.5%±44.2%). However the 
increase in tumor volume was suppressed to 33.1%±17.1% for  cRGD-GNP-RTand 
was even less increase (15.2%±17.8%) for the I-125- cRGD-GNP-RT.  
 
Also, the functionalized PEG which was used in this research showed good stability 
and clearance avoiding the uptake by RES. The in vivo toxicity of PEG covered GNPs 
and cRGD-GNPs was found to be low which was verified because there was no 
obvious loss of weight of mice. 
 
Popovtzer et al.(33) used 1 mg of cetuximab(CTX) alone or 200uL; 25mg mL
-1
 Au of 
30nm with Ig G or CTX coating, injected IV into the tail vein of mice having a A431 
head and neck cancer model of diameter 10mm, then irradiated after 24 hrs with 6MV, 
25Gy X-ray. In contrary to the results obtained by Hainfeld et .al  where there was the 
shrinkage of tumor, here the results showed that there was no increase in tumor 
diameter at all for CTX-GNP+RT compared to 1.0cm increase in tumor diameter for 
the control case, 0.4cm for CTX+RT, 0.6 for Ig G-GNP+RT, 0.3cm for RT only and 
0.9cm for  CTX only cases. This shows that the radiation is enhanced by the tumor 
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targeted GNPs. A set of experiments to study the biological mechanism of  
radiosensitized GNPs was done. Decreased vasculatization in tumors was seen after 1 
and 6 weeks of  the treatment in CTX-GNP+RT group than control, RT only and 
CTX+RT groups. Also Tunnel assay results showed that apoptosis was higher after 1 
week and less apoptosis after 6 weeks of treatment in  CTX-GNP+RT group compared 
to RT only group. And other results showed that the level of proliferation and tissue 
repair was reduced in CTX-GNP+RT group compared to other groups.. Further, no 
cytotoxic effect was seen on the mice.  
 
Conclusion 
The papers reviewed in this article demonstrate the potential effectiveness of gold 
nanoparticles in the enhancement of radiation of tumors. Major results and 
methodologies are summarized in Table 1. Future experiments with gold nanoparticles 
and radiotherapy will likely involve the following areas: trials in humans, experiments 
using targeted gold nanoparticles and different radiation energies/types.  
The eventual goal of gold nanoparticle treatments is to become viable for use in 
humans. One potential roadblock is that treatment with kilo-voltage x-rays is only 
capable of penetrating human tissue to a shallow depth. Perhaps trials using this 
treatment could be done starting with melanoma or other tumors, which could be 
accessed via catheterization, and future advances in engineering could help to 
eliminate this roadblock. 
The roadblock mentioned in the paragraph above may also inspire more work with 
different radiation energies and radiation types. For example, the result of Kim et al. 
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(35) with protons seems particularly promising. Additionally, in vitro studies (6, 10) 
have shown radiation enhancement with gold nanoparticles and higher energy 
photons, although the enhancement is generally somewhat less than kilo-voltage 
photon results. 
Regardless of the radiation type, it appears that tumor targeting will be of great use in 
this type of therapy. To conclude, we can say that GNPs modified with tumor 
targeting agents as pHLIP, cetuximab, cRGD and trastuzumab successfully enhanced 
the radio sensitization of GNPs which can lead to more effective  clinical radiotherapy 
with less toxicity in near future(7, 16, 27, 33). Additional trials with other targeting 
methods would be beneficial and important.  
In summary, gold nanoparticles are a promising research area with the potential to 
reduce the amount of radiation necessary in cancer treatments. Successful 
experimental work has already been done in this area, including work in mammals. 
More work is needed, and this future work has the potential of pushing the field into 
clinical relevance.  
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Table 1: Summary of major in vivo experimental results 
 
 
 
First author Year
Animal 
model
Tumor model
Coating 
of GNPs
Size  
GN
Ps, 
nm
Time to 
RT
Radiation
Dos
e, 
Gy
Group
Route and Dose 
of 
Administration
Control            
RT only   
Au+RT   
cRGD+Au+RT 
125I+cRGD+A
u+RT
IV injection 
100µL 1mgAu 
50mg/kg
Ig G CTX X-rays 6MV
Control            
RT only        
CTX only 
CTX+RT          
IgG-Au+RT        
CTX-Au+RT 
IV injection 
200µL;25mg/mL
24 h
proton 
45MeV
10     
41
Control            
Au only            
RT only            
Fe only     
Au+RT      
Fe+RT
IV injection 
100mg/kg 
300mg/kg
2h           
24h
X-rays 
160kVp
3         
2
Control 
BSA+Au RT 
only 
BSA+Au+RT
IV injection   
250µL, 
1.3mg/mL
x-rays    175 
kVp
20
Control            
Au only           
RT only   
Au+RT
IV injection 
1.25gAu/kg
Kim 2012
Balb/c 
mice
CT26: murine 
colon 
carcinoma 
DTPA+ 
cysteine 
FeNPs+algi
nate
14 
10.6
Joh 2013
U251: human 
glioblastoma
PEG 23 48 h
Intracerebral 
infusion (5 
µL)(5µL)  
25mg/mL 
50mg/mL
Hainfeld 2013
B6C3f1 
mice 
11 15 h
x-rays   100 
kVp
30   
35
Control            
Au only           
RT only    
Au+RT
IV injection  
4gAu/kg
Intraperitoneal(I
P) injection 
4mg/kg
Bobyk 2013
Fischer 
rats
F98: rat glioma 
9   
15
20 m
x-rays 
88keV
15
Control            
Au only           
RT only    
Au+RT
Intratumoral 
(IT) injection 
0.8mg Au or 
4.8mg/g tumor
Zhang 2012
Female 
BALB/c 
mice
U14: murine 
cervical 
carcinoma 
PEG
4.8 
6.6 
12.1 
27.3
Γ-rays 5
Control            
Au only           
RT only     
Au+RT
IV injection 
1.9fAu/kg
Chattopadhya
y
2012
CD1 nude 
mice
Trastu-
zumab
30 24 h
x-rays         
100 kVp
11
Control            
Au only           
RT only   
Au+RT
IV injection 
1.35gAu/kg      
2.7g Au/kg
   IV injection 
1gAu/kg 
Hainfeld 2010
C3H/HeJ 
mice
1.9 1 m
x-rays        
68 keV 
157keV
30   
42   
44 
50.6
RT only    
Au+RT
30   
26
Chang 13 24 h 25
Control            
Au only           
RT only    
Au+RT
Control            
Au only           
RT only    
Au+RT
Hainfeld 2004
Balb/C 
mice
2008
C57BL/6 
mice
1.9 2 m
x-rays 
250kVp
4h Γ-rays 5
Popovtzer 2016 Nude mice
A431: 
squamous head 
and neck 
carcinoma
30 24
1.4/
min
Su 2015
Balb/c 
mice
NCI-
H446:human 
lung carcinoma
Iodine-
125+cRGD
20
Chen 2015
Nude 
athymic 
mice
U87:glioblasto
ma
BSA 28
MDA-MB-361: 
human breast 
adenocarcinom
a
soon 
after 
the 
injectio
Tu-2449: 
murine highly 
malignant brain 
tumor
 nude 
female 
athymic 
mice
EMT-6: 
murine 
mammary 
carcinoma 
B16F10: 
murine 
melanoma 
electrons        
6 MeV
SCCVII: head 
and neck 
squamous 
carcinoma 
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Abstract 
 
Biological indicators would be of use in radiation dosimetry in situations where an 
exposed person is not wearing a dosimeter, or when physical dosimeters are 
insufficient to estimate the risk caused by the radiation exposure. In this work, we 
investigate the use of gene expression as a dosimeter. Gene expression analysis was 
done on 15,222 genes of Drosophila melanogaster (fruit flies) at days 2, 10 and 20 
post irradiation, with x-ray exposures of 10, 1000, 5000, 10000 and 20000 roentgens. 
Several genes were identified which could serve as a bio dosimeter in an irradiated 
drosophila melanogaster model. Many of these genes have human homologues. 6 
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genes showed a linear response (R
2
 > 0.9) with dose at all time points. One of these 
genes, Irbp, is a known DNA repair gene and has a human homologue (XRCC6). The 
lowest dose, 10 R, is very low for fruit flies. If the lowest dose is excluded, 13 genes 
showed a linear response with dose at all time points. This includes 5 of 6 genes that 
were linear with all radiation doses included. Of these 13 genes, 4 have human 
homologues and 8 have known functions. The expression of this panel of genes, 
particularly those with human homologues, could potentially be used as the biological 
indicator of radiation exposure in dosimetry applications.  
Keywords: gene expression, radiation biology, radiation dosimetry 
 
Introduction 
 
In the occurrence of a large-scale nuclear event, such as those at Hiroshima, Nagasaki, 
Chernobyl and Fukushima Daiichi, the measurement of radiation dose in exposed 
humans can be of crucial importance to survival (1, 2). However, in this situation it is 
very likely that many people who are exposed will not be wearing dosimeters. Thus, a 
method of estimating radiation dose to a patient without a dosimeter would be a very 
useful procedure.   
One possible methodology for this procedure is the use of gene expression 
[polymerase chain reaction (PCR), gene sequencing, microarray analysis, and other 
methods]. The hypothesis is that the expression of genes will change due to the 
absorbed radiation, and that this change can aid or even substitute for physical 
dosimeters and act as a biomarker to estimate the distributed dose or the overall 
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exposure. It also helps then to predict the long-term risks of both acute and chronic 
exposure (3-6). 
In addition to not requiring equipment, such as a dosimeter, another potential 
advantage of a gene-expression dosimeter is the time scale over which the 
measurements can be made. Even after the radiation exposure has taken place, the 
biological indicators for bio dosimetry can still be determined. This would certainly be 
an advantage compared to the physical dosimetry (7). Some biodosimetric techniques 
could be used long times after exposure (from 6mths to more than 50 years) which 
makes it unique compared to the requirements for methods used for immediate dose 
estimation (8). 
Biological dosimetry not only provides information about the range of radiation dose 
but also along with this provides information about the individual radio sensitivity, 
which depends on age, smoking habits or other environmental toxins. Thus, biological 
indicators are also a measure of the biological, medical radiation damage. Hence, we 
can predict about the possible radiation damage by the determination of biological 
indicators (5, 7, 9, 10). 
The possibility of using gene expression changes has been an exciting method to 
measure and predict the damage due to ionizing radiation. The exposure of cells or 
animals to ionizing radiation may cause DNA damage and trigger the highly complex 
molecular response, resulting in changes of gene expression. These molecular 
responses may provide the prospective indicator of exposure(1, 3). Previous work in 
this area showed that the variation in the response of genes is due to dose, dose rate, 
radiation quality and time after radiation exposure. This suggests that gene expression 
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analysis may be an informative marker of radiation exposure and hence can be used as 
a potential biomarker. It is important to understand the cellular response to ionizing 
radiation or biological effects of radiation exposure in order to develop the predictive 
markers for the risk assessment due to radiation exposure on humans(1). The rigorous 
research going on in genomics and bioinformatics enables the development of gene 
expression profiling as a useful biological indicator of radiation exposure (10, 11).   
Work on this area until now has shown that the fold change in gene expression in 
response to radiation must be measured directly to develop a gene expression 
biomonitor. The expression of the genes would then be a suitable biomarker of 
radiation exposure (6). The biodosimetry platform obtained by the experiment could 
also be used for personalized monitoring of radiotherapy treatments received by 
patients (12). 
Several studies have been done to identify the potential biomarkers of radiation 
exposure. Tucker et al 2013 used reverse transcription real time PCR (qPCR) to 
quantify the expression of selected 106 genes as a function of time up to 7 days post 
exposure and concluded that the gene expression analysis by qPCR shows a promising 
method for radiation bio dosimetry. In their experiment the mice were exposed to C0-
60 gamma rays source at doses from 0 to 10Gy. The result showed that only 4-7 
different genes explained the variance (R
2) ≥ 0.69 whereas for the receiver operator 
characteristics (a measure of sensitivity and specificity) were ≥ 0.93 at each time 
point. At radiation doses up to 6 Gy, the dosimetry was very accurate. Above 6 Gy, 
the gene expression dosimetry had limitation. Similar analysis in humans could be 
done to assess exposures in mass casualty situations (5). 
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Gene expression analysis in response to radiation was done in human lymphocytes and 
peripheral blood leukocytes using three different techniques: microarray, multiplex 
quantitiative real time PCR (MQRT-PCR) and nCounter Analysis System. A set of 
genes was found to be suitable for biological dosimetry using peripheral blood. Four 
of the genes (CDKN1A, GADD45A, PHPT1, and CCNG1) show good agreement 
between the three methods and the up-regulation of expression in blood and 
lymphocytes was detected by all the three techniques. These biomarkers could 
potentially be used for monitoring radiation exposure during radiotherapy and 
radiological incidents (13). 
A novel study was done using blood from patients receiving targeted radiotherapy 
(
131
I-mIBG)  to characterize biomarkers that may be useful for bio dosimetry. As an 
alternative biodosimety approach, real time PCR analysis was done for the gene 
expression and the data showed that transcripts which have already been proven as 
biomarkers of external exposures in radiotherapy patients are also good early 
indicators of internal exposure. Three transcripts showed that modulation in gene 
expression were still significant enough to differentiate between exposed and 
unexposed samples after 96 hrs of radiopharmaceutical treatment.  A bio dosimetry 
model for gene expression was developed to predict absorbed dose based on 
modulation of gene transcripts within whole blood. Thus, this biodosimetry for 
internal radiation dose or the panel of responsive genes obtained from this study could 
be used for establishing triage in affected areas due to dirty bombs or nuclear reactor 
accidents at least by rapidly sorting out the 
131 
I-exposed from unexposed individuals.  
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Thus, these selected genes could be strong biomarkers of both external and internal 
exposures to humans (14). 
A comprehensive analysis of bone marrow endothelial cell (BMEC ) gene expression 
over time in wild type mice after total body irradiation of 5 Gy was done with a 
particular focus on the secreted gene products. This study is done to characterize the 
molecular response of BMECs to ionizing radiation to identify the cellular 
mechanisms and paracrine factors through which BMECs regulate hematopoietic 
regeneration. The result of a microarray experiment showed that the gene expression 
of BMECs is altered within 24 hrs after total body irradiation of 5 Gy and by 14 days 
this molecular response is resolved. And a number of genes that encode secreted 
proteins are strongly upregulated (Inhbb, Ccl2, Ptn) and are down regulated (Chl1, 
Galnt10, Ryk, Pon2, Sdha) more than 10 fold in ECs in response to radiation after 6h 
(15). 
Amundson et al (1999) showed the dose/response relationship for the induction of 5 
genes (CDKN1A, GADD45, MDM2, ATF3 and BAX) exposed to γ rays between the 
doses of 2-50 cGy.  As a follow up, Amundson et al.  (2003) studied the dose response 
relationships by reducing the dose rate over three orders of magnitude and found some 
protection against the induction of apoptosis. They studied the response of 10 cGy and 
less exposure of γ rays in the ML-1 human cell line and showed that the gene 
expression could be triggered by the low doses. At different dose responses between 2 
and 50 cGy, a linear increase in expression of three genes CDKN1A, GADD45A and 
MDM2 was observed in the cell line ML-1, whereas dose rate effect was observed 
only for GADD45A and CDKN1A.The data obtained from the microarray analysis on 
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RNA samples 2 hours post irradiation with low dose y rays indicate that some genes 
show a dose rate effect while others don’t. This indicates the potential usefulness of 
gene expression as a biomarker for radiation exposure (4). 
Stassen et al. (2003) examined 1176 genes expressed by MCF-7 human mammary 
carcinoma cells exposed to 2 and 6 Gy of X rays and found that six of them were 
radiation induced gene targets over 1(3 genes), 2(2 genes) and 3(1 gene) days which 
was confirmed by quantitative reverse transcription PCR  (RTQ-PCR). Of those six 
(GLUT-1, PCKI, WAF-1, ISGF3G, MRP8, PSME3) the last three were novel gene 
targets showing a correlation with radiation dose and clonogenicity which suggested 
an individual dose dependency for all selected genes (16). 
Omaruddin et al. (2013) examined the gene expression of the genes MADH7, SEC 
PRO and CC3 using relative quantitative RT – PCR in blood samples of patients 
before and after undergoing radiation therapy. This gave a wide range of values, 
stating the complexity of the response. SEC PRO was found to be down-regulated, 
while the gene MADH7 was found to be up-regulated in most of the patients. So the 
gene MADH7 could be used as a molecular marker for radiation exposure (6). 
 Filiano et al. (2011) performed gene expression analysis using real time quantitative 
PCR in blood samples from cancer patients undergoing total body irradiation.  A set of 
eight biodosimetry genes (ACTA2, BBC3, CCNG1, CDKN1A, GADD45A, MDK, 
SERPINE1, TNFRSF10B) was identified. In addition, gene expression analysis was 
done in C57BL/6 mice at doses 0-8 Gy and times 5, 12, 23 and 48 hours after 
irradiation. The results showed a significant increase in the expression of five of the 
above genes (BBC3, CCNG1, CDKN1A, SERPINE1 and TNFRSF10B) (10).  
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This article focuses on gene expression analysis of Drosophila melanogaster (fruit 
flies). Compared to humans, biodosimetry information can be obtained in a more 
controlled manner in animal models because the dose received in humans are usually 
not known, the exposures may be non uniform and the dose rates may not be known. 
Data collection may not be reliable and uniform post irradiation because a lot of 
variables have to be taken into consideration like age, health, sex, genotype,  time 
since exposure to radiation, personal lifestyle like cigarette smoking, tobacco and 
alcohol habits (5, 17). Drosophila melanogaster is a model organism with a useful 
lifespan (  ̴ 2 months) and a long history in radiation experiments. Its genome has been 
sequenced, and many genes in Drosophila are homologous with human genes (18, 19).  
This article makes use of a previous gene expression analysis done by Antosh et al. 
(2014). The experiment was performed in order to discover the biological effects at 
different levels of ionizing radiation in D.  melanogaster. The results showed a 
threshold effect in response to the radiation, both in gene expression and in survival. 
The gene expression results suggest stress, metabolism, reproduction and 
mitochondrial function as mechanisms involved in the radiation response (20). The 
data was taken for five radiation doses (plus a control), at 3 time points. The setup of 
this data allows it to be repurposed for a new analysis that examines the response of 
genes as a function of radiation dose. 
The aim of this study is to secure a set of genes that are responsive to radiation in a 
predictable way. These genes, particularly if homologous to human genes, have 
potential uses in radiation dosimetry. 
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Methodology 
 
The data used in this paper is obtained from data submitted to the gene expression 
omnibus by Antosh et al (posted under the reference number GSE47999). Normalized 
data was calculated using the DESeq (21) package in Bioconductor (22).  
The data was obtained from an RNA-sequencing gene expression experiment on 
drosophila melanogaster. at ages 2, 10 and 20 days after irradiating them Flies were 
irradiated with x-ray exposures of 0, 10, 1000, 5000, 10000 and 20000 roentgen (a 1 
roentgen radiation exposure  is ≈ 0.01 gray; here we will use the terms “exposure” and 
“dose” equivalently). The irradiation came inside a chamber containing cesium-137. 
Samples were taken at 2, 10 and 20 days after irradiation, with 3 samples per 
experimental condition (except for sample for 0R, Day 20, where one sample failed 
quality check).  Our re-analysis of this data was done to identify the genes that 
changed in a predictable way from control, as a function of dose. Genes that behave in 
a predictable way could potentially be used in a future bio dosimeter. 
The fold changes in the expression of genes depending on dose and time after 
exposure were measured in the fruit fly model. To calculate the fold change, average 
value of the gene expression of the samples at each time point and radiation dose was 
divided by the average value of gene expression of control at the same time point 
(control being zero added radiation). Fold changes were ignored (in a present/absent 
cutoff) if the average expression in both experimental and control samples was less 
than a bottom quartile cutoff ( ~18-20 counts).  
One analysis performed was based on linear regression. For each time point, the R
2 
value for a linear fit to (fold change vs. radiation dose) was calculated for each gene. 
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Genes with R
2
>0.9 were selected as behaving linearly. In a secondary analysis, the 
data for 10 R flies was removed (since this is a very small dose of radiation for fruit 
flies). The linear analysis described above was run again. In both of these analyses, 
genes were only selected as linear if at least four radiation doses passed the 
present/absent cutoff (described in the paragraph immediately before this). 
As an additional analysis, gene expression data was examined for “spikes” in fold 
change. For each gene, at each time point, a set of fold changes was examined (one 
fold change for each radiation dose). Genes were marked as having a spike if the 
largest fold change was at least five times greater than the second largest fold change. 
Additionally, genes were only counted as having a spike if the fold change of the spike 
was > 1 (meaning that the average expression at the spike dose was greater than 
average gene expression in the corresponding control). 
For each time point, and for overlaps between time points, genes found to be 
significant (meaning, linear or spiking) were analyzed as a group using GOStat (23) to 
see if any biological functions were had a statistically significant amount of genes in 
the group. Gene ontologies with a corrected p value < 0.05 were selected. 
Genes were examined for human homologues using homologene (19) and functional 
information was found using flybase (18). 
 
Results 
Analysis of Linear Behavior with Full Dataset 
Figure 1 shows the number of genes with a linear response in fold change as a 
function of radiation dose, at each of the three time points (2, 10 and 20 days 
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postirradiation). Seventy-eight genes showed a linear response at day 2 after 
irradiation; 677 genes showed a linear response at day 10 after irradiation; 432 genes 
showed linear response at day 20 after irradiation. A set of 6 genes (FBgn0011774, 
FBgn0030189, FBgn0031713, FBgn0032393, FBgn0037020, and FBgn0051864) was 
found to have a linear response in all time points. Table 1 shows the set of those 6 
genes, including homology to human genes (19) and functional information (18). 4 out 
of these 6 genes have homologues in humans. Genes found to behave linearly across a 
fairly wide range of times are perhaps most promising for a possible radiation 
dosimeter. The median lifespan of control flies in this experiment was    ̴50 days; our 
time range here is 18 days. 
A GOStat analysis (23) was run on genes found to be linear at each time point, and 
also separately on overlaps between time points. Full lists of significant gene 
ontologies from the analysis can be found in Supplemental Table S1A-1G. Several of 
the results suggest that the genes that behave linearly are involved in stress responses. 
At 2 days postirradiation, 78 genes show linear behavior with dose. These 78 genes 
contain 13 out of the 23 genes related to protein kinase CK2 regulator activity (a p 
value of 2.2X10
-24
). The protein kinase CK2 inhibits apoptosis following ionizing 
radiation (24). Gene ontologies for spermatogenesis and reproduction are also affected 
2 days postirradiation. Genes found to be linear at 10 days postirradiation were 
statistically over representative of gene ontologies for oxidoreductase activity (a 
possible response to radiation damage) and growth factor activity. At 20 days 
postirradiation, overrepresented gene ontologies included stress-related pathways such 
as response to stress, receptor activity, signal transducer activity, detection of 
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bacterium and biotic stimulus and response to DNA damage stimulus. In the genes 
found in the overlap of day 2 and day 10, overrepresented gene ontologies included 
peroxisomal transport and NADPH activity. In the genes found in the overlap of day 2 
and day 20, overrepresented gene ontologies included several pathways related to the 
peroxisome, DNA helicase activity, response to hypoxia and telomere maintenance. 
The overlap between genes in days 10 and 20 found the gene ontology for stress 
response to be overrepresented. Gene ontologies overrepresented in genes found to be 
linear at all three time points (2, 10 and 20 days) included peroxisome, DNA helicase 
activity, ATPase activity and telomere maintenance.  
 
Analysis of Linear Behavior with Lowest Dose Not Included 
In the lifespan experiment that accompanied this dataset (20), lifespan effects on fruit 
flies were not seen until a radiation exposure of 10,000 roentgen (an approximate 
radiation dose of 100 Gy). The smallest dose in this analysis is 10 roentgen, which is 
0.1% of that dose. It is possible that the 10 roentgen dose in this experiment may 
produce some gene expression at the level of noise. To address that possibility, a 
secondary analysis for linear behavior was run where the data from 10 roentgen were 
not included. The results are summarized in figure 2. In this analysis, 13 genes are 
found to be linear at all three time points. This list includes 5 of the 6 genes found to 
behave linearly at all three data points when the 10 R data was included in the analysis 
(Table 1). The 6
th
 gene, FBgn0031713, was excluded only because R
2
 = 0.88 at day 
20. The 13 genes in the overlap are described in Table 2. Of these 13 genes, 4 have 
human homologues.  
 80 
 
A GOStat analysis (23) was run on genes found to be linear at each time point, and 
also separately on overlaps between time points. Full lists of significant gene 
ontologies from the analysis can be found in Supplemental Table 2A-2G. As with the 
analysis with all radiation doses, several of the results suggest that the genes that 
behave linearly are involved in stress responses.  
At 2 days postirradiation, overrepresented gene ontologies include protein kinase CK2 
regulator activity and spermatogenesis. Genes found to be linear at 10 days 
postirradiation were statistically over representative of gene ontologies for 
oxidoreductase activity (a possible response to radiation damage), growth factor 
activity, GTPase activity, hydrolase activity, electron carrier activity and pathways 
related to peroxisomes. At 20 days postirradiation, overrepresented gene ontologies 
included detection of biotic stimulus and bacterium and metabolism of toxins, 
xenobiotics, insecticide and water-soluble vitamins. In the genes found in the overlap 
of day 2 and day 20, overrepresented gene ontologies included peroxisomal transport, 
NADPH regeneration, telomere maintenance, DNA helicase activity, transferase 
activity and ATPase activity. The overlap between genes in days 10 and 20 found 
several gene ontologies related to peroxisomes to be overrepresented. Gene ontologies 
overrepresented in genes found to be linear at all three time points (2, 10 and 20 days) 
included pathways related to peroxisomes, telomere maintenance and Wnt signaling. 
No gene ontologies were significantly overrepresented in the overlap between genes 
linear at day 2 and day 10 postirradiation. 
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Analysis of Genes for Spikes in Expression 
In addition to linear behavior, another potential methodology for using gene 
expression as a dosimeter would involve genes that “spike”; meaning that a given gene 
sees a large amount of expression (compared to control flies) at a given radiation dose. 
In order to search for such an effect in this dataset, we looked for genes where the fold 
change was at least 5 times higher at one radiation dose than at any other radiation 
dose examined. The results are shown in figure 3A, and in Supplemental Tables 3A-G 
and 4A-G. Zero genes were found in the overlap between all three time points, which 
suggests that there may be no good candidate genes for a biological dosimeter. 
Similar to the linear analysis, we performed the analysis a second time with the data 
for 10 roentgen radiation exposure removed. Results are shown in Figure 3B, and 
Supplemental Table 4H-4N. In this analysis, one gene was found to be changing at all 
three time points. This gene, FBgn0085364, has no human homologue and no listed 
functions in Flybase (in Flybase, a search for this gene is directed towards 
FBgn0267910). 
For the spike analysis, GOStat analyses were run with the genes being separated by 
the radiation dose where a spike is found. Any spikes at the largest radiation dose were 
not considered, because it is likely that a highest expression value at the highest 
radiation dose is indicative of a gene that is merely increasing with dose (not 
necessarily in a linear fashion). The radiation doses at which each gene spikes are 
listed in Supplemental Tables 3A-G and 4A-G. Overall, the GOStat results on spiking 
genes showed an effect on reproduction and some effect on stress responses. 
The analysis with all radiation doses included the following: 
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 For genes with spikes at day 2 postirradiation at radiation dose 5000 roentgen, 
overrepresented gene ontologies are all due to FBgn0013745 and are related to 
reproduction and behavior.  
 For genes with spikes at day 2 postirradiation at radiation dose 1000 R, the 
only two genes are yolk protein 1 and yolk protein 2 (note: in this section, all 
full gene names were found in Flybase). Overrepresented gene ontologies 
include vitellogenesis, reproductive development and chromatin remodeling. 
 For genes with spikes at day 10 postirradiation, only five genes are not from 
the highest radiation dose. These five genes are all from dose 10 R. 
Overrepresented gene ontologies include those related to chorion (from 
chorion protein 15 and chorion protein 18) and sensing of chemical stimulus 
(from odorant binding protein 19c). 
 For genes with spikes at day 20 postirradiation, only one gene is not from the 
highest radiation dose. This gene, FBgn53222, spiked at dose 5000 roentgen 
and gave overrepresented gene ontologies related to ribosomes. 
The analysis with the lowest radiation dose (10 roentgen) did not include the 
following: 
 For genes with spikes at day 2 postirradiation, only four genes spiked at doses 
less than the maximum dose. Two genes spiked at dose 5,000 R; all 
overrepresented pathways in GOstat were due to FBgn0013745 (similar to the 
analysis including 10 roentgen). Two genes spiked at dose 10,000 R – yolk 
protein 1 (as in the analysis including 10 roentgen) and FBgn0013675, which 
resulted in overrepresented gene ontologies related to oxidative response. 
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 For genes with spikes at day 10 postirradiation, seven genes spiked at dose 
10,000 roentgen. Six of these seven genes were related to reproduction, and 
include yolk proteins 1, 2 and 3.  
 For genes with spikes at day 20 postirradiation, one gene (FBgn0053222) 
spiked at dose 5000 R (the same gene as the analysis including 10 roentgen). 
GOstat results related to the results reported above can be found in Supplemental 
Tables 5A-H. 
 
Discussion 
 
A radiation dosimeter based on gene expression could result in the better diagnosis of 
radiation dose in patients, and thus may help in saving lives after a nuclear event or 
accidental radiation exposure. The results of this paper indicate several candidate 
genes that have potential to be used for that purpose. In particular, it seems that the 
best candidates may be the genes listed in Tables 1 and 2 that have human 
homologues. 
One particularly interesting candidate gene is Irbp (inverted Repeat Binding Protein), 
which was found to behave linearly in all three data points, both with the full data set 
and with the lowest dose removed. Irbp is related to DNA repair. It is reasonable to 
predict that DNA damage is linear with radiation dose; thus, it is logical that some 
DNA repair genes may respond linearly in expression. Irbp has homologues in 
organisms that are as complex as humans and chimpanzees, and also in organisms 
such as Japanese rice (19). 
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Another possibility, based on the application of GOstat results, is to look at particular 
cellular functions. In particular, the function of protein kinase CK2 may be useful at 
time points soon after radiation exposure. Protein kinase CK2 was overrepresented in 
the GOstat analysis for genes found to behave linearly 2 days after irradiation, with a 
very high statistical significance. Perhaps the functionality of this protein kinase could 
be measured directly as a function of radiation to produce a different type of radiation 
dosimeter. 
Several genes listed in Tables 1 and 2 had no known functions in Flybase (18). These 
results suggest that they are related to radiation responses, and possibly to stress 
responses. 
From a dose-response standpoint, one interesting characteristic of the linear analysis 
results is that some genes with a linear response in fold change have fold changes that 
are less than 1 (radiation expression less than control expression) at lower doses, but 
then transition to fold changes greater than 1 (radiation expression greater than control 
expression) at high doses. For example, in the linear analysis with all radiation doses 
the genes FBgn0011774, FBgn0030189, FBgn0037020 and FBgn0051864 are linear 
at all three time points and exhibit this behavior at day 2 postirradiation. Descriptions 
of these genes can be found in table 1. This could be representative of some biological 
effects being in one direction at lower doses of radiation, and in the opposite direction 
at higher doses of radiation. Fold changes and R
2
 values are given in Supplemental 
Tables 3A-3F. 
Future questions related to this research could include:  
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 How well do results in Drosophila genes with human homologues translate to 
results in humans?  
 Do the genes in Tables 1 and 2 continue to respond linearly at more times 
postirradiation, including times < 2 days?  
 How are these results affected by the energy and type of irradiation? 
Further development of this methodology is needed before it can be applied to 
patients, but these results suggest the possibility of a successful gene expression 
radiation dosimeter.  
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Tables 
 
Table 1. Name, homology and functional information on 6 genes found to 
respond linearly to radiation at all time points examined. 
 
 
 
 
 
Flybase ID
Chromosome(G
ramates, 
Marygold et al. 
2017)
Gene Symbol 
(from 
flybase)(Gramates
, Marygold et al. 
2017)
Human Gene 
Homolog (From 
Homologene)-
2016
Biological 
Function(Gramates, 
Marygold et al. 2017)
Molecular 
Function(Gramates, 
Marygold et al. 2017)
FBgn0011774 3R Irbp XRCC6
Double-strand break 
repair via 
nonhomologous end 
joining, telomere 
maintenence
Contributes to DNA 
binding, protein 
heterodimerization activity, 
ATP-dependent,ATP-
dependent DNA helicase 
activity,damage  DNA 
binding,Telomeric DNA 
binding inferred
FBgn0030189 X CG2909 none Not known Not known
FBgn0031713 2L CG7277 COQ6
Oxidation reduction 
process,Ubiquinone 
biosynthetic process
FAD 
binding,Oxidoreductase 
activity, acting on  paired 
donors, with incorporation 
or reduction of molecular 
oxygen, NAD(P)H as one 
donor, and incorporation of 
one atom of oxygen
FBgn0032393 2L CG12264 NFS1
Alanine biosynthetic 
process, Iron-sulfur, 
cluster assembly,[2Fe-
2S] cluster assembly
Cystathionine gamma-lyase 
activity, Cysteine 
desulfurase 
activity,Pyridoxal 
phosphate  binding
FBgn0037020 3L Pex14 PEX14
Peroxisome 
organization,Protein 
import into peroxisome 
matrix,docking,Protein 
targeting to peroxisome
Receptor binding
FBgn0051864 2L Qtzl none Not known Not known
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Table 2. Genes found to behave linearly at all three time points, if the lowest radiation 
dose (10 R) is not included. Name, homology and functional information on 13 genes 
found to respond linearly to radiation at all time points examined. 
 
 
 
 
 
FBgn0030189 X CG2909 none Not known Not known
FBgn0033927 2R CR10102 none Not known Not known
FBgn0034184 2R CG9646 none Not known Not known
FBgn0036290 3L CG10638 none
Oxidation – reduction 
process inferred
Oxidoreductase activity, 
inferred
FBgn0037850 3R CG14695 none Not known Not known
FBgn0046763 3R CG17278 none
Negative regulation of Wnt 
signaling pathway inferred 
from genetic interaction
Not known
FBgn0051864 2L Qtzl none Not known Not known
Molecular Function 
(Gramates, Marygold et al. 
2017)
DNA binding,Protein 
heterodimerization  activity
ATP binding, Protein
Cystathionine gamma-
lyase activity,Cysteine 
desulfurase 
activity,Pyridoxal 
phosphate  binding
Alanine biosynthetic 
process,Iron-sulfur cluster 
assembly,[2Fe-2S] cluster 
assembly
Behavioral response to 
starvation,Muscle system 
process
Not known
FBgn0037020 3L Pex14 PEX14 Peroxisome organization, Not known
FBgn0032393 2L CG12264 NFS1
FBgn0033926 2R Arc1 none
Methylated-DNA-[protein]-
cysteine S-
methyltransferase activity
FBgn0027101 4 Dyrk3 DYRK2 Protein phosphorylation
FBgn0024912 3R agt none
DNA dealkylation involved 
in DNA repair
Flybase ID
Chromosome(Gra
mates, Marygold 
et al. 2017)
FBgn0011774 3R Irbp XRCC6
Double-strand break repair 
via nonhomologous end 
joining, telomere 
maintenance
Gene 
Symbol(Gramates
, Marygold et al. 
2017)
Human Gene 
Homologue (2016)
Biological Function 
(Gramates, Marygold et al. 
2017)
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Figures 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.  . Number of genes with linear response at each time point, with overlaps 
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Figure 2.  Analysis of linear behavior, not including data from dose 10 Roentgen. 
Number of genes with linear response (R
2
 > 0.9) are given for each time point, with 
overlaps. 
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Figure 3. Number of “spike” genes at each time point, with (3A) and without (3B) the 
lowest radiation dose. 
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Supplementary Tables 
 
 
 
Table S1A. Gene Ontologies Overrepresented in Genes Found to Behave Linearly at 
Day 2 Post-Irradiation. (Analysis with all data included.) 
 
 
 
 
 
GO Count Total P Value GO Name 
GO:0008605 13 23 2.21E-24 protein kinase CK2 regulator activity 
GO:0005956 13 23 2.21E-24 protein kinase CK2 complex 
GO:0043549 12 35 2.19E-19 regulation of kinase activity 
GO:0051338 12 35 2.19E-19 regulation of transferase activity 
GO:0045859 12 35 2.19E-19 regulation of protein kinase activity 
GO:0019887 13 53 5.02E-19 protein kinase regulator activity 
GO:0019207 13 55 7.39E-19 kinase regulator activity 
GO:0050790 12 57 1.10E-16 regulation of catalytic activity 
GO:0065009 12 70 1.41E-15 regulation of a molecular function 
GO:0007283 10 150 1.13E-08 spermatogenesis 
GO:0048232 10 150 1.13E-08 male gamete generation 
GO:0043234 19 1371 8.22E-08 protein complex 
GO:0032991 20 1652 1.45E-06 macromolecular complex 
GO:0007276 11 704 0.00244 gamete generation 
GO:0019953 11 730 0.00307 sexual reproduction 
GO:0065007 15 1459 0.00307 biological regulation 
GO:0044464 30 4358 0.00372 cell#cell part 
GO:0005623 30 4358 0.00372 cell 
GO:0005737 16 1833 0.0213 cytoplasm 
GO:0044459 6 305 0.0303 plasma membrane part 
GO:0035147 2 14 0.0311 branch fusion, open tracheal system 
GO:0035146 2 14 0.0311 branching morphogenesis of a tube#tube fusion 
GO:0005634 13 1420 0.0416 nucleus 
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Table S1B. Gene Ontologies Overrepresented in Genes Found to Behave Linearly at 
Day 10 Post-Irradiation. (Analysis with all data included.) 
 
 
 
GO Count Total P Value GO Name 
GO:0016021 33 608 0.00106 integral to membrane 
GO:0031224 33 613 0.00106 intrinsic to membrane 
GO:0016020 58 1367 0.0016 membrane 
GO:0006950 15 211 0.0069 response to stress 
GO:0044459 19 305 0.0069 plasma membrane part 
GO:0005887 14 169 0.0115 integral to plasma membrane 
GO:0044425 43 1002 0.0115 membrane#membrane part 
GO:0031226 14 172 0.0115 intrinsic to plasma membrane 
GO:0004872 23 424 0.0115 receptor activity 
GO:0004888 20 355 0.0139 transmembrane receptor activity 
GO:0004871 26 517 0.0139 signal transducer activity 
GO:0060089 26 517 0.0139 molecular transducer activity 
GO:0009595 3 5 0.0139 detection of biotic stimulus 
GO:0016045 3 5 0.0139 detection of bacterium 
GO:0030425 4 12 0.0139 dendrite 
GO:0006281 8 67 0.0164 DNA repair 
GO:0001871 6 36 0.0164 pattern binding 
GO:0042834 4 13 0.0164 peptidoglycan binding 
GO:0000270 3 7 0.0353 peptidoglycan metabolic process 
GO:0006974 8 79 0.0448 response to DNA damage stimulus 
 
 
Table S1C. Gene Ontologies Overrepresented in Genes Found to Behave Linearly at 
Day 20 Post-Irradiation. (Analysis with all data included.) 
GO Count Total P Value GO Name 
GO:0008083 6 17 0.0333 growth factor activity 
GO:0016491 38 541 0.0333 oxidoreductase activity 
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GO Count Total P Value GO Name 
GO:0004123 1 2 0.0243 cystathionine gamma-lyase activity 
GO:0006625 1 2 0.0243 protein targeting to peroxisome 
GO:0016226 1 2 0.0243 iron-sulfur cluster assembly 
GO:0043574 1 2 0.0243 peroxisomal transport 
GO:0031163 1 2 0.0243 metallo-sulfur cluster assembly 
GO:0004090 1 3 0.0331 carbonyl reductase (NADPH) activity 
 
Table S1D. Gene Ontologies Overrepresented in Genes Found to Behave Linearly at 
Days 2 and 10 Post-Irradiation. (Analysis with all data included.) 
 
 
 
 
 
 
GO Count Total P Value GO Name 
GO:0006950 9 211 0.00111 response to stress 
 
Table S1E. Gene Ontologies Overrepresented in Genes Found to Behave Linearly at 
Days 10 and 20 Post-Irradiation. (Analysis with all data included.) 
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Table S1F. Gene Ontologies Overrepresented in Genes Found to Behave Linearly at 
Days 2 and 20 Post-Irradiation. (Analysis with all data included.) 
 
 
 
 
 
 
 
 
 
 
GO Count Total P Value GO Name 
GO:0004123 1 2 0.00745 cystathionine gamma-lyase activity 
GO:0006625 1 2 0.00745 protein targeting to peroxisome 
GO:0016226 1 2 0.00745 iron-sulfur cluster assembly 
GO:0043574 1 2 0.00745 peroxisomal transport 
GO:0031163 1 2 0.00745 metallo-sulfur cluster assembly 
GO:0016846 1 6 0.0206 carbon-sulfur lyase activity 
GO:0001666 1 9 0.0268 response to hypoxia 
GO:0032200 1 10 0.0268 telomere organization and biogenesis 
GO:0000723 1 10 0.0268 telomere maintenance 
GO:0044439 1 12 0.0268 peroxisomal part 
GO:0044438 1 12 0.0268 microbody#microbody part 
GO:0031903 1 12 0.0268 microbody membrane 
GO:0005778 1 12 0.0268 peroxisomal membrane 
GO:0007031 1 13 0.0276 peroxisome organization and biogenesis 
GO:0008652 1 20 0.0388 amino acid biosynthetic process 
GO:0004003 1 20 0.0388 ATP-dependent DNA helicase activity 
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GO Count Total P Value GO Name 
GO:0004123 1 2 0.00517 cystathionine gamma-lyase activity 
GO:0006625 1 2 0.00517 protein targeting to peroxisome 
GO:0016226 1 2 0.00517 iron-sulfur cluster assembly 
GO:0043574 1 2 0.00517 peroxisomal transport 
GO:0031163 1 2 0.00517 metallo-sulfur cluster assembly 
GO:0016846 1 6 0.0141 carbon-sulfur lyase activity 
GO:0032200 1 10 0.0182 telomere organization and biogenesis 
GO:0000723 1 10 0.0182 telomere maintenance 
GO:0044439 1 12 0.0182 peroxisomal part 
GO:0044438 1 12 0.0182 microbody#microbody part 
GO:0031903 1 12 0.0182 microbody membrane 
GO:0005778 1 12 0.0182 peroxisomal membrane 
GO:0007031 1 13 0.0187 peroxisome organization and biogenesis 
GO:0008652 1 20 0.0258 amino acid biosynthetic process 
GO:0004003 1 20 0.0258 ATP-dependent DNA helicase activity 
GO:0008094 1 29 0.0331 DNA-dependent ATPase activity 
GO:0042579 1 31 0.0331 microbody 
GO:0005777 1 31 0.0331 peroxisome 
GO:0009309 1 34 0.0331 amine biosynthetic process 
GO:0044271 1 35 0.0331 nitrogen compound biosynthetic process 
GO:0043231 3 2283 0.0331 intracellular membrane-bound organelle 
GO:0043227 3 2287 0.0331 membrane-bound organelle 
GO:0003678 1 36 0.0331 DNA helicase activity 
 
 
Table S1G: Gene Ontologies Overrepresented in Genes Found to Behave Linearly at 
Days 2, 10 and 20 Post-Irradiation. (Analysis with all data included.) 
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Table S2A. Gene Ontologies Overrepresented in Genes Found to Behave Linearly at 
Day 2 Post-Irradiation. (Analysis with lowest dose discluded.) 
 
 
 
 
 
 
 
 
GO Count Total P Value GO Name 
GO:0008605 13 23 5.14E-13 xprotein kinase CK2 regulator activity 
GO:0005956 13 23 5.14E-13 protein kinase CK2 complex 
GO:0043549 12 35 4.92E-09 regulation of kinase activity 
GO:0051338 12 35 4.92E-09 regulation of transferase activity 
GO:0045859 12 35 4.92E-09 regulation of protein kinase activity 
GO:0019887 13 53 6.60E-08 protein kinase regulator activity 
GO:0019207 13 55 9.35E-08 kinase regulator activity 
GO:0050790 12 57 1.63E-06 regulation of catalytic activity 
GO:0065009 13 70 1.72E-06 regulation of a molecular function 
GO:0007283 17 150 1.68E-05 xspermatogenesis 
GO:0048232 17 150 1.68E-05 male gamete generation 
GO:0022411 5 13 0.00115 cellular component disassembly 
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Table S2B. Gene Ontologies Overrepresented in Genes Found to Behave Linearly at 
Day 10 Post-Irradiation. (Analysis with lowest dose discluded.) 
 
 
 
 
 
 
GO Count Total P Value GO Name 
GO:0003924 17 102 0.0028 GTPase activity 
GO:0016798 16 102 0.0118 hydrolase activity, acting on glycosyl bonds 
GO:0005102 19 136 0.0129 receptor binding 
GO:0004553 15 96 0.0129 hydrolase activity, hydrolyzing O-glycosyl compounds 
GO:0009055 21 166 0.0282 electron carrier activity 
GO:0005624 14 93 0.0334 membrane fraction 
GO:0005515 79 974 0.0334 protein binding 
GO:0000267 14 96 0.0411 cell fraction 
GO:0016740 70 851 0.0411 transferase activity 
GO:0008083 6 17 0.0411 growth factor activity 
GO:0005778 5 12 0.0427 peroxisomal membrane 
GO:0044438 5 12 0.0427 microbody#microbody part 
GO:0031903 5 12 0.0427 microbody membrane 
GO:0044439 5 12 0.0427 peroxisomal part 
GO:0016491 48 541 0.0499 oxidoreductase activity 
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GO Count Total P Value GO Name 
GO:0005887 16 169 0.0205 integral to plasma membrane 
GO:0031226 16 172 0.0205 intrinsic to plasma membrane 
GO:0000270 4 7 0.0205 peptidoglycan metabolic process 
GO:0042834 5 13 0.0205 peptidoglycan binding 
GO:0017143 4 9 0.0328 insecticide metabolic process 
GO:0006805 4 9 0.0328 xenobiotic metabolic process 
GO:0009404 4 9 0.0328 toxin metabolic process 
GO:0009410 4 9 0.0328 response to xenobiotic stimulus 
GO:0016020 70 1367 0.0355 membrane 
GO:0046903 15 172 0.0361 secretion 
GO:0019752 14 156 0.0361 carboxylic acid metabolic process 
GO:0006082 14 156 0.0361 organic acid metabolic process 
GO:0009056 15 174 0.037 catabolic process 
GO:0044459 22 305 0.0377 plasma membrane part 
GO:0016192 26 386 0.0377 vesicle-mediated transport 
GO:0006767 4 11 0.0377 water-soluble vitamin metabolic process 
GO:0009595 3 5 0.0377 detection of biotic stimulus 
GO:0016045 3 5 0.0377 detection of bacterium 
GO:0030425 4 12 0.0486 dendrite 
GO:0016021 36 608 0.0486 integral to membrane 
 
Table S2C. Gene Ontologies Overrepresented in Genes Found to Behave Linearly at 
Day 20 Post-Irradiation. (Analysis with lowest dose discluded.) 
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(none) 
      
Table S2D. Gene Ontologies Overrepresented in Genes Found to Behave Linearly at 
Days 2 and 10 Post-Irradiation. (Analysis with lowest dose discluded.) 
 
 
 
 
 
 
 
 
 
 
 
 
Table S2E. Gene Ontologies Overrepresented in Genes Found to Behave Linearly at 
Days 10 and 20 Post-Irradiation. (Analysis with lowest dose discluded.) 
 
 
 
 
 
GO Count Total P Value GO Name 
GO:0005778 3 12 0.0165 peroxisomal membrane 
GO:0044438 3 12 0.0165 microbody#microbody part 
GO:0044439 3 12 0.0165 xperoxisomal part 
GO:0031903 3 12 0.0165 microbody membrane 
GO:0007031 3 13 0.0171 peroxisome organization and biogenesis 
 103 
 
GO Count Total P Value GO Name 
GO:0000723 2 10 0.0169 telomere maintenance 
GO:0032200 2 10 0.0169 telomere organization and biogenesis 
GO:0004003 2 20 0.0217 ATP-dependent DNA helicase activity 
GO:0016772 5 446 0.0217 
transferase activity, transferring  
phosphorus-containing groups 
GO:0008094 2 29 0.0217 DNA-dependent ATPase activity 
GO:0043296 2 36 0.0217 
apicolateral plasma membrane#apical 
 junction complex 
GO:0003678 2 36 0.0217 DNA helicase activity 
GO:0016740 6 851 0.0217 transferase activity 
GO:0016327 2 40 0.0237 apicolateral plasma membrane 
GO:0005911 2 50 0.0302 intercellular junction 
GO:0006081 1 2 0.0302 aldehyde metabolic process 
GO:0004105 1 2 0.0302 choline-phosphate cytidylyltransferase activity 
GO:0031163 1 2 0.0302 metallo-sulfur cluster assembly 
GO:0004345 1 2 0.0302 glucose-6-phosphate dehydrogenase activity 
GO:0004123 1 2 0.0302 cystathionine gamma-lyase activity 
GO:0006625 1 2 0.0302 protein targeting to peroxisome 
GO:0016226 1 2 0.0302 iron-sulfur cluster assembly 
GO:0043574 1 2 0.0302 peroxisomal transport 
GO:0016337 2 59 0.0361 cell-cell adhesion 
GO:0017116 1 3 0.0415 
single-stranded DNA-dependent ATP-dependent  DNA 
 helicase activity 
GO:0043142 1 3 0.0415 single-stranded DNA-dependent ATPase activity 
GO:0016779 2 68 0.0438 nucleotidyltransferase activity 
GO:0008026 2 70 0.0443 ATP-dependent helicase activity 
GO:0051186 2 75 0.0443 cofactor metabolic process 
GO:0030054 2 75 0.0443 cell junction 
GO:0006740 1 4 0.0443 NADPH regeneration 
GO:0009225 1 4 0.0443 nucleotide-sugar metabolic process 
GO:0006098 1 4 0.0443 pentose-phosphate shunt 
GO:0006739 1 4 0.0443 NADP metabolic process 
GO:0005923 1 4 0.0443 
apicolateral plasma membrane#apical junction  
complex#tight junction 
GO:0016616 2 79 0.0471 
oxidoreductase activity, acting on the CH-OH group  
of donors, NAD or NADP as acceptor 
 
Table S2F. Gene Ontologies Overrepresented in Genes Found to Behave Linearly at 
Days 2 and 20 Post-Irradiation. (Analysis with lowest dose discluded.) 
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GO Count Total P Value GO Name 
GO:0004123 1 2 0.0123 cystathionine gamma-lyase activity 
GO:0006625 1 2 0.0123 protein targeting to peroxisome 
GO:0006081 1 2 0.0123 aldehyde metabolic process 
GO:0016226 1 2 0.0123 iron-sulfur cluster assembly 
GO:0043574 1 2 0.0123 xperoxisomal transport 
GO:0031163 1 2 0.0123 metallo-sulfur cluster assembly 
GO:0004032 1 6 0.0323 aldehyde reductase activity 
GO:0016846 1 6 0.0323 carbon-sulfur lyase activity 
GO:0004033 1 8 0.0405 aldo-keto reductase activity 
GO:0004674 2 190 0.0412 protein serine/threonine kinase activity 
GO:0032200 1 10 0.0412 telomere organization and biogenesis 
GO:0000723 1 10 0.0412 xtelomere maintenance 
GO:0030178 1 11 0.0412 xnegative regulation of Wnt receptor signaling pathway 
GO:0044439 1 12 0.0412 peroxisomal part 
GO:0044438 1 12 0.0412 microbody#microbody part 
GO:0031903 1 12 0.0412 microbody membrane 
GO:0005778 1 12 0.0412 peroxisomal membrane 
GO:0007031 1 13 0.0429 peroxisome organization and biogenesis 
 
Table S2G. Gene Ontologies Overrepresented in Genes Found to Behave Linearly at 
Days 2, 10 and 20 Post-Irradiation. (Analysis with lowest dose discluded.) 
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Table S3A. Values of Spike Ratio and Fold Changes for Genes Found to Spike at Day 
2 Post-Irradiation. (Analysis with all data included.) Spike ratio = (largest fold 
change)/(second largest fold change) 
 
 
 
 
 
Flybase ID 
Spike 
Ratio 
Dose 
Causing 
Spike 
Day 2 
Fold 
Change 
10R 
Day 2 
Fold 
Change 
1000R 
Day 2 
Fold 
Change 
50000R 
Day 2 
Fold 
Change 
10000R 
Day 2 Fold 
Change 
20000R 
FBgn0005391 6.018 10000R 2.573 0.888 0.545 15.486 1.268 
FBgn0004045 15.787 10000R 0.936 0.447 0.849 16.168 1.024 
FBgn0038191 5.379 1000R 0.248 1.332 0.141 0.183 0.154 
FBgn0013672 7.952 20000R 1.114 0.656 0.783 0.651 8.855 
FBgn0013678 7.046 20000R 1.028 0.774 0.681 0.729 7.242 
FBgn0034152 6.826 20000R 0.780 6.282 2.196 6.885 46.999 
FBgn0013676 6.461 20000R 1.278 0.876 1.026 0.772 8.256 
FBgn0013674 6.025 20000R 1.271 1.155 0.874 0.985 7.656 
FBgn0259968 5.361 20000R 0.945 1.163 0.673 0.789 6.237 
FBgn0013675 13.108 20000R 1.336 0.673 0.855 0.522 17.518 
FBgn0013745 7.176 5000R 0.371 0.966 11.772 1.155 1.640 
FBgn0262099 6.609 5000R 0.591 5.446 44.237 6.693 5.023 
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Flybase ID 
SpikeRa
tio 
Dose 
Causing 
Spike 
Day10 
Fold 
Change 
10R 
Day10 
Fold 
Change 
1000R 
Day10 
Fold 
Change 
5000R 
Day10 Fold 
Change 
10000R 
Day10 
Fold 
Change 
20000R 
FBgn0013679 9.785 20000R 2.051 1.087 1.137 1.197 20.065 
FBgn0025740 9.617 20000R 0.429 0.708 0.469 0.462 6.805 
FBgn0013672 9.472 20000R 0.758 0.864 1.744 0.981 16.520 
FBgn0085364 9.183 20000R 1.107 1.655 1.378 1.306 15.201 
FBgn0013676 8.690 20000R 0.921 0.799 1.255 1.007 10.907 
FBgn0031111 8.280 10R 13.211 1.114 1.485 1.011 1.596 
FBgn0013681 7.360 20000R 1.370 0.709 1.617 0.388 11.902 
FBgn0000427 68.582 20000R 164.035 1.051 1.101 1.066 2.392 
FBgn0259968 6.846 20000R 1.012 1.200 1.482 1.239 10.143 
FBgn0041709 6.434 10R 24.479 0.793 0.771 1.388 3.805 
FBgn0013686 6.416 20000R 0.563 0.882 0.650 0.863 5.657 
FBgn0021738 6.346 20000R 0.478 0.673 0.860 0.708 5.455 
FBgn0262972 6.089 20000R 0.770 0.886 0.821 0.256 5.397 
FBgn0000357 52.726 10R 76.612 0.932 1.159 1.218 1.453 
FBgn0039916 5.769 20000R 0.351 0.749 1.016 0.939 5.862 
FBgn0037836 5.715 20000R 0.869 1.050 1.071 0.741 6.122 
FBgn0036790 5.703 20000R 0.355 0.705 0.575 0.469 4.018 
FBgn0036985 5.546 20000R 0.568 1.104 0.578 0.905 6.126 
FBgn0032946 5.427 20000R 1.689 1.590 1.541 1.264 9.167 
FBgn0086782 5.393 20000R 0.684 0.802 0.592 0.965 5.205 
FBgn0052350 5.357 20000R 0.610 0.803 0.900 1.126 6.034 
FBgn0013675 5.229 20000R 0.857 0.937 2.220 0.813 11.611 
FBgn0039925 35.389 20000R 0.305 0.413 0.446 0.518 18.324 
FBgn0013680 28.243 20000R 1.126 1.065 1.218 0.802 34.413 
FBgn0053855 21.401 20000R 2.643 0.651 0.897 2.320 56.555 
FBgn0053858 21.234 20000R 2.791 0.722 0.928 2.390 59.260 
FBgn0053810 20.386 20000R 2.449 0.632 0.869 1.988 49.934 
FBgn0053831 19.800 20000R 2.574 0.582 0.855 1.974 50.972 
FBgn0053837 19.797 20000R 2.442 0.651 0.838 1.921 48.348 
FBgn0053822 19.649 20000R 2.621 0.607 0.794 2.017 51.495 
FBgn0053816 19.527 20000R 2.529 0.583 0.874 1.958 49.377 
FBgn0053861 19.524 20000R 3.118 0.737 0.932 2.407 60.868 
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Table S3B. Values of Spike Ratio and Fold Changes for Genes Found to Spike at Day 
10 Post-Irradiation. (Analysis with all data included.) Spike ratio = (largest fold 
change)/(second largest fold change) 
 
 
 
FBgn0053819 19.465 20000R 2.609 0.640 0.853 2.004 50.776 
FBgn0053807 19.436 20000R 2.337 0.593 0.804 1.836 45.416 
FBgn0053828 19.260 20000R 2.519 0.617 0.848 1.931 48.524 
FBgn0053825 19.255 20000R 2.568 0.628 0.829 1.966 49.449 
FBgn0053843 19.255 20000R 2.712 0.715 0.846 1.989 52.223 
FBgn0053864 19.048 20000R 2.565 0.597 0.861 1.925 48.861 
FBgn0053852 19.034 20000R 2.534 0.624 0.825 1.921 48.235 
FBgn0053813 18.977 20000R 2.776 0.680 0.875 2.202 52.672 
FBgn0053846 18.904 20000R 2.613 0.603 0.845 1.988 49.390 
FBgn0051617 18.804 20000R 2.440 0.540 0.811 1.893 45.879 
FBgn0053801 18.653 20000R 2.549 0.612 0.815 1.928 47.551 
FBgn0053849 18.323 20000R 2.771 0.623 0.858 1.975 50.782 
FBgn0053840 17.922 20000R 2.677 0.660 0.830 1.901 47.978 
FBgn0053804 17.761 20000R 2.622 0.601 0.851 1.913 46.573 
FBgn0013678 15.720 20000R 0.806 0.784 1.009 0.988 15.862 
FBgn0000355 141.389 10R 130.305 0.922 0.687 0.127 0.165 
FBgn0013685 14.707 20000R 1.367 0.670 0.853 0.396 20.105 
FBgn0052602 13.143 10R 20.045 0.874 0.626 0.624 1.525 
FBgn0052580 124.695 20000R 0.208 0.620 0.240 0.751 93.597 
FBgn0013674 12.216 20000R 0.910 0.963 0.947 1.071 13.085 
FBgn0262952 12.152 20000R 1.639 1.050 0.703 1.111 19.912 
FBgn0013684 11.816 20000R 1.266 0.696 0.642 0.729 14.954 
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Table S3C. Values of Spike Ratio and Fold Changes for Genes Found to Spike at Day 
20 Post-Irradiation. (Analysis with all data included.) Spike ratio = (largest fold 
change)/(second largest fold change) 
 
 
 
 
 
 
Flybase ID 
Spike 
Ratio 
Dose 
Causing 
Spike 
Day 20 
 Fold 
Change 
 10R 
Day 20 
 Fold  
Change  
1000R 
Day 20  
Fold  
Change 
 5000R 
Day 20  
Fold  
Change  
10000R 
Day 20 
Fold 
Change  
20000R 
FBgn0053222 9.209 5000R 1.164 1.180 10.869 0.146 0.026 
FBgn0085364 8.050 20000R 1.094 1.610 0.895 1.364 12.963 
FBgn0039480 6.902 20000R 0.158 0.105 0.090 0.173 1.193 
FBgn0040637 6.835 20000R 1.457 1.511 2.097 NA 14.334 
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FlyBase 
ID 
Spik
e 
Rati
o 
Day
2 
Dose 
Causi
ng 
Spike 
Day2 
Spik
eRat
io 
Day1
0 
Dose 
Causi
ng 
Spike 
Day10 
Day 
2 
Fold 
Cha
nge 
10R 
Day 
2 
Fold 
Cha
nge 
100
0R 
Day 
2 
Fold 
Cha
nge 
5000
0R 
Day 
2 
Fold 
Chan
ge 
1000
0R 
Day 2 
Fold 
Chang
e 
20000
R 
Day1
0 Fold 
Chan
ge 
10R 
Day10 
Fold 
Chang
e 
1000R 
Day10 
Fold 
Chang
e 
5000R 
Day10 
Fold 
Chang
e 
10000
R 
Day10 
Fold 
Chang
e 
20000
R 
FBgn0013
672 
7.95
2 
20000
R 9.472 
20000
R 
1.11
4 
0.65
6 
0.78
3 0.651 8.855 0.758 0.864 1.744 0.981 16.520 
FBgn0013
678 
7.04
6 
20000
R 8.690 
20000
R 
1.02
8 
0.77
4 
0.68
1 0.729 7.242 0.921 0.799 1.255 1.007 10.907 
FBgn0013
676 
6.46
1 
20000
R 6.846 
20000
R 
1.27
8 
0.87
6 
1.02
6 0.772 8.256 1.012 1.200 1.482 1.239 10.143 
FBgn0013
674 
6.02
5 
20000
R 5.229 
20000
R 
1.27
1 
1.15
5 
0.87
4 0.985 7.656 0.857 0.937 2.220 0.813 11.611 
FBgn0259
968 
5.36
1 
20000
R 15.72 
20000
R 
0.94
5 
1.16
3 
0.67
3 0.789 6.237 0.806 0.784 1.009 0.988 15.862 
FBgn0013
675 
13.1
08 
20000
R 
12.21
6 
20000
R 
1.33
6 
0.67
3 
0.85
5 0.522 17.518 0.910 0.963 0.947 1.071 13.085 
 
 
 
Table S3D. Values of Spike Ratio and Fold Changes for Genes Found to Spike at 
Days 2 and 10 Post-Irradiation. (Analysis with all data included.) Spike ratio = (largest 
fold change)/(second largest fold change) 
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Flybase 
ID 
Spik
eRat
io 
Day 
10 
Dose 
Causi
ng 
Spike 
Day1
0 
Spik
eRat
io 
Day 
20 
Dose 
Caus
ing 
Spik
e 
Day2
0 
Day
10 
Fold 
Cha
nge 
10R 
Day1
0 Fold 
Chan
ge 
1000
R 
Day1
0 
Fold 
Chan
ge 
5000
R 
Day1
0 Fold 
Chan
ge 
10000
R 
Day1
0 Fold 
Chan
ge 
20000
R 
Day 
20 
Fold 
Chan
ge 
10R 
Day 
20 
Fold 
Chan
ge 
1000
R 
Day 
20 
Fold 
Chan
ge 
5000
R 
Day 
20 
Fold 
Chan
ge 
10000
R 
Day 
20 
Fold 
Chan
ge 
20000
R 
FBgn0085
364 
9.18
3 
20000
R 
8.05
0 
2000
0R 
1.10
7 1.655 1.378 1.306 
15.20
1 1.094 1.610 0.895 1.364 
12.96
3 
 
 
 
 
Table S3E. Values of Spike Ratio and Fold Changes for Genes Found to Spike at 
Days 10 and 20 Post-Irradiation. (Analysis with all data included.) Spike ratio = 
(largest fold change)/(second largest fold change) 
 
 
 
(none) 
      Table S3F. Values of Spike Ratio and Fold Changes for Genes Found to Spike at 
Days 2 and 20 Post-Irradiation. (Analysis with all data included.) Spike ratio = (largest 
fold change)/(second largest fold change) 
 
 
 
 
 
(none) 
    Table S3G. Values of Spike Ratio and Fold Changes for Genes Found to Spike at 
Days 2, 10 and 20 Post-Irradiation. (Analysis with all data included.) Spike ratio = 
(largest fold change)/(second largest fold change) 
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Flybase ID 
SpikeRa
tio 
Dose 
Causing 
Spike 
Day 2 
Fold 
Change 
1000R 
Day 2 
Fold 
Change 
5000R 
Day 2 Fold 
Change 
10000R 
Day 2 Fold 
Change 
20000R 
FBgn0013678 9.356 20000R 0.774 0.681 0.729 7.242 
FBgn0013680 9.132 20000R 0.563 0.683 0.420 6.233 
FBgn0013676 8.044 20000R 0.876 1.026 0.772 8.256 
FBgn0013673 7.347 20000R 0.466 0.685 0.372 5.031 
FBgn0013683 7.239 20000R 0.944 0.695 0.318 6.832 
FBgn0013745 7.176 5000R 0.966 11.772 1.155 1.640 
FBgn0034152 6.826 20000R 6.282 2.196 6.885 46.999 
FBgn0013674 6.631 20000R 1.155 0.874 0.985 7.656 
FBgn0262099 6.609 5000R 5.446 44.237 6.693 5.023 
FBgn0013681 6.558 20000R 0.798 0.916 0.515 6.005 
FBgn0013684 6.476 20000R 0.788 0.633 0.788 5.102 
FBgn0013679 5.956 20000R 1.004 0.879 0.867 5.981 
FBgn0085364 5.415 20000R 1.298 0.718 0.916 7.026 
FBgn0259968 5.361 20000R 1.163 0.673 0.789 6.237 
FBgn0013685 24.186 20000R 0.338 0.246 0.237 8.163 
FBgn0013675 20.490 10000R 0.673 0.855 0.522 17.518 
FBgn0004045 15.787 10000R 0.447 0.849 16.168 1.024 
FBgn0013672 11.306 20000R 0.656 0.783 0.651 8.855 
 
Table S4A. Values of Spike Ratio and Fold Changes for Genes Found to Spike at Day 
2 Post-Irradiation. (Analysis with lowest dose discluded.) Spike ratio = (largest fold 
change)/(second largest fold change) 
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Flybase ID 
Spike 
Ratio 
Dose 
Causing 
Spike 
Day 10 
Fold 
Change 
1000R 
Day 10 
Fold 
Change 
5000R 
Day 10 
Fold 
Change 
10000R 
Day 10 
Fold 
Change 
20000R 
FBgn0004045 87.528 10000R 1.684 2.465 515.653 5.891 
FBgn0260780 7.925 10000R 1.245 1.084 19.861 2.506 
FBgn0002962 7.160 10000R 1.413 2.257 16.159 1.356 
FBgn0003023 5.911 10000R 0.741 0.755 8.156 1.380 
FBgn0004047 34.886 10000R 0.937 1.088 37.960 1.078 
FBgn0004649 19.854 10000R 1.338 0.734 26.571 0.523 
FBgn0005391 158.647 10000R 1.399 1.805 391.716 2.469 
FBgn0025740 9.617 20000R 0.708 0.469 0.462 6.805 
FBgn0013672 9.472 20000R 0.864 1.744 0.981 16.520 
FBgn0085364 9.183 20000R 1.655 1.378 1.306 15.201 
FBgn0013676 8.690 20000R 0.799 1.255 1.007 10.907 
FBgn0013681 7.360 20000R 0.709 1.617 0.388 11.902 
FBgn0259968 6.846 20000R 1.200 1.482 1.239 10.143 
FBgn0013686 6.416 20000R 0.882 0.650 0.863 5.657 
FBgn0262972 6.089 20000R 0.886 0.821 0.256 5.397 
FBgn0032946 5.765 20000R 1.590 1.541 1.264 9.167 
FBgn0037836 5.715 20000R 1.050 1.071 0.741 6.122 
FBgn0036790 5.703 20000R 0.705 0.575 0.469 4.018 
FBgn0086782 5.393 20000R 0.802 0.592 0.965 5.205 
FBgn0052350 5.357 20000R 0.803 0.900 1.126 6.034 
FBgn0013675 5.229 20000R 0.937 2.220 0.813 11.611 
FBgn0039925 35.389 20000R 0.413 0.446 0.518 18.324 
FBgn0013680 28.243 20000R 1.065 1.218 0.802 34.413 
FBgn0053843 26.253 20000R 0.715 0.846 1.989 52.223 
FBgn0053831 25.818 20000R 0.582 0.855 1.974 50.972 
FBgn0053849 25.717 20000R 0.623 0.858 1.975 50.782 
FBgn0053822 25.530 20000R 0.607 0.794 2.017 51.495 
FBgn0053864 25.387 20000R 0.597 0.861 1.925 48.861 
FBgn0053819 25.332 20000R 0.640 0.853 2.004 50.776 
FBgn0053861 25.293 20000R 0.737 0.932 2.407 60.868 
FBgn0053840 25.241 20000R 0.660 0.830 1.901 47.978 
FBgn0053816 25.222 20000R 0.583 0.874 1.958 49.377 
FBgn0053837 25.174 20000R 0.651 0.838 1.921 48.348 
FBgn0053825 25.150 20000R 0.628 0.829 1.966 49.449 
FBgn0053828 25.132 20000R 0.617 0.848 1.931 48.524 
FBgn0053810 25.121 20000R 0.632 0.869 1.988 49.934 
FBgn0053852 25.107 20000R 0.624 0.825 1.921 48.235 
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FBgn0053846 24.838 20000R 0.603 0.845 1.988 49.390 
FBgn0053858 24.791 20000R 0.722 0.928 2.390 59.260 
FBgn0053807 24.743 20000R 0.593 0.804 1.836 45.416 
FBgn0053801 24.666 20000R 0.612 0.815 1.928 47.551 
FBgn0053855 24.373 20000R 0.651 0.897 2.320 56.555 
FBgn0053804 24.341 20000R 0.601 0.851 1.913 46.573 
FBgn0051617 24.233 20000R 0.540 0.811 1.893 45.879 
FBgn0053813 23.919 20000R 0.680 0.875 2.202 52.672 
FBgn0013684 20.510 20000R 0.696 0.642 0.729 14.954 
FBgn0262952 17.927 20000R 1.050 0.703 1.111 19.912 
FBgn0013679 16.768 20000R 1.087 1.137 1.197 20.065 
FBgn0013678 15.720 20000R 0.784 1.009 0.988 15.862 
FBgn0052580 124.695 20000R 0.620 0.240 0.751 93.597 
FBgn0013674 12.216 20000R 0.963 0.947 1.071 13.085 
 
Table S4B. Values of Spike Ratio and Fold Changes for Genes Found to Spike at Day 
10 Post-Irradiation. (Analysis with lowest dose discluded.) Spike ratio = (largest fold 
change)/(second largest fold change) 
 
 
 
 
 
Flybase ID 
Spike 
Ratio 
Dose 
Causing 
Spike 
Day 20 
Fold 
Change 
1000R 
Day 20 
Fold 
Change 
5000R 
Day 20 
Fold 
Change 
10000R 
Day 20 
Fold 
Change 
20000R 
FBgn0053222 9.209 5000R 1.180 10.869 0.146 0.026 
FBgn0085364 8.050 20000R 1.610 0.895 1.364 12.963 
FBgn0039480 6.902 20000R 0.105 0.090 0.173 1.193 
 
 
Table S4C. Values of Spike Ratio and Fold Changes for Genes Found to Spike at Day 
20 Post-Irradiation. (Analysis with lowest dose discluded.) Spike ratio = (largest fold 
change)/(second largest fold change) 
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Table S4D. Values of Spike Ratio and Fold Changes for Genes Found to Spike at 
Days 2 and 10 Post-Irradiation. (Analysis with lowest dose discluded.) Spike ratio = 
(largest fold change)/(second largest fold change) 
 
 
 
 
 
Flybase ID 
Spike 
Ratio 
Day2 
Dose 
Causi
ng 
Spike 
Day2 
Spik
e 
Ratio 
Day1
0 
Dose 
Causin
g Spike 
Day10 
Day 
2 
Fold 
Chan
ge 
1000
R 
Day 
2 
Fold 
Chan
ge 
5000
R 
Day 2 
Fold 
Chang
e 
10000
R 
Day 2 
Fold 
Chang
e 
20000
R 
Day 10 
Fold 
Change 
1000R 
Day 
10 
Fold 
Chan
ge 
5000
R 
Day 
10 
Fold 
Chan
ge 
1000
0R 
Day 10 
Fold 
Chang
e 
20000
R 
FBgn0004045 15.787 
10000
R 
87.52
8 10000R 0.447 0.849 16.168 1.024 1.684 2.465 
515.6
53 5.891 
FBgn0013672 11.306 
20000
R 9.472 20000R 0.656 0.783 0.651 8.855 0.864 1.744 0.981 16.520 
FBgn0013674 6.631 
20000
R 
12.21
6 20000R 1.155 0.874 0.985 7.656 0.963 0.947 1.071 13.085 
FBgn0013675 20.490 
20000
R 5.229 20000R 0.673 0.855 0.522 17.518 0.937 2.220 0.813 11.611 
FBgn0013676 8.044 
20000
R 8.690 20000R 0.876 1.026 0.772 8.256 0.799 1.255 1.007 10.907 
FBgn0013678 9.356 
20000
R 
15.72
0 20000R 0.774 0.681 0.729 7.242 0.784 1.009 0.988 15.862 
FBgn0013679 5.956 
20000
R 
16.76
8 20000R 1.004 0.879 0.867 5.981 1.087 1.137 1.197 20.065 
FBgn0013680 9.132 
20000
R 
28.24
3 20000R 0.563 0.683 0.420 6.233 1.065 1.218 0.802 34.413 
FBgn0013681 6.558 
20000
R 7.360 20000R 0.798 0.916 0.515 6.005 0.709 1.617 0.388 11.902 
FBgn0013684 6.476 
20000
R 
20.51
0 20000R 0.788 0.633 0.788 5.102 0.696 0.642 0.729 14.954 
FBgn0085364 5.415 
20000
R 9.183 20000R 1.298 0.718 0.916 7.026 1.655 1.378 1.306 15.201 
FBgn0259968 5.361 
20000
R 6.846 20000R 1.163 0.673 0.789 6.237 1.200 1.482 1.239 10.143 
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Flybase ID 
Spike 
Ratio 
Day 
10 
Dose 
Causi
ng 
Spike 
Day 10 
Spike 
Ratio 
Day 
20 
Dose 
Causing 
Spike 
Day 20 
Day 
10 
Fold 
Chan
ge 
1000
R 
Day 10 
Fold 
Change 
5000R 
Day 10 
Fold 
Chang
e 
10000R 
Day 
10 
Fold 
Chan
ge 
20000
R 
Day 
20 
Fold 
Chan
ge 
1000
R 
Day 
20 
Fold 
Chan
ge 
5000
R 
Day 
20 
Fold 
Chan
ge 
10000
R 
Day 
20 
Fold 
Chang
e 
20000
R 
FBgn008536
4 9.183 
20000
R 8.050 20000R 1.655 1.378 1.306 
15.20
1 1.610 0.895 1.364 12.963 
 
 
Table S4E. Values of Spike Ratio and Fold Changes for Genes Found to Spike at 
Days 10 and 20 Post-Irradiation. (Analysis with lowest dose discluded.) Spike ratio = 
(largest fold change)/(second largest fold change) 
 
 
 
 
Flybase ID 
Spike 
Ratio 
Day 2 
Dose 
Causin
g 
Spike 
Day 2 
Spike 
Ratio 
Day 20 
Dose 
Causin
g 
Spike 
Day20 
Day 2 
Fold 
Chang
e 
1000R 
Day 
2 
Fold 
Cha
nge 
5000
R 
Day 2 
Fold 
Chang
e 
10000
R 
Day 2 
Fold 
Chang
e 
20000
R 
Day 
20 
Fold 
Chan
ge 
1000R 
Day 
20 
Fold 
Chan
ge 
5000
R 
Day 
20 
Fold 
Cha
nge 
1000
0R 
Day 
20 
Fold 
Chan
ge 
2000
0R 
FBgn0085364 5.415 
20000
R 8.050 
20000
R 1.298 
0.71
8 0.916 7.026 1.610 0.895 
1.36
4 
12.96
3 
 
 
Table S4F. Values of Spike Ratio and Fold Changes for Genes Found to Spike at 
Days 2 and 20 Post-Irradiation. (Analysis with lowest dose discluded.) Spike ratio = 
(largest fold change)/(second largest fold change) 
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Flybase ID 
Spik
e 
Ratio 
Day 
2 
Dose 
Causi
ng 
Spike 
Day 2 
Spik
eRat
io 
Day 
10 
Dose 
Causi
ng 
Spike 
Day 
10 
Spik
e 
Rati
o 
Day 
20 
Dose 
Causi
ng 
Spike 
Day 
20 
Day 
2 
Fold 
Cha
nge 
1000
R 
Day 
2 
FC 
500
0R 
Day 
2 
FC 
100
00R 
Da
y 2 
FC 
20
00
0R 
Day 
10 
FC 
100
0R 
Day 
10 
FC 
500
0R 
Day 
10 
FC 
100
00R 
Day 
10 
FC 
200
00R 
Day 
20 
FC 
100
0R 
Day 
20 
FC 
5000
R 
Da
y 
20 
FC 
10
00
0R 
Da
y 
20 
FC 
200
00
R 
FBgn008536
4 5.415 
20000
R 
9.18
3 
20000
R 
8.05
0 
20000
R 
1.29
8 
0.71
8 
0.91
6 
7.0
26 
1.65
5 
1.37
8 
1.30
6 
15.2
01 
1.61
0 
0.89
5 
1.3
64 
12.
963 
 
 
Table S4G. Values of Spike Ratio and Fold Changes (FC) for Genes Found to Spike 
at Days 2, 10 and 20 Post-Irradiation. (Analysis with lowest dose discluded.) Spike 
ratio = (largest fold change)/(second largest fold change) 
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GO Count Total P Value GO Name 
GO:0045434 1 7 0.00511 negative regulation of female receptivity, post-mating 
GO:0007621 1 8 0.00511 negative regulation of female receptivity 
GO:0048521 1 8 0.00511 negative regulation of behavior 
GO:0046008 1 10 0.00511 regulation of female receptivity, post-mating 
GO:0045924 1 16 0.00511 regulation of female receptivity 
GO:0060180 1 16 0.00511 mating behavior#female mating behavior 
GO:0060181 1 16 0.00511 female receptivity 
GO:0045297 1 18 0.00511 post-mating behavior 
GO:0050795 1 18 0.00511 regulation of behavior 
GO:0005179 1 47 0.012 hormone activity 
GO:0033057 1 69 0.0139 reproductive behavior in a multicellular organism 
GO:0032504 1 81 0.0139 multicellular organism reproduction 
GO:0048609 1 81 0.0139 
multicellular organism reproduction#reproductive process in a 
multicellular organism 
GO:0007617 1 82 0.0139 mating behavior 
GO:0051705 1 82 0.0139 behavioral interaction between organisms 
GO:0019098 1 87 0.0139 reproductive behavior 
GO:0007618 1 94 0.0141 mating 
GO:0005102 1 136 0.0193 receptor binding 
GO:0022414 1 203 0.0271 reproduction#reproductive process 
GO:0051704 1 212 0.0271 multi-organism process 
 
 
 
Table S5A. Overrepresented Gene Ontologies in Genes Found to Spike at Day 2 Post-
Irradiation at Dose 5000 R. (Analysis with all data included.) 
 
 
 
 
 118 
 
 
GO Count Total P Value GO Name 
GO:0007296 2 8 1.81E-05 vitellogenesis 
GO:0007548 2 57 0.000515 sex differentiation 
GO:0003006 2 77 0.00063 reproductive developmental process 
GO:0007028 2 109 0.000951 cytoplasm organization and biogenesis 
GO:0005811 2 129 0.00107 lipid particle 
GO:0022414 2 203 0.00221 reproduction#reproductive process 
GO:0016590 1 6 0.00584 ACF complex 
GO:0005678 1 9 0.00767 chromatin assembly complex 
GO:0007292 2 528 0.00999 female gamete generation 
GO:0007276 2 704 0.0156 gamete generation 
GO:0019953 2 730 0.0156 sexual reproduction 
GO:0016585 1 33 0.0187 chromatin remodeling complex 
 
 
Table S5B. Overrepresented Gene Ontologies in Genes Found to Spike at Day 2 Post-
Irradiation at Dose 10,000 R. (Analysis with all data included.) 
 
GO Count Total P Value GO Name 
GO:0005213 2 9 8.52E-05 structural constituent of chorion 
GO:0007306 2 64 0.00229 
ovarian follicle cell development#chorion-
containing eggshell formation#eggshell chorion 
formation 
GO:0007304 2 88 0.00229 
ovarian follicle cell development#chorion-
containing eggshell formation 
GO:0030703 2 89 0.00229 eggshell formation 
GO:0030707 2 184 0.00779 ovarian follicle cell development 
GO:0048646 2 235 0.0105 
anatomical structure development#anatomical 
structure morphogenesis#anatomical structure 
formation 
GO:0048477 2 519 0.0385 oogenesis 
GO:0007292 2 528 0.0385 female gamete generation 
GO:0005549 1 54 0.0496 odorant binding 
 
 
Table S5C. Overrepresented Gene Ontologies in Genes Found to Spike at Day 10 
Post-Irradiation at Dose 10,000 R. (Analysis with all data included.) 
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(none) 
     
 
Table S5D. Overrepresented Gene Ontologies in Genes Found to Spike at Day 2 Post-
Irradiation at Dose 5000 R. (Analysis with all data included.) 
 
GO Count Total P Value GO Name 
GO:0045434 1 7 0.00511 
negative regulation of female receptivity, post-
mating 
GO:0007621 1 8 0.00511 negative regulation of female receptivity 
GO:0048521 1 8 0.00511 negative regulation of behavior 
GO:0046008 1 10 0.00511 regulation of female receptivity, post-mating 
GO:0045924 1 16 0.00511 regulation of female receptivity 
GO:0060180 1 16 0.00511 mating behavior#female mating behavior 
GO:0060181 1 16 0.00511 female receptivity 
GO:0045297 1 18 0.00511 post-mating behavior 
GO:0050795 1 18 0.00511 regulation of behavior 
GO:0005179 1 47 0.012 hormone activity 
GO:0033057 1 69 0.0139 
reproductive behavior in a multicellular 
organism 
GO:0032504 1 81 0.0139 multicellular organism reproduction 
GO:0048609 1 81 0.0139 
multicellular organism 
reproduction#reproductive process in a 
multicellular organism 
GO:0007617 1 82 0.0139 mating behavior 
GO:0051705 1 82 0.0139 behavioral interaction between organisms 
GO:0019098 1 87 0.0139 reproductive behavior 
GO:0007618 1 94 0.0141 mating 
GO:0005102 1 136 0.0193 receptor binding 
GO:0022414 1 203 0.0271 reproduction#reproductive process 
GO:0051704 1 212 0.0271 multi-organism process 
 
 
Table S5E. Overrepresented Gene Ontologies in Genes Found to Spike at Day 2 Post-
Irradiation at Dose 5000 R. (Analysis with lowest dose discluded.) 
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Table S5F. Overrepresented Gene Ontologies in Genes Found to Spike at Day 2 Post-
Irradiation at Dose 10,000 R. (Analysis with lowest dose discluded.) 
 
 
 
 
 
 
 
 
GO Count Total P Value GO Name 
GO:0007296 1 8 0.0268 vitellogenesis 
GO:0006123 1 14 0.0268 
organelle ATP synthesis coupled electron 
transport#mitochondrial electron transport, cytochrome c 
to oxygen 
GO:0005751 1 17 0.0268 
mitochondrial inner membrane#mitochondrial respiratory 
chain#mitochondrial respiratory chain complex IV 
GO:0045277 1 17 0.0268 respiratory chain complex IV 
GO:0004129 1 18 0.0268 cytochrome-c oxidase activity 
GO:0016675 1 18 0.0268 oxidoreductase activity, acting on heme group of donors 
GO:0016676 1 18 0.0268 
oxidoreductase activity, acting on heme group of donors, 
oxygen as acceptor 
GO:0015002 1 18 0.0268 heme-copper terminal oxidase activity 
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GO Count Total P Value GO Name 
GO:0007296 4 8 4.14E-10 vitellogenesis 
GO:0007292 6 528 1.55E-06 female gamete generation 
GO:0003006 4 77 2.64E-06 reproductive developmental process 
GO:0007276 6 704 4.37E-06 gamete generation 
GO:0019953 6 730 4.37E-06 sexual reproduction 
GO:0007028 4 109 5.40E-06 cytoplasm organization and biogenesis 
GO:0022414 4 203 5.63E-05 reproduction#reproductive process 
GO:0007548 3 57 7.52E-05 sex differentiation 
GO:0005737 6 1833 0.000616 cytoplasm 
GO:0005811 3 129 0.000708 lipid particle 
GO:0048134 2 20 0.000944 germ cell development#germ-line cyst formation 
GO:0048477 4 519 0.00136 oogenesis 
GO:0016043 5 1962 0.0134 cellular component organization and biogenesis 
GO:0044424 6 3454 0.0134 intracellular#intracellular part 
GO:0005622 6 3465 0.0134 intracellular 
GO:0032502 5 2243 0.0217 developmental process 
GO:0008283 2 133 0.0222 cell proliferation 
GO:0007542 1 5 0.0252 
multicellular organismal development#germ-line sex 
determination#primary sex determination, germ-line 
GO:0019099 1 5 0.0252 female germ-line sex determination 
GO:0016590 1 6 0.0278 ACF complex 
GO:0018992 1 6 0.0278 
multicellular organismal development#germ-line sex 
determination 
GO:0007281 2 170 0.0291 germ cell development 
GO:0016709 1 7 0.0297 
oxidoreductase activity, acting on paired donors, with 
incorporation or reduction of molecular oxygen, NADH or 
NADPH as one donor, and incorporation of one atom of 
oxygen 
GO:0008156 1 8 0.0297 negative regulation of DNA replication 
GO:0020037 1 8 0.0297 heme binding 
GO:0046906 1 8 0.0297 tetrapyrrole binding 
GO:0044464 6 4358 0.0297 cell#cell part 
GO:0005623 6 4358 0.0297 cell 
GO:0051053 1 9 0.0297 negative regulation of DNA metabolic process 
GO:0005678 1 9 0.0297 chromatin assembly complex 
GO:0006275 1 9 0.0297 regulation of DNA replication 
GO:0044444 4 1537 0.0297 cytoplasm#cytoplasmic part 
GO:0030237 1 11 0.0344 multicellular organismal development#female sex 
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determination 
GO:0006378 1 12 0.0356 mRNA polyadenylation 
GO:0043631 1 12 0.0356 RNA polyadenylation 
GO:0045495 1 14 0.0405 pole plasm 
GO:0031124 1 16 0.0451 mRNA 3'-end processing 
GO:0007280 1 17 0.0457 pole cell migration 
GO:0031123 1 17 0.0457 RNA 3'-end processing 
GO:0007538 1 18 0.0472 
multicellular organismal development#primary sex 
determination 
 
Table S5G. Overrepresented Gene Ontologies in Genes Found to Spike at Day 10 
Post-Irradiation at Dose 10,000 R. (Analysis with lowest dose discluded.) 
 
 
 
(none) 
     
Table S5H. Overrepresented Gene Ontologies in Genes Found to Spike at Day 20 
Post-Irradiation at Dose 5000 R. (Analysis with lowest dose discluded.) 
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Abstract 
Photodynamic therapy is a promising cancer treatment method. However, one possible 
limitation is its dependence on light that is not highly penetrating. Copper-Cysteamine 
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nanoparticles are a new type of photosensitizer, which generates cytotoxic singlet 
oxygen molecules upon activation by x-rays. In this paper, we report  the use of  
copper cysteamine nanoparticles, targeted to tumors using pH-Low Insertion Peptide. 
In an in vivo study, results show significant tumor destruction under x-ray activation. 
An analysis of variance shows that mice treated with targeted particles had a 
significantly different tumor sizes than mice treated with no particles, as well as mice 
treated with non-targeted particles. An additional analysis of variance shows that the 
use of targeted copper-cysteamine nanoparticles affected the survival time after 
irradiation, compared to irradiation using no particles on mice. This work confirms the 
effectiveness of Copper-Cysteamine nanoparticles, targeted to tumors, as a 
photosensitizer when activated by radiation therapy. Combined with radiation therapy, 
targeted and non-targeted Cu-Cy nanoparticles are good candidates for photodynamic 
therapy in deeply seated tumors. 
 
Introduction 
 
Photodynamic therapy (PDT) involves the use of light, a photosensitizer (PS) and 
molecular oxygen to kill cells (1-16). Photosensitizers induce the production of 
reactive oxygen species (ROS) at the tumor site after the absorption of light energy, 
killing the tumor cells. (5, 8, 9, 14, 15, 17, 18). Singlet oxygen has a short lifetime in 
biologic systems, less than 0.04 µs, and therefore has a short radius of action of less 
than 0.02 µm (17, 19). Photodynamic therapy is safe (2, 10, 12), minimally invasive 
and can be used with methods to selectively target cancerous cells, avoiding side 
effects to the healthy tissues (1-3, 10-12, 17, 20). Ma et al. successfully used copper 
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cysteamine nanoparticles (NPs) activated by microwaves for production of singlet 
oxygen to treat cancer using microwave induced photodynamic therapy (21). Copper 
sulfide (CuS) nanoparticles excited by 808 nm lasers produced reactive oxygen 
species and strong anticancer effects in vitro and in vivo (22). Organically modified 
silica  (ORMOSIL) nanoparticles (approximately 20 nm) generated cytotoxic singlet 
molecules upon photo irradiation after uptake by tumor cells (23). Zinc Oxide (ZnO) 
nanoparticles conjugated to porphyrin derivatives showed high phototoxicity in human 
ovarian carcinoma cell line when activated with 365 nm UV light, showing a potential 
use in photodynamic therapy for deeper cancer treatment (24).  
Some advantages of PDT are the available options for photosensitizer and therapeutic 
dose, time of irradiation post treatment and light fluence rate (which can be adjusted to 
target biological tissues (8)). Although many photosensitizers have been developed, 
only a few have shown successful results in vitro and in vivo and made it to clinical 
trials(14). One of the drawbacks of PDT is tissue penetration ability because of the 
fact that the wavelengths of light for most of the clinically approved photosensitizers 
are in the UV/visible range. This limits the use of conventional PDT methods to skin 
(surface) tumors only and are not effective for deep tumors (11, 12, 25-28). Another 
disadvantage is that the quantum yield of ROS production is lowered under 
physiological conditions because photosensitizing drugs have poor solubility in water 
and are easily aggregated due to a hydrophobic nature (3, 11, 28). Recently, 
nanomaterials combined with photosensitization drugs have been an important method 
in photodynamic therapy to overcome the limitation of conventional 
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photosensitization drugs by increasing the cellular uptake and solubility of drugs in 
water (3). 
As stated above, one important issue with photodynamic therapy is the tissue depth at 
which it can be used as a treatment. One way to address this issue is to use particles 
that can interact with more energetic photons. Depending on the source of excitation 
energy, nanoparticles can be designed to be excited by near infrared light (NIR), 
internal light and X-rays (12). Near infrared light (NIR) can be used to excite 
upconversion nanoparticles deep in tissue, with higher penetrating capacity compared 
to visible light and low phototoxicity to normal cells and tissues (26, 29). The 
upconversion nanoparticles showed a strong photodynamic effect on MB49 cells upon 
irradiation with 980 nm near infrared light (30). However, its penetration ability is still 
limited compared to X-rays, and it requires high laser light intensity. Further, it is 
difficult to design and synthesize because the energy gap of near infrared-absorbing 
photosensitizers is narrow, and the quantum yield of singlet oxygen is usually low 
(12). Another method for photodynamic therapy is to attach a nanoscintillator to a 
photosensitizer. When this is done in vivo and exposed to radiation, the nanoparticles 
emit scintillation. This light is absorbed by the  photosensitizers, resulting in the 
release of singlet oxygen at the tumor site for effective cancer killing. Another 
alternative strategy is to use luminescent nanoparticles instead of light sources in vivo 
to support photodynamic therapy with more localized therapy and less potential 
damage to healthy cells (18, 27). X-rays (0.05 – 6 MeV) have more tissue penetrating 
ability than UV/visible/infrared light, which makes it a potential candidate to initiate 
photodynamic therapy for deeply seated tumors (12). At present, the use of high 
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energy X-rays has been the most common radiation therapy treatment (31). However, 
radiation therapy often impacts healthy tissue as well as tumors. If the effect of 
radiation on the tumor can be enhanced, less radiation could be used to get the same 
effect thus reducing the side effects and damage to the healthy tissues (32). A 
combination of conventional radiation therapy with photodynamic therapy has been an 
exciting technique for deep tumor penetration (33) and has the potential to result in 
lower doses of radiation when scintillation nanoparticles are attached to 
photosensitizers (12, 18). The nanoparticles emit light when induced by ionizing 
radiation; the scintillation activates the photosensitizers and results in the release of 
singlet oxygen. In this case, photodynamic therapy takes place even without the aid of 
an external light source, and the effectiveness of the radiation is increased (18). Since 
the site of damage from photodynamic therapy depends on the location of the 
photosensitizer at the time of irradiation, (20) conjugating the particles with tumor 
specific targeting molecules can enhance the uptake of particles with efficient cancer 
treatment reducing the damage to the healthy tissues and important organs near the 
tumor with the reduced radiation dose (32). X-rays can initiate the photodynamic 
agent (LaF3 : Tb
3+
- meso-tetra ( 4-carbosyphenyl) porphine (MTCP)) scintillating 
nanoparticle, even at low dose, for deep cancer treatment (34). The core of a 
nanoscintillator coated with a mesoporous silica forms an integrated nanosystem 
which when irradiated by X-rays (25). Liu et al. (2008) showed enhanced X-ray 
damage by gold nanoparticles treated with a new synthesis method of polyethylene 
glycol modification. Trifluorocerium-verteporfin (CeF3
 –VP) conjugates, lanthanide 
complexes, Copper and cobalt co-doped zinc sulfide  (ZnS:Cu,Co) afterglow NPs, and 
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nanoscintillator coupled porphyrins have been shown to produce singlet oxygen when 
activated by X-ray and are effective for cancer cell destruction (4, 5, 35, 36). Zhang et 
al. used a conjugated semiconductor scintillator particle as a photosensitizer with 
ionizing radiation, and found diminished oxygen dependence (37). The combined 
effect of radiation therapy and photodynamic therapy with indocyanine green as a 
sensitizer resulted in killing of MCF7 human breast cancer cells with a reduction in 
percentage cell viability, down to 3.42%. A one way ANOVA was used to analyze 
data for statistical differences (p < 0.05) (38). When activated by X-rays at 90 kV, 
energy was transferred from Ce
3+
-doped lanthanum(iii) fluoride  (LaF3:Ce
3+
)/DMSO 
nanoparticles to protoporphyrin IX (PPIX) with the production of singlet oxygen to 
kill cancer cells (39). Porphyrin conjugated with SiC/SiOx nanowires has been an 
efficient source of singlet oxygen at low doses of 6MV X-rays (0.4 – 2 Gy), showing 
the enhancement of radiation therapy for cancer treatment (40). 
In addition to improving upon the depth that photodynamic therapy can reach, another 
opportunity for improvement is the use of active targeting agents like peptides, 
antibodies and proteins. These agents could reduce the side effects to the surrounding 
healthy tissues (3, 41) and problems associated with multidrug resistance (11). There 
is a need for more precise photosensitization drug delivery into target cells and tissues 
(3), and efforts have been made to search for alternative photodynamic therapy 
methods for deep tissue penetration (26, 27).  Targeted photodynamic therapy has 
been a new promising therapeutic strategy that enhances specificity and efficiency of 
photodynamic therapy by improving the delivery of photosensitizers to cancer tissue 
(15). Yoon et al. successfully inhibited tumor growth using the hydrophobic 
 129 
 
photosensitizer chlorin e6 (Ce6), conjugated with tumor targeting hyaluronic acid 
nanoparticles (HANPs), to generate singlet oxygen in tumor cells when irradiated by 
laser. They analyzed the differences between experimental and control groups using a 
one-way analysis of variance (ANOVA) and found their results to be considered 
statistically significant if p<0.05 (42). 
Copper cysteamine nanoparticles (Cu-Cy, Cu3cl(SR)2) are a new option for 
photosensitization and radiation therapy. They were used to kill SW620 colorectal 
cancer cells by inducing apoptosis as well as autophagy. The difference between the 
control and experimental groups was determined using Student’s t test and a one one-
way analysis of variance (ANOVA) (43). Copper cysteamine particles under X-ray 
activation generated singlet oxygen ( 
1
O2 ) and were successful at killing MCF-7 cells 
both in vitro and in vivo and can be used in the treatment of  both shallow and deep 
cancers (44, 45). Copper cysteamine has been demonstrated as an X-ray activated 
nanoparticle in photodynamic therapy for cancer treatment, which when conjugated by 
tumor specific targeting molecules can enhance the uptake (44).  
In this paper, we demonstrate the use of copper cysteamine nanoparticles to enhance 
radiation therapy, using photodynamic therapy. We targeted copper cysteamine 
nanoparticles to tumors using the targeting peptide pH-Low Insertion Peptide 
(pHLIP), which targets molecules to tumors using the property that tumors have low 
pH. Among many uses, pHLIP has been used to effectively target gold nanoparticles 
to tumors and to treat cancer using gold nanoparticles (46-49). 
 
Materials and methods 
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Preparation of pHLIP conjugated copper cysteamine nanoparticles 
2 mg of Var3 pHLIP (Ala-28-Gly), from CS Bio Company, was added in 5 mL of 
deionized water followed by the addition of 3.19 mg of 1 Ethyl-3-(3-
dimethylaminopropyl) carbodiimide (EDC) under mild stirring for 10 minutes at room 
temperature. After adjusting the pH to 7.5 using NaoH, 5 mL of 1 mM copper 
cysteamine water solution was added under constant stirring overnight at room 
temperature in a dark environment. The copper cysteamine-pHLIP conjugates were 
centrifuged at 4400 rpm for 25 minutes and washed with deionized water 3-4 times. 
Cell Culture 
JC Breast murine cancer cells of BALB/cRos strain were purchased from American 
Type Culture Collection (ATCC) and were grown in Roswell Park Memorial Institute 
(RPMI) medium with L-glutamine and sodium bicarbonate, 10% Fetal Bovine Serum 
(Sigma-Aldrich) and 0.1% Ciprofloxacin. The cells were maintained in a humidified 
atmosphere at 5% carbon dioxide at 37 degrees centigrade in an incubator. 
Animal Models and Cell Injection 
All animal work followed the guidelines of URI IACUC protocol AN1516-003. Males 
and Females, 18-25g Balb/c AnNHsd, 3-4 weeks mice were ordered from Envigo. 
This strain of mice came to Harlan Sprague Dawley (Hsd-now Envigo) from National 
Institutes of Health, Bethesda. The NIH received this strain from Andevont (An). 1.5 
million cells suspended in 100uL RPMI were injected subcutaneously on the right 
flank of the mice using 1 mL 27 G
1/2
 latex free BD syringes. 
Radiation Therapy on Mice 
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Mice were divided into 6 treatment groups: i) targeted copper cysteamine + radiation 
ii) untargeted copper cysteamine + radiation iii) PBS (control) + radiation iv) targeted 
copper cysteamine v) untargeted copper cysteamine vi) PBS (control). In total, 51 
mice (24 males and 27 females) were used for the experiment. 
Treatment was undertaken when the tumor size reached approximately 4-8mm. Mice 
were anesthetized using isoflurane gas. For groups of mice given nanoparticles, the 
particles were injected intratumorally in 20 μL PBS at a particle concentration of 0.8 
μg/μL. For the groups given radiation therapy, the mice were irradiated 30 minutes 
post injection of particles at an irradiation dose of 5 Gy. No external X-ray filter was 
used, and the source to surface distance was set to 30.5 cm with a field size of 18.3 by 
20.1 cm. The current and voltage settings of the X-ray machine (a Faxitron MultiRad 
350) were 90 kVp and 30 mA. The non-irradiated mice were placed in the x-ray 
chamber in the same settings but with no irradiation. The tumor size was measured 
daily using digital Vernier calipers (VCD001, from United Scientific Supply) to get 
the tumor volume. The tumor volume was calculated using the formula: tumor volume 
= ½ length * width
2
 (50). Mice were euthanized if they reached the endpoint size of 20 
mm, or if they showed signs of distress. 
Particle characterization 
The copper – cysteamine nanoparticles were synthesized in The University of Texas at 
Arlington in Wei Chen’s lab along with the singlet oxygen measurement and 
photoluminescence and X- ray luminescence measurements (44).  
Statistics and Analysis of Data 
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In total, 51 mice were used - 24 males and 27 females. Each of the radiation therapy 
groups had 3 males and 4 females, whereas the non-RT groups had 5 males and 5 
females. 
The effect of experimental variables on tumor size in our experiment was quantified 
by running an analysis of variance (ANOVA), using the command “anova” in the 
statistical computer language R (51). The input given was a linear model (lm 
command in R). The independent variable in the linear model was tumor volume, and 
the dependent variables were treatment type, time of measurement after irradiation, 
age at irradiation, radiation dose (0 or 5 Gy), sex (M or F) and original tumor volume. 
Treatment types were run two at a time to generate a comparison between the 
following pairs of treatments: i) targeted copper cysteamine particles and untargeted 
copper cysteamine particles; ii) targeted copper cysteamine particles and no particles; 
iii) untargeted copper cysteamine particles and no particles. p values for individual 
variables, as well as interactions of variables were determined using the F test (part of 
the anova command in R). p values were ruled significant if the Bonferroni correction 
criteria was met. Including interactions, 59 p values were found for each pairwise 
comparison of treatment types. We used 0.05/59 = 0.000847 as the cutoff P value for 
statistical significance. 
 
Results 
Tumor Size Data and Analysis of Variance 
Figures 1A and 1B show tumor volume versus time, for male mice (fig. 1) and female 
mice (fig. 2) after the intra-tumoral injection of targeted (CuCyP), untargeted (CuCy) 
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or no particles (PBS) followed by irradiation with 5 Gray after 30 minutes. In these 
figures, each individual curve represents one mouse. Figures 2A (males) and 2B 
(females) show tumor volume as a function of time for mice given targeted particles 
and either 0 or 5 Gray of radiation. Figures 3A (males) and 3B (females) show tumor 
volume growth as a function of time post different treatments either at 0 or 5 Gray 
radiation. Supplemental figures 1A, 1B, 2A and 2B show tumor volume as a function 
of time for mice given non-targeted particles and no particles. 
 
An analysis of variance (ANOVA) was performed to compare the effects of (targeted 
copper cysteamine particles + radiation) with the effects of (non-targeted copper 
cysteamine particles + radiation). As described in detail in the methods section, the 
dependent variable of the analysis was tumor size and the independent variables were 
time after irradiation, sex (male or female), radiation dose (0 or 5 Gy), treatment type 
(targeted particles or non-targeted particles), age of mouse at irradiation, and volume 
of tumor at time of irradiation. Mice with a treatment of no particles were excluded 
from this analysis, so that the variable for treatment type would be a 2-factor 
comparison of targeted and non-targeted particles. 
Table 1 shows the ANOVA results for an analysis where only two treatment types 
were included: targeted and non-targeted particles. In this analysis, the p value for 
treatment type is significant (less than 0.000847, the Bonferroni cutoff). This indicates 
that mice treated with targeted particles had a significantly different tumor size than 
mice treated with non-targeted particles, even when other relevant experimental 
variables were also considered.  
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In addition to treatment type, the p values for the following variables were also 
significant: time after irradiation, radiation dose, treatment type, age of mouse at 
irradiation, volume of tumor at time of irradiation. The p value for sex of the mice 
shows that sex does not play an important role in the experimental outcome. Several 
interaction terms were also significant in the analysis of variance. Of particular note 
are: the interactions between time after irradiation and radiation dose (p value < 
2.2*10
-16
), radiation dose and treatment type (p < 5.02*10
-9
), time after irradiation and 
age at irradiation (p<2.2*10
-16
), treatment type and age at irradiation (p< 3.576*10
-11
), 
time after irradiation and tumor volume at irradiation (p< 6.739*10
-10
), age at 
irradiation and tumor volume at irradiation  (p<0.000219). See supplemental table 1 
for full information on interaction terms for this analysis. 
 
Table 2 shows the ANOVA results when the following treatment types were included: 
non-targeted particles and no particles. In this analysis, all experimental variables 
tested had a significant effect on tumor size, including sex. Notable significant 
interaction terms included: time after irradiation and radiation dose (p<2.2*10
-16
), time 
after irradiation and age at irradiation (p<2.2*10
-16
), radiation dose and age at 
irradiation (p<2.308*10
-13
), time after irradiation and tumor volume at irradiation (p< 
2.2*10
-16
), radiation dose and tumor volume at irradiation (p< 6.238*10
-6
), treatment 
type and tumor volume at irradiation (p<1.001*10
-6
), age at irradiation and tumor 
volume at irradiation (p<0.0029175). See supplemental table 2 for full information on 
interaction terms for this analysis. 
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Table 3 shows the analysis of variance when the following treatment types were 
included: targeted particles and no particles. Similar to table 1, all experimental 
variables included were significant except sex.  Notable significant interaction terms 
included: time after irradiation and sex (p<5.753*10
-5
), time after irradiation and 
radiation dose (p<2.2*10
-16
), radiation dose and treatment type (p<1.15*10
-8
), time 
after irradiation and age at irradiation (p<2.2*10
-16
), treatment type and age at 
irradiation (p<1.243*10
-10
), time after irradiation and tumor volume at irradiation 
(p<2.2*10
-16
), radiation dose and tumor volume at irradiation (p<0.002), age at 
irradiation and tumor volume at irradiation (p<0.003374). See supplemental table 3 for 
full information on interaction terms for this analysis. 
 
ANOVA Analysis of Survival 
The number of mice used in this experiment was insufficient to run an effective log 
rank test for differences between survival curves. As a substitute analysis, an analysis 
of variance was run with time between irradiation and death as the dependent variable. 
(Here, death is defined as either actual death or as reaching a humane endpoint 
following our institution’s IACUC policies.) The independent variables were sex (M 
or F), radiation dose (0 or 5 Gy), treatment type (targeted particles, non-targeted 
particles, no particles), age of mouse at time of irradiation, and size of the mouse’s 
tumor at time of irradiation. Including interaction terms, there were 29 variable 
combinations assessed for significance; we used a Bonferroni cutoff p value of 0.05/29 
= 0.00172 to claim significance.  
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A comparison using mice treated with targeted particles or no particles found a 
statistically significant effect from treatment (targeted particles versus no particles), 
sex and radiation dose. Thus, the anova analysis indicates that targeted particles 
increase survival time, compared to irradiation using no particles. Notable interaction 
terms that were significant included radiation dose with treatment type, and radiation 
dose with tumor size at time of irradiation. The input and output of this analysis is 
supplemental tables 4 and 5. Analyses run with the other combinations of treatments 
(targeted particles versus non-targeted particles, non-targeted particles versus no 
particles) found no significant effects from the treatment differences. 
 
Discussion 
In this paper, we demonstrated that copper cysteamine nanoparticles, targeted with 
pH-Low Insertion Peptide, can be used to reduce tumor size and to increase survival in 
mammals. Copper cysteamine can be used in the treatment of both shallow and deep 
tumors because it can be activated by X-rays as well as light (44). In this result, we 
particularly emphasize the effect on tumor size.  
The targeted Copper cysteamine particles showed the enhanced radiation effect with 
better tumor killing in both the male and female mice. The sex of the mice might not 
be an important variable in this kind of experiment as this parameter was not 
statistically significant in targeted vs non tartgeted and targeted versus no particles. 
However for nontargeted versus no particles it played an important role. The original 
volume of tumor and age factor of mice at irradiation time are also very important to 
be considered while performing the experiment. The dose of the radiation given to the 
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mice could be altered to see the affect in the tumor size as the radiation dose is 
statistically significant. 
One particularly important variable that was not tested in this paper is radiation 
energy. Few, if any, photoluminescent particles have been shown to work at energies 
as high as 90 kVp, as shown in this paper. However, most clinically relevant energies 
are higher still.  
Overall, this paper represents a firm demonstration of the effectiveness of copper-
cysteamine nanoparticles in the treatment of mammalian cancer.  
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Tables: 
Table 1. Analysis of variance results, comparing treatment with targeted copper 
cysteamine particles to treatment with non-targeted particles. 
 
pHLIP Targeted Copper Cysteamine Particles Vs Non-targeted Copper Cysteamine 
Particles 
Variable p Value 
Time After Irradiation (Days) < 2.2*10
-16
 
Sex < 0.9968 
Radiation Dose (Gray) < 2.2*10
-16
 
Treatment Type < 0.0006079 
Age of Mouse at Irradiation (Days) < 2.2*10
-12
 
Volume of Tumor at Irradiation (mm
3
) < 2.2*10
-10
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Table 2. Analysis of variance results, comparing treatment with non-targeted copper 
cysteamine particles to treatment with no particles. 
 
Non-targeted Copper Cysteamine Particles Vs No Particles 
Variable pValues 
Day after irradiation(days) < 2.2*10
-16
 
Sex < 0.0001556 
Radiation Dose (Gray) < 2.2*10
-16
 
Treatment Type < 2.467*10
-7
 
Age at irradiation (Days) < 2.2*10
-16
 
Original Tumor Volume(mm
3
) < 2.2*10
-16
 
 
Table 3. Analysis of variance results, comparing treatment with targeted copper 
cysteamine particles to treatment with no particles. 
 
pHLIP Targeted Copper Cysteamine Vs No Particles 
Variable pValues 
Day after irradiation(days) < 2.2*10
-16
 
Sex < 0.282 
Radiation Dose (Gray) < 2.2*10
-16
 
Treatment Type < 2.49*10
-19
 
Age at irradiation (Days) < 4.11*10
-13
 
Original Tumor Volume(mm
3
) < 2.2*10
-16
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Figure 1B 
 
 
Figure 1. Tumor size as a function of time, for mice given 5 Gray of radiation. Each 
individual curve represents one mouse. CuCyP mice were given a targeted copper-
cysteamine treatment; CuCy mice were given a non-targeted copper-cysteamine 
treatment; PBS mice were injected with a control solution containing no particles. 
Figure A is male mice; figure B is female mice. 
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Figure 2A 
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Figure 2B 
 
Figure 2. Tumor size as a function of time, for mice given a targeted copper 
cysteamine treatment. Each individual curve represents one mouse. Red curves are 
mice given 5 Gy of radiation; green curves are mice given 0 Gy of radiation. Figure A 
is male mice; figure B is female mice. 
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Figure 3A 
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Figure 3B 
 
 
Figure 3. Tumor size as a function of time, for mice given different treatments. Each 
individual curve represents a single treatment either at 5 Gy or at 0 Gy of radiation. 
Figure A is male mice; figure B is female mice. 
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SUPPLEMENTARY DATA 
 
 
Supplemental Figures 1A – 2 B 
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Figure S1B 
 
 
 
 Figure S1. Tumor size as a function of time, for mice given a non-targeted copper 
cysteamine treatment. Each individual curve represents one mouse. Red curves are 
mice given 5 Gy of radiation; green curves are mice given 0 Gy of radiation. Figure A 
is male mice; figure B is female mice. 
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Figure S2A 
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Figure S2B 
 
Figure S2. Tumor size as a function of time, for mice given a control (no particles) 
treatment. Each individual curve represents one mouse. Red curves are mice given 5 
Gy of radiation; green curves are mice given 0 Gy of radiation. Figure A is male mice; 
figure B is female mice. 
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Table S1: Information on interaction terms for targeted and non-targeted 
copper-cysteamine 
 
day.after.irradiation                                                                                                       < 2.2e-16 
sex                                                                                                                                                                 0.9968423 
radiation.dose.Gy.                                                                                                          < 2.2e-16 
treatment.type                                                                                                              0.0006079 
age.at.irradiation.days.                                                                                                    1.07E-12 
Original.tumor.volume                                                                                                       < 2.2e-16 
day.after.irradiation:sex                                                                                              0.0052499 
day.after.irradiation:radiation.dose.Gy.                                                                               < 2.2e-16 
sex:radiation.dose.Gy.                                                                                                 0.2877592 
day.after.irradiation:treatment.type                                                                                   0.2422588 
sex:treatment.type                                                                                                                                        0.925823 
radiation.dose.Gy.:treatment.type                                                                                      5.02E-09 
day.after.irradiation:age.at.irradiation.days.                                                                         < 2.2e-16 
sex:age.at.irradiation.days.                                                                                           0.0581423 
radiation.dose.Gy.:age.at.irradiation.days.                                                                            0.0741023 
treatment.type:age.at.irradiation.days.                                                                                3.58E-11 
day.after.irradiation:Original.tumor.volume                                                                            6.74E-16 
sex:Original.tumor.volume                                                                                              0.0893735 
radiation.dose.Gy.:Original.tumor.volume                                                                               0.3569157 
treatment.type:Original.tumor.volume                                                                                   0.3732059 
age.at.irradiation.days.:Original.tumor.volume                                                                         0.000219 
day.after.irradiation:sex:radiation.dose.Gy.                                                                      0.0002324 
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day.after.irradiation:sex:treatment.type                                                                          0.0642263 
day.after.irradiation:radiation.dose.Gy.:treatment.type                                                           2.48E-09 
sex:radiation.dose.Gy.:treatment.type                                                                             0.4166221 
day.after.irradiation:sex:age.at.irradiation.days.                                                                0.002378 
day.after.irradiation:radiation.dose.Gy.:age.at.irradiation.days.                                                 0.709861 
sex:radiation.dose.Gy.:age.at.irradiation.days.                                                                   0.0825586 
day.after.irradiation:treatment.type:age.at.irradiation.days.                                                     0.690005 
sex:treatment.type:age.at.irradiation.days.                                                                       1.10E-06 
radiation.dose.Gy.:treatment.type:age.at.irradiation.days.                                                        1.54E-10 
day.after.irradiation:sex:Original.tumor.volume                                                                   0.0023348 
day.after.irradiation:radiation.dose.Gy.:Original.tumor.volume                                                    0.0098703 
sex:radiation.dose.Gy.:Original.tumor.volume                                                                      0.9326714 
day.after.irradiation:treatment.type:Original.tumor.volume                                                        0.0147587 
sex:treatment.type:Original.tumor.volume                                                                          0.1858568 
radiation.dose.Gy.:treatment.type:Original.tumor.volume                                                           0.0021191 
day.after.irradiation:age.at.irradiation.days.:Original.tumor.volume                                              4.63E-06 
sex:age.at.irradiation.days.:Original.tumor.volume                                                                0.0001083 
radiation.dose.Gy.:age.at.irradiation.days.:Original.tumor.volume                                                 0.914267 
treatment.type:age.at.irradiation.days.:Original.tumor.volume                                                     2.10E-15 
day.after.irradiation:sex:radiation.dose.Gy.:treatment.type                                                  0.1826445 
day.after.irradiation:sex:radiation.dose.Gy.:age.at.irradiation.days.                                        0.0002631 
day.after.irradiation:sex:treatment.type:age.at.irradiation.days.                                            0.0017918 
day.after.irradiation:radiation.dose.Gy.:treatment.type:age.at.irradiation.days.                             1.41E-10 
sex:radiation.dose.Gy.:treatment.type:age.at.irradiation.days.                                               0.0015014 
day.after.irradiation:sex:radiation.dose.Gy.:Original.tumor.volume                                           0.0008715 
day.after.irradiation:sex:treatment.type:Original.tumor.volume                                               1.16E-11 
day.after.irradiation:radiation.dose.Gy.:treatment.type:Original.tumor.volume                                0.7065459 
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sex:radiation.dose.Gy.:treatment.type:Original.tumor.volume                                                  < 2.2e-16 
day.after.irradiation:sex:age.at.irradiation.days.:Original.tumor.volume                                     0.8580931 
day.after.irradiation:radiation.dose.Gy.:age.at.irradiation.days.:Original.tumor.volume                      5.60E-06 
day.after.irradiation:treatment.type:age.at.irradiation.days.:Original.tumor.volume                          0.0001225 
sex:treatment.type:age.at.irradiation.days.:Original.tumor.volume                                           0.8950907 
radiation.dose.Gy.:treatment.type:age.at.irradiation.days.:Original.tumor.volume                             1.82E-09 
day.after.irradiation:sex:radiation.dose.Gy.:treatment.type:age.at.irradiation.days.                    1.67E-05 
day.after.irradiation:sex:radiation.dose.Gy.:treatment.type:Original.tumor.volume                       < 2.2e-16 
day.after.irradiation:sex:treatment.type:age.at.irradiation.days.:Original.tumor.volume                 0.0282005 
day.after.irradiation:radiation.dose.Gy.:treatment.type:age.at.irradiation.days.:Original.t
umor.volume  
0.1153768 
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Table S2: Information on interaction terms for non-targeted copper-cysteamine 
 and no particles  
 
day.after.irradiation                                                                                                       < 2.2e-16 
sex                                                                                                                         0.0001556 
radiation.dose.Gy.                                                                                                          < 2.2e-16 
treatment.type                                                                                                              2.47E-07 
age.at.irradiation.days.                                                                                                    < 2.2e-16 
Original.tumor.volume                                                                                                       < 2.2e-16 
day.after.irradiation:sex                                                                                              0.0137652 
day.after.irradiation:radiation.dose.Gy.                                                                               < 2.2e-16 
sex:radiation.dose.Gy.                                                                                                 0.8973791 
day.after.irradiation:treatment.type                                                                                   0.0412466 
sex:treatment.type                                                                                                     0.4474246 
radiation.dose.Gy.:treatment.type                                                                                      0.2525226 
day.after.irradiation:age.at.irradiation.days.                                                                         < 2.2e-16 
sex:age.at.irradiation.days.                                                                                           0.5539768 
radiation.dose.Gy.:age.at.irradiation.days.                                                                            2.31E-13 
treatment.type:age.at.irradiation.days.                                                                                0.0036885 
day.after.irradiation:Original.tumor.volume                                                                            < 2.2e-16 
sex:Original.tumor.volume                                                                                              0.0793622 
radiation.dose.Gy.:Original.tumor.volume                                                                               6.24E-06 
treatment.type:Original.tumor.volume                                                                                   1.00E-06 
age.at.irradiation.days.:Original.tumor.volume                                                                         0.0029175 
day.after.irradiation:sex:radiation.dose.Gy.                                                                      0.6529036 
day.after.irradiation:sex:treatment.type                                                                          0.4082707 
day.after.irradiation:radiation.dose.Gy.:treatment.type                                                           0.0155393 
sex:radiation.dose.Gy.:treatment.type                                                                             0.0153287 
day.after.irradiation:sex:age.at.irradiation.days.                                                                0.3772449 
day.after.irradiation:radiation.dose.Gy.:age.at.irradiation.days.                                                 1.73E-06 
sex:radiation.dose.Gy.:age.at.irradiation.days.                                                                   5.69E-06 
day.after.irradiation:treatment.type:age.at.irradiation.days.                                                     0.4607212 
sex:treatment.type:age.at.irradiation.days.                                                                       0.1209064 
radiation.dose.Gy.:treatment.type:age.at.irradiation.days.                                                        < 2.2e-16 
day.after.irradiation:sex:Original.tumor.volume                                                                   0.9639791 
day.after.irradiation:radiation.dose.Gy.:Original.tumor.volume                                                    0.0003828 
sex:radiation.dose.Gy.:Original.tumor.volume                                                                      0.2379018 
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day.after.irradiation:treatment.type:Original.tumor.volume                                                        0.0007917 
sex:treatment.type:Original.tumor.volume                                                                          9.74E-10 
radiation.dose.Gy.:treatment.type:Original.tumor.volume                                                           0.710651 
day.after.irradiation:age.at.irradiation.days.:Original.tumor.volume                                              0.2090692 
sex:age.at.irradiation.days.:Original.tumor.volume                                                                1.78E-12 
radiation.dose.Gy.:age.at.irradiation.days.:Original.tumor.volume                                                 1.06E-05 
treatment.type:age.at.irradiation.days.:Original.tumor.volume                                                     0.2889579 
day.after.irradiation:sex:radiation.dose.Gy.:treatment.type                                                  0.1049055 
day.after.irradiation:sex:radiation.dose.Gy.:age.at.irradiation.days.                                        0.0222449 
day.after.irradiation:sex:treatment.type:age.at.irradiation.days.                                            0.0038017 
day.after.irradiation:radiation.dose.Gy.:treatment.type:age.at.irradiation.days.                             < 2.2e-16 
sex:radiation.dose.Gy.:treatment.type:age.at.irradiation.days.                                               0.0013554 
day.after.irradiation:sex:radiation.dose.Gy.:Original.tumor.volume                                           4.04E-11 
day.after.irradiation:sex:treatment.type:Original.tumor.volume                                               2.50E-14 
day.after.irradiation:radiation.dose.Gy.:treatment.type:Original.tumor.volume                                3.51E-06 
sex:radiation.dose.Gy.:treatment.type:Original.tumor.volume                                                  0.0003807 
day.after.irradiation:sex:age.at.irradiation.days.:Original.tumor.volume                                     6.10E-13 
day.after.irradiation:radiation.dose.Gy.:age.at.irradiation.days.:Original.tumor.volum
e                      
1.42E-09 
day.after.irradiation:treatment.type:age.at.irradiation.days.:Original.tumor.volume                          1.40E-07 
sex:treatment.type:age.at.irradiation.days.:Original.tumor.volume                                            0.0119215 
radiation.dose.Gy.:treatment.type:age.at.irradiation.days.:Original.tumor.volume                             < 2.2e-16 
day.after.irradiation:sex:radiation.dose.Gy.:treatment.type:age.at.irradiation.days.                    0.0005915 
day.after.irradiation:sex:radiation.dose.Gy.:treatment.type:Original.tumor.volume                       0.2044633 
day.after.irradiation:sex:treatment.type:age.at.irradiation.days.:Original.tumor.volum
e                 
3.34E-08 
day.after.irradiation:radiation.dose.Gy.:treatment.type:age.at.irradiation.days.:Origin
al.tumor.volume  
2.23E-09 
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Table S3: Information on interaction terms for targeted copper-cysteamine 
particles and no particles  
 
day.after.irradiation                                                                                                       < 2.2e-16 
sex                                                                                                                          0.282695 
radiation.dose.Gy.                                                                                                          < 2.2e-16 
treatment.type                                                                                                              2.49E-14 
age.at.irradiation.days.                                                                                                    4.11E-13 
Original.tumor.volume                                                                                                       < 2.2e-16 
day.after.irradiation:sex                                                                                              5.75E-05 
day.after.irradiation:radiation.dose.Gy.                                                                               < 2.2e-16 
sex:radiation.dose.Gy.                                                                                                 0.554205 
day.after.irradiation:treatment.type                                                                                   0.002546 
sex:treatment.type                                                                                                     0.422989 
radiation.dose.Gy.:treatment.type                                                                                     1.15E-08 
day.after.irradiation:age.at.irradiation.days.                                                                         < 2.2e-16 
sex:age.at.irradiation.days.                                                                                            0.303295 
radiation.dose.Gy.:age.at.irradiation.days.                                                                            0.66228 
treatment.type:age.at.irradiation.days.                                                                                1.24E-10 
day.after.irradiation:Original.tumor.volume                                                                           < 2.2e-16 
sex:Original.tumor.volume                                                                                              0.0287 
radiation.dose.Gy.:Original.tumor.volume                                                                               0.002048 
treatment.type:Original.tumor.volume                                                                                   0.880755 
age.at.irradiation.days.:Original.tumor.volume                                                                         0.003374 
day.after.irradiation:sex:radiation.dose.Gy.                                                                     0.103475 
day.after.irradiation:sex:treatment.type                                                                         0.82539 
day.after.irradiation:radiation.dose.Gy.:treatment.type                                                          1.84E-10 
sex:radiation.dose.Gy.:treatment.type                                                                            0.652948 
day.after.irradiation:sex:age.at.irradiation.days.                                                               4.55E-05 
day.after.irradiation:radiation.dose.Gy.:age.at.irradiation.days.                                                 0.069363 
sex:radiation.dose.Gy.:age.at.irradiation.days.                                                                   0.399175 
day.after.irradiation:treatment.type:age.at.irradiation.days.                                                     0.025123 
sex:treatment.type:age.at.irradiation.days.                                                                        0.003863 
radiation.dose.Gy.:treatment.type:age.at.irradiation.days.                                                       < 2.2e-16 
day.after.irradiation:sex:Original.tumor.volume                                                                   0.012177 
day.after.irradiation:radiation.dose.Gy.:Original.tumor.volume                                                    0.538656 
sex:radiation.dose.Gy.:Original.tumor.volume                                                                      < 2.2e-16 
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day.after.irradiation:treatment.type:Original.tumor.volume                                                        2.31E-06 
sex:treatment.type:Original.tumor.volume                                                                           0.302969 
radiation.dose.Gy.:treatment.type:Original.tumor.volume                                                           < 2.2e-16 
day.after.irradiation:age.at.irradiation.days.:Original.tumor.volume                                              0.337459 
sex:age.at.irradiation.days.:Original.tumor.volume                                                                 0.265691 
radiation.dose.Gy.:age.at.irradiation.days.:Original.tumor.volume                                                 1.31E-05 
treatment.type:age.at.irradiation.days.:Original.tumor.volume                                                     0.653384 
day.after.irradiation:sex:radiation.dose.Gy.:treatment.type                                                 2.43E-05 
day.after.irradiation:sex:radiation.dose.Gy.:age.at.irradiation.days.                                       3.60E-11 
day.after.irradiation:sex:treatment.type:age.at.irradiation.days.                                          6.86E-05 
day.after.irradiation:radiation.dose.Gy.:treatment.type:age.at.irradiation.days.                             < 2.2e-16
sex:radiation.dose.Gy.:treatment.type:age.at.irradiation.days.                                              7.71E-07 
day.after.irradiation:sex:radiation.dose.Gy.:Original.tumor.volume                                           < 2.2e-16 
day.after.irradiation:sex:treatment.type:Original.tumor.volume                                               0.061314 
day.after.irradiation:radiation.dose.Gy.:treatment.type:Original.tumor.volume                                4.88E-10
sex:radiation.dose.Gy.:treatment.type:Original.tumor.volume                                                  5.73E-06 
day.after.irradiation:sex:age.at.irradiation.days.:Original.tumor.volume                                     0.612714 
day.after.irradiation:radiation.dose.Gy.:age.at.irradiation.days.:Original.tumor.vo
lume                     
1.64E-09 
day.after.irradiation:treatment.type:age.at.irradiation.days.:Original.tumor.volu
me                          
8.51E-07 
sex:treatment.type:age.at.irradiation.days.:Original.tumor.volume                                             0.15134 
radiation.dose.Gy.:treatment.type:age.at.irradiation.days.:Original.tumor.volum
e                              
0.008293 
day.after.irradiation:sex:radiation.dose.Gy.:treatment.type:age.at.irradiation.day
s.                    
0.024138 
day.after.irradiation:sex:radiation.dose.Gy.:treatment.type:Original.tumor.volum
e                        
0.00421 
day.after.irradiation:sex:treatment.type:age.at.irradiation.days.:Original.tumor.v
olume                  
0.35164 
day.after.irradiation:radiation.dose.Gy.:treatment.type:age.at.irradiation.days.:O
riginal.tumor.volume 
5.02E-07 
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Table S4: Survival Experiment Data 
 
Mouse  
Number 
Days 
between 
Irradiation 
and death 
Sex Irradiatio
n 
Dose 
(Gy) 
Treatment  
Type 
Age at 
Irradiatio
n (days) 
Size of 
tumor 
on day of 
irradiation 
222             93             
M 
            5             CuCyP 59 49.36 
234             64             
M 
            5             CuCyP 66 68.26 
251             74             
M 
            5             CuCyP 66 80.76 
229             66             F             5             CuCyP 48 75.16 
239             65             F             5             CuCyP 94 78.14 
280             79             F             5             CuCyP 90 82.86 
282             10
3 
            F             5             CuCyP 96 57.24 
225             70             
M 
            5             CuCy 59 64.71 
235             66             
M 
            5             CuCy 66 54.05 
253             68             
M 
            5             CuCy 66 71.35 
250             68             F             5             CuCy 83 61.58 
240             73             F             5             CuCy 59 63.01 
281             29             F             5             CuCy 90 139.66 
283             82             F             5             CuCy 96 72.15 
226             19             
M 
            5 No Particles 59 66.13 
237             17             
M 
            5 No Particles 66 57.74 
252             73             
M 
            5 No Particles 66 61.9 
232             91             F             5 No Particles 83 52.65 
236             64             F             5 No Particles 52 50.66 
254             48             F             5 No Particles 66 58.16 
284             49             F             5 No Particles 117 104.97 
223             39             
M 
            0             CuCyP 59 76.46 
243             57             
M 
            0             CuCyP 73 65.59 
247             26             
M 
            0             CuCyP 76 72.04 
347             24             
M 
            0             CuCyP 67 68.36 
228             40             F             0             CuCyP 83 64.09 
241             51             F             0             CuCyP 59 73 
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278             25             F             0             CuCyP 100 83.48 
296             38             F             0             CuCyP 125 134.57 
348             34             F             0             CuCyP 67 107.4 
224             65             
M 
            0             CuCy 59 96 
244             44             
M 
            0             CuCy 59 96 
248             39             
M 
            0             CuCy 76 70.63 
264             44             
M 
            0             CuCy 80 68.88 
355             35             
M 
            0             CuCy 90 93.88 
230             62             F             0             CuCy 48 75.57 
242             57             F             0             CuCy 59 60.15 
279             29             F             0             CuCy 100 78.42 
297             25             F             0             CuCy 125 173.94 
350             41             F             0             CuCy 75 64.85 
227             39             
M 
            0 No Particles 59 41.65 
245             40             
M 
            0 No Particles 59 174.44 
249             28             
M 
            0 No Particles 76 81.57 
335             39             
M 
            0 No Particles 49 62.53 
356             28             
M 
            0 No Particles 48 62.72 
238             49             F             0 No Particles 52 91.39 
258             45             F             0 No Particles 52 93.95 
344             37             F             0 No Particles 59 83.15 
345             28             F             0 No Particles 59 77.13 
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Table S5 Analysis of Variance Results on Survival Data 
data$sex                                                                                                            0.0013965 
data$radiation_dose.Gy.                                                                                              8.55E-05 
data$treatment_type                                                                                                 0.0016282 
data$age_at_irradiation.days.                                                                                       0.0066644 
data$size_of_tumor_on_day_of_irradiation                                                                           0.0400424 
data$sex:data$radiation_dose.Gy.                                                                                    0.0072156 
data$sex:data$treatment_type                                                                                        0.0095929 
data$radiation_dose.Gy.:data$treatment_type                                                                         0.0005156 
data$sex:data$age_at_irradiation.days.                                                                              0.018785 
data$radiation_dose.Gy.:data$age_at_irradiation.days.                                                               0.0426896
data$treatment_type:data$age_at_irradiation.days.                                                                   0.123847 
data$sex:data$size_of_tumor_on_day_of_irradiation                                                                   0.0038603
data$radiation_dose.Gy.:data$size_of_tumor_on_day_of_irradiation                                                    0.0008749 
data$treatment_type:data$size_of_tumor_on_day_of_irradiation                                                        0.0410717
data$age_at_irradiation.days.:data$size_of_tumor_on_day_of_irradiation                                              0.0049635 
data$sex:data$radiation_dose.Gy.:data$treatment_type                                                                0.0599268 
data$sex:data$radiation_dose.Gy.:data$age_at_irradiation.days.                                                      0.0598588
data$sex:data$treatment_type:data$age_at_irradiation.days.                                                          0.1531105 
data$radiation_dose.Gy.:data$treatment_type:data$age_at_irradiation.days.                                           0.0024378
data$sex:data$radiation_dose.Gy.:data$size_of_tumor_on_day_of_irradiation                                           0.0047904 
data$sex:data$treatment_type:data$size_of_tumor_on_day_of_irradiation                                               0.0026771
data$radiation_dose.Gy.:data$treatment_type 
:data$size_of_tumor_on_day_of_irradiation                                
0.0397707 
data$sex:data$age_at_irradiation.days 
.:data$size_of_tumor_on_day_of_irradiation                                     
0.1807822 
data$radiation_dose.Gy.:data$age_at_irradiation.days 
.:data$size_of_tumor_on_day_of_irradiation                      
0.0224007 
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data$treatment_type:data$age_at_irradiation.days 
.:data$size_of_tumor_on_day_of_irradiation                          
0.0023849 
data$sex:data$radiation_dose.Gy.:data$treatment_type 
:data$age_at_irradiation.days.                                  
0.0060847 
data$sex:data$radiation_dose.Gy.:data$treatment_type 
:data$size_of_tumor_on_day_of_irradiation                       
0.0006902 
data$sex:data$treatment_type:data$age_at_irradiation.days 
.:data$size_of_tumor_on_day_of_irradiation                 
0.0283519 
data$radiation_dose.Gy.:data$treatment_type:data$age_at_irradiation.days 
.:data$size_of_tumor_on_day_of_irradiation  
0.0291779 
